var title_f17_52_18240="Cephalopelvic disproportion in osteomalacia radiographic finding";
var content_f17_52_18240=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F87020&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F87020&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cephalopelvic disproportion in osteomalacia: Radiographic findings",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 384px; height: 513px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Historical radiograph of a pregnant patient with osteomalacia secondary to lack of exposure to sunlight and dietary causes resulting in cephalopelvic disproportion. Examination of the pelvis shows distortion of the iliopubic regions (white arrows) with narrowing of the pelvic outlet. The fetal head (yellow arrowhead) is deep in the pelvis and appears too large for the pelvic outlet. The fetal spine is seen to the patient's right (thick blue arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_52_18240=[""].join("\n");
var outline_f17_52_18240=null;
var title_f17_52_18241="SCIT prescription form";
var content_f17_52_18241=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F74859&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F74859&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 648px\">",
"   <div class=\"ttl\">",
"    Immunotherapy prescription form, blank",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 628px; height: 791px; background-image: url(data:image/gif;base64,R0lGODlhdAIXA9UAAP////Ly8ubm5gAAAIiIiJmZmURERIGBgSIiIkFBQbu7u7Gxsampqd3d3Xt7ez09PTMzM2ZmZiAgIMfHx5GRkRERER8fH2FhYdLS0u7u7jAwMOLi4lxcXMzMzC4uLoqKilVVVRAQEMLCwg8PD7i4uE1NTVFRUXd3d9fX16qqqqGhoXFxcWtrawAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAB0AhcDAAb/wIFwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CwWCwom8/otHrNbrvf8Lh8Tq/b7/i8fm8f8P+AgYKDhIWGh25CiIuMjY6PkJGJkpSVlpeYhoqZnJ2en6BsfqGkpaand5uoq6ytrmqjr7KztI2qtbi5uoexu76/wGi3wcTFxgK9x8rLpMPMz9CnydHU1YzO1tnaj9OODN15Awzb5JDYZg9DDrDjyO2J7+XyyuBnQxbx4Qzfwvl04vzSBDwzcJ7BRPUEPOAg4BuJNOL++TtIMVfCMgM+CHAwIlBBPhEritxzrszCMiM+WBBigQSHIRMilhDiAcU3DwNGuIRpxoGF/5U1Y9K0OWDliJkDWAiYgHMAQ4UPRkrV9CajABIDYqrkwFQIQxZDSHQdUOLbtw8AB+Bs6e5mzocOhkQ9g7Rj2o0/1RJd2rSsH7Re8QJF0TDk1GclFTJEO8GMBaUhxTmoKcCDA7OK3aHxOQFFSjMxC2C2EBWtgBIMJ+iEerg1oIvINHKwgKxEGdRLdQ4oYKbE3MLr2g54WMJ22nELsfJ28BtvY4z7/HD2/IGfbzMF0aKY/hmz62WJ0wn5gOJl4MgMzHsNyIGh4TLMy1j4QEJ8xoAP1vFbOUTj9/96wHbPQyHxN55PTqEwH3ax3IWXcGW0pxJ8zbVnT3QbzTXffv4VJv/AB01lFZ8ACwLITHhPfTgAYR64x5s7kxFWBnsubqbhBxx4IAAK942Sn4e4nfFAcyYWOUkiHWp2WopnpHTdjA1iWJl7UraHFXHNcWbGXSNu6MeTHj4mQAEi3ljYREZalNBJZYxlAUPmxTQOUj1GCKcQz2UoX3UjFFWnQvr5MVZWrKVp6BoCJhnSoCT0qddYfm0ZHU2NOWiheaShIZ5dGHZZnaB98ROXnxN4euahvySG6qq6wOZJkKyiqmqstL7iKibieZBnrUbOyuuvptwK7LCO+ErssZkIi+yygxjL7LPcQCvtNcpOa22z12YriLPadhugt+DiwW245MZRbbngjov/7rqwsOsuLOe+62688kqrricfEfuNYe+58WM09FJIUMD1ihSeOuxAB0e/eeS7jVBCKKXGiHNY1o+QwaET3L/QuEomkwIzWDCtKBb20MVzMIyHw9rE1BgDHtiWBsVyjJCPyhiblDFicAw5gow9NcfyyEWWLEBK/LWknpynDeWWTkv3lFdNpglgoZ9O0VTYWnCxROBWyOwcjMtlYIUCYE5BzFVTII/qwU5F2dOURj9mZGBGD7BtEpHAwBYTCSWOOkBUDBiYYVwTIEW1ow6Q0NepRJNTMmOOQdaOZJRZhtlJ/XL3QdVXrzPbBHI6dFoJjT7EgnEyh30M2QqXod2IuKl2//JVw1kdVb8DrMMRoLXpvHdhjQ15DGyT6YnVOPGNEChezGfOnMQb6cggmpF3vGZ/5Q1BJXTqOUWjkkHvCfr3IzroE9px40wM7GaDCFOXRHQ4YUO08T7ONxPU3c6/P4IdPd5wtwncjzlkE9VcwscBmA1OLDPxQJKytw2jqYhFNYIRZaBkJ2S8qHwk+hTpWqSZ9EmpRam70JbEBowEklBMZCqV9WB1hiudZnc3GwcLaOM/k0gsgIQynjEu8g0ZPYAFNryO8zYinbnEKA2w8gnkKGgNC7rpTlmRSX/GFycQLigdIyBhREy4L7U0RnDfwwgLfwGx3sGHJVlpVNpCtCu3Ef/oZixBzjpCApgPALF4fEuVGzjQug90xDweKA1Nmtib/oinJYLTiHeoWI17UTJbBLskyTKpyWdxspOy+iQojyXKUfaqlKb8FSpT+R9LshJZq3xla1wpy2HFspZSoSUueXXLXVZEl76MVS+DaRBgElNWxySWMZOZpmEys4IB41gbpPlMeWSSmojCXjVTVY/wDU5Ta0wDNrepjYvczY05q4o2a1XGbwJrViobpzjDSc5KwoFl8kTZsvgHSwHtjz90853XkDE3hehtLErxyWCYWJSHTLKes3BVQAo3HuApjihcI2hFESoYvTTNo3FxDT/l47Vv8IaEITURPMfxmQJ0JD//KVyd635nPP4V5yo281xMbfNQiNrqnqNo6Usd8ETN5e6mbpTiTRvFAM8VVaAiJcI7YHgUJzqzGCttY1byw7787W+r63BZiR7wAU911aetAupSitA/BzAwIFKMyITGWtYbMRBAI+1eYKy2okOt9GhJgulqJCWAHQLPZUuVzI1SeD20RlStgMXYEzk4Jc1MKLFNvdFk3xjV52insgUgjVWL5k/8sQR4aERGHg+bFY6aKrU9dewqJDoKisbtR3T6FKUsSxvXmim3TOxsm5ryJocoiCEpBdAyVShbaxJiaM3dxXIJG13JPfeq1a3EdLM7D+xyl5vfrZV3w9uq8ZIXPOed/6V50ztE9k5lu+6lxnrj2wr40pdn96WIffM7QP4Wc77+xQWAAxyKMRj4wAhOsIIXzOAGO/jBEI6whCccgApb+MIYzrCGN8zhDnv4wyAOsYhHTOISm/jEKE6xilfM4ha7+MUwjrGFBwCAGtv4xjjOsY53zOMe+/jHQA6ykIdM5BsLQcZITrKSl8zkJjv5yVCOspRjTOMiW/nKWM6ylrfM4yNP+ctgDrOYx0zmMpv5y1XmsprXzOY2X9nLZ46znOdM5zrb+c4pTrOb98znPrMZzngOtKAHTehCG3rFevazohfNaB8D+tCQjrSkJ01pMSc6ywQwAAAGoIBGe/rTO370lP8TMIAEhPgApiYzqi286iRjQAIDOEClZ93iASxA0AsYwKEvPeQT7KbGmd50p0ENgGAP2QAEILaVRX3hCwxBA7fOcK5TrIIQbEDErW7ytDe8altn+8IJkHUAwo3iFaTaybaWtq5nne4Ob/vbJ141uQPQbhXXW8OtnjeJt41hfc+Z10HOQAUMoOlia5rTyja2kJGt7CIz28IXuECFnS0CdacY3h7GeJL5neFsa9zfKDaBuMPM8UnfW8Mlb/G8T45kjY845eMe+b+xXIAKNGAADTC4sBsAASFEwOAEwHnPhdBpEAgBAhkgAAIQMACk3zjoA0BABwhg8wZUgEw+R7YBEBD/gSEUAAAKYPoAoP7rGhtg6D/H+gB+rvSjDz0FxRaC1OOu5odPXOIVNsEKMPDsDcB6ABLAgAaEIPEVDKHiFiZ1qUUwBApY2PBCEMEFUi0BChxAAiEYgAY2IILBD8AEATCBEDYv+CEsYPIVrnzoR7+By8N683+XwIUPMARTe9vUEpA13ynQeHIrPgEbyPXgQyCCzgsB9BXmvRB4n2sK/D74gB9ACEQ/gBXM/u8a8LwKAuDs5dN7AcKXvghiX/oBSNz1mt+A8s0fAPRvfvXSh//7LUz9ELR/9CIIP/HvH3naA77imrd83TcAzEeAfRd7q+Z/GgCAnud4FqYBMqd3qLZ+/7zXgBdWfhfwata3ApsXgAT4fbnWfM/GeIRHbgqYfwG4fxa2AH+na+t3ARTofxIgAhugePYXglIGcEBmACcAAAwXbJwGAj9ndVOHAEUHATXGaQTgdBBAAErXAAL3dTXWARXQAQBwAiBwhRDQhDrngxCQczYWAUhYAclmdmVoYwQHdjhnY2SSdAjQADeXbBFgAFRohVhId1xmd9yHd+13bnynAttmAhKHAcQ3ANuHYZe3ARsAgfBmiBBHeZYnAYqYewegAaz2fhBoAqlma6gXAJVXidfGiIG3ASFAASXHeLfWbQuwarkXAHyHAfMWbom4iAeAgwlwAZWoYeSWa7I2i/8QiIMSYGq8d30YwHey1okTZ4m2ZosXEIiDSHyXhwGk6IABwHutN4qlGI0VBooBAIGsFngVxngVN3nMiIrhuH8rAHqx1n6yl268eIGG+G4JII7cZ3u9KHuPB3q3GADQaGord48XJoiuSHyEaALguI4HYH/LuI4W9of5dgD0SI7pto8WFgKyxnHWSG4igI4mkGvXVmE4GGU66GM3NwQIoHOcJnZCUADGhgBSyGldNwQR0JJSCABqF3U1hgBI2IUMV2wVIHc3B4Y+eIZmCABBWQBDh3PGhnCZdpMn+WfrtmERR38rIAKKR4Db1oIEeHnm95F7uI24eG7bCGsXsAGd+In/qXaLGCB6GkABA2h+qvd9Z+mWRBCWqWeKUZl8+KiKrKh7AwCL4hZuU9l+zbhuEbeWmkeNMRcA2zaYB1CYFbaLedlq6ZaAmQd4IGiYkOmJRGB5kEgBnveXrVZ5g8l9dQlxfEgB+MiCjQmD+FiNRNCOt6aa38eY62aVjSePtMmYslmNrxkA1WZ5GlBtfbiYtbmbqdeZsHmI7viXCxmOV+mZkXkAu8mamtmQf2mb1RiagAmbQyB7hmeRYTaSPbaENSZwKQCECiCET1dwIJCFHaCETgdsBeeSNlaHN3YCW5ds5jmURjkAcHcCJ0mGaNiDN8ZwQYkAPZgCSllwTEmHVfh0/+QpZHo4mM6GARdgiRuAlQNwbQKZYaX4jZN4AC6XjbK3ANloaoRIjZfHjXkHeqh4eYyZjfNXnJ6Il14ZAPSoid8nb+f3lwlgfTE3i7nXmt8Ibhe5bkRai+smmbO3iamYAH8YACsgm63pkaHHhzZaeRJgfSogmpCoje1Xo9+IAeE4ABWnia1pjjqqghWWbrTpiI2poRx6bai2o7Y3m7/JjyGAAQkJevImpHD6mx9aYQV5kLdWpZmZjAGwocI5nXhqpBXZi7rWpcAJpNa3kYh3YYyHASEJZRO6YwhwhhEAAurJc0PQAMbWAUzHdEXndTQpoT6ndBkQnwVAhWvXkwYgd/8nqQA/OXZYV5MIqpRy16BJ2GnBRnZsF6pAVqEjOKPRRwGLCHjlh6aXSabP922kyHqvpnnZOASA2njwR4DjF30L0K0aEKLUt5WQOK2/2X0akKerlmsBiAHK53yy9nyt6X8fmHhJmnhCAHzb5qSsBqXFqXgSYKWa6a7V6qdhKgSw5rB3OW5CYH/rqpg2yH8LaKT8KgL8KnGDapoGCJKZB2vSOni5Z2oneJx7yqOOWpz3GrINyZ2taAIdCLG39pzQarIbaX4miH+Smnyjp2sy+Jf3+rH0yn6f+mTMumfxKZQNF7VEpoe0VptVe7VYy2Qsl7Us1rRrpgBDQJRSO7bNmpf/XPum0Xa2aru2J7a1bGtiXku2cttwVPu2dnu3eJu3eTa3fNu3Rma2ehu4gju4hDtjfnu4c1u3hbu4jNu4kha3iBu5baa4jlu5lnu5cQa5kru5W0a5mPu5oBu6Wsu5pNtoniu6qJu6qgu3pdu6fna6HOZyU9atMrdxgHu3pGimKqeYd+u2Upa7LQa84+m6xOtmdldtH8l3bPqkZmZuKrahaZuytaudgut8LkaIOSpjb8m7uji9FyaPbZu2BStl1tti5Tu8xZu+eXi7FemAuchtYilmIrdiH4qlKMe+b5sA3Itij8lkpcliMEdiLCe7Saa/LmbAlqa+Cpxleui8nihr/7b2gjY6ZuuHarQHiwF7jaOnfReGvNynjwfAd6wXwLPredaXAJ6npS2GvS4mAeKLZP+LwsBJfChMeDEXggbIegiosvhHbxY4s6b3giJsfizofUu7wtaGxNk7ZZq7wAush4wXfElcb9ZIwFFmgi7MjoooisW4jshYYSGgAqR4a/r2hyQsZSYAoyGwAAlgarmmuy62AkLKYipgif6rnBpgAms8bjCKpuH2jtgJiEo6j2haj/QGkPRnsELbeqkWosR5xCwmx3E8x+jrxJYcZFQLgYMZwdxpxVBmgqnmmHZZm/CWjrsZbri5fGccZXGpv+T2ijDmpvTrvTH2v65YfdP5pv/4um2pzKHbqL+r2ZvIeaNoC5pDILFDLARwHGOyrGLNjGaXHM0/RrWXt8ffZ6lfKrFlBspjOaKUGaUYxnjeGHMZ2qi+XGZprKO29srZ6WJ17GIbusTaq8J5PJGyls1/bJh0iqN9iKcsG5B9zIJeKpp2HKIr6Lsn9s4tptBj1sTS7LpUu6Gv6W0QC6Zmxs2RmcHfPMEP2M5/XLLnTGbld8J+ucyz7GIHgHx33HuASsNDkK9MSrLR6q4J2MMyG46vR9HRhwE924yxZ5svfNItNr9k5tAPXbqwu7prG88uNpzbTMtL3aHBK9VFfdRW/be1jAVX+QRBPWXr9wRbTQVQzWH/WnkEYX0E0VsEZ80EI/eWVBC/JAZygZbMSLDWRZDWRGDXStDWWDDWH2bUVy25Sa3UhF3YqwvYgY24g23YjN3YlovYie23i+3YlF3ZgQvZkc23k23ZnN3ZZ4vZmS23m+3ZpF3aJhfa0jzapr3arB1ooI3aUqvarT3btG1mrw3bdIu/tb3bvF1nt43bxCbbvT3cxI1kvw3cnybcxb3czL23yK3Ayt3c0j3df/3c0K3b1J3d2t221q2+0b3d4C3dx93diibbnvxktKtt2K22wstiCJy3CA1l7f28fZrA5E28x5vEt7y841tmDoxi0Gth0mtx1QvXKMbCSra9HybX3zvI/+HbcQa+ZOe7YhMOzfcN0bpt0O+LbxE+ZUSdYvVL1QQeuO+9Yv27ZLasYqsMYgPc4QW8vydW4hZ+4Uit2w7cihE8BOfn4lBWweEGpBqNfRxsYR58ASA8xJu34uhtwuOWwjGG4CyWxSiupTJcbVbp5PksgjoMsTWteQzofUAsBAsgxDpexB8IySsG5Sqm5jNO45wLxR2KotdGxR163k6GxakoibQYjcZoyBcWxmNsnLcsyGaWzhvJxm7czpPsznaM4nisx2Tcx1bJpDJnxoMckfbIjgGpyLDJyGDseI8c3yYmyS1G6vbt5m+O3ZqMd5x8zHbeZBgtyhtdyiZwyhAZnf9K7mStjK+3bNIr9swh59ctZst8J6Qrt8u3ieuDXJ3C/Jtx2erKvGp07esuBuwnZu0iieqkS82YF222hs0W/dQ2uqSzHr/iHJiPuc+53mSGvs4l/WIMvWJM7b/0LHpkfM9AGtPcp+5SfaeFzKM3HXoBDe5+WtCKiebU1ugrFu/jOWEO//BJ4GESPWOrWNHaTGYYTbGl5umkDNeDp7sfHa3rzmQjvZiw7GIfbuIq7egs3X4uLQQwvW0oOtMo2+UL+M8WVq6DV/E73dNmfqKiTmIpr2JDD2YDdkrhHWjzzmJOjfHCnrVL/7wibmmR890iawV6nQRdTb5SkPVO8PQYVtb/RuD19VbWZG8EfH0FPO5hDH5ndG3WTIDXtScFaW8FYL9hR09aSb/3fP/XVb/efR/42j1MNCMJ7+E+wQL4gr/4ze0q9qErCQNXgcQN8YD4bOAw/2L54aD4jN/5w+34DOEZaxQRkn8Jh79OdJBPgWD1nt/6jQ36udE1agE3RGAB8TEqbIEOeoM2DPEA/OH7OdEYF3UGSUMgBaUWFWU3DQRQhgQfHsAP6vE5/SEOrjU1KOA4QtA6C8P5rt/9q+34QyBBNsQBOOQhGbJTQkI4hCI7K2I8aDEOtv9UaiAmSWUXvmMXMiNU1AFYBQEEHI/g4RAIBoxSSUAaMRyWCWr0cQyP/1ntVjsYBMBh8ZhcNp/RafWa3Xa/4XH5nF633/F5/Z4fHnABHziOHAaijhgskBgEGP4EHB4+vLwUs4oEJgYmPjwoJzAdj4o4KAcGj1BKvQaTGjddHTUZNU0nIgsURR1GKomMFi0+Rq0ejoQnSgY8hgGdvfqipaepq62vsbO1t/kenS9ReUkGSARKjAcKXlEgH5zKuTA1JyxYBAo2Qx+Lrti3Jtl5aMWIhSJXBRcdqaJFkwUjstIJQPjA3qIlTZJEOtYMkqVvW6BxEzmSZEmTJ1GmFOnt4wNKwiB58VBuFQlPDo0VYqVF3iadFvI93GdEmReOEzwNsNCqEqOXThk1Av+q9AiHEexEuVSqaNKASQyQerGnUYAwnV4/cgmpkm1bt2/hxpVLh2Vau3fx5tW7l29fvmvnBhY8mHBhw3bq+lW8mHFjx3sBH5Y8mXJlyyUTP9a8mXPntJEvhxY9mnRpNJk9p1a92i/oOAcSpMQgYcABawu+mF6zIQSGPAko6E4zYAFK3r7vHMfMmnlz559zl1ERYgMYDANEECcDO+WK2HQ2aAcjAbbtMbiFq6Hw/Q4G6tQumAqeJoF5M+gDcI8jXoz+bOvzABCzAggs0MADEUxQwQUZbNDBByGMUMIJDXQtjBDmO0CDM/wzyQT75jDhAjBwq64M/NI7A7g8DhgRPhf/8UBxDv7C6PCaFfHAkSTUnnNMnR6BPMJCMLwbzzbiKKBkRBtHStKL8gbAIAEvEtjgANoG0EADL1QQY7rqLjAhgPqu80KDDWQsCYMtB1hhTDZhzMM9E++QoLgXxUhgw+lE0NOLEevDDTcns9wAS/JiO8BMEQLI0ov5rGMTSSXLHOCCBbAMTlA+5sSj0+WC5OzHUJ8bMoDs0HyPvyStZM+k+vKzM9YNNtDggCsxuM62C1wNIAQVeCsOVusGUCFNkkwQU4QQFkggNtyQy2MFN/FQYcNq4qMkOA1MYHZMZbELtDYxrjM2N9iyY5TXRm27UgwTvlt1gFbBwDCA6QLYdI9p/6WlFlRSHxsVYOZMDcDWC1xEUlIMmBwJVv0QBqNF/bSzcQUTKJAAjPr61PbYkSSYDzhYr4sWjxAYxeNDayImt82NzRtgvQPw6/hR/GDLmESNtdM5jJDBUJgShmOr1AuT90A5D6VN4nHgvQR+WrWCr/S2UUzdVCHKhkV6+LsraSWP4uJszM5WmC/YMDwKPhYp2VOJIzlKPazNIzw6p2k5DG61g1VrKWnOLe0A1i4xvwTSDQDeqwPwGYy3s8P63q2vtTcMffOou9prm5a6sag976zg8DQOegFFB6CN6JS8DmPKAaoc+3AytkQu0BBSl7ltbtb0wk25ka5jZTwOEJNl+f8SEPMAlF8fV1wScaeNglpT5w51DRjtuXQwRKBty9O9UH1ZSzENP18a7xg+fRB3DH0x0PVyJQv53UciuhTx1+buPDTo8qRh8yeG/SVnXiipSy1MEZW+rIISxugM/ByBiggCgn4JCcQmRoHB5hQsDtkyxQdBGMLmhZCEdyoJoUgowhSu8IPsWwOWUjjCEv7sgzJk4ZPC4MEbxpAOAByM0UhoQxCaEIZU2mELc3jEFbrQDaghi2MqKCpAOGIA7CgFKkCiQAvGYwD2qMUEnMPBAI6RjGU0YxOdoRFHOOIDRfEAO9zIjgc4MIuqgeAAikAFgcRkGeVIQli8wIg5bmGOV2H/gUvAuMH7nZGRjXSkI51oDEcYoR8C8IADKnlJItCxC1qUIhfY6BAOCGIcNEGHEhzoikHyZJQfqIIGCbbIR86SlrUkTSRfURVTcICBp/hIFDdzR3qQQxAfsEQigtEMYI6CA5MogSzCKEtbTpOa1ZwLLkUBiTdmoZKX4OT8PBnMKfrEGKQkhzlOeZFxCPKbghDAE6CpSGvOk571NGAaJemNoqBln8NYZR1TI0xw8HEmiyABUDzBTkJiMZ6xtOdDIRrRaTitfh+BX0UbI0aJbpSjHR0DRTEKiIuGVDEa9ehJUVpPkJJUCyNl6V+kmVKZznSeK33pPW4KxZjSlKc9hWRO/+3iUqDexaQ+NepRS5MZEmjlFP54jCooUQJ4KOaiNqkEMLTwRECgYJ8VIVVRkRpWsUomMVRgQiM8kMjHPCCtmSgBR/wCvwmMIBxnzeo3t+CBbTIAC1/d6VgBG1jDJOYQhIzEUijxARRoZQQSoYQfsYoRtfoIEFf4ByU4gMBWRHYcTn0aWM3ANd7Rhol82B3+lJMjSJERfSNJrR1euxIujFJIXgBFW7MgBEc4NSLzi+wkMoiW91UWi5dFwRMNoQVkhm5IXyJW5LbTK5IUCTz8QZQLT5siAbXnPXmTjxp8SAacSZcNrRWtNLZrh/TKdguFzURQCNELqrBgACOgJFA44P/ZLIxDrTAZLhfce4ROfEKrW+Avc/9qOQ1xiLxuK60bRESiAp7orynSkR1ahK042SG7azBvg6dx4TqImBuJmesD2MHfnqgDIUc4sEKGkVwt6BUeC/nvFuZ6VgeUoB738ElfZZwFvYKRrwMzFXXJczVCLQnE2iAUlKREJSthSUtc8tJ7wjSmA1TqTB3GRu9e5idLcaq7dTKhNPT2pnsxD05aFpTMKHGmQ1lvUY1i02rBPKk/VepSmTrfmT1V5jp8qn1cWCpmFwsMrVjAAlRsqny3GeRUMFCqjLkoX2WCyUpswgm+lHQmGOvVUJkKVQtQlQlZdV5tPExWYKvVrSSQq3H/rUsMvwqWlsNQLi9fA3LMctb5glcHfm3ueNoyWLeEBa4+BQ5Euj4X4rATgHWNy11hWBzjwJDq79gLX5jr17c7N9RvCFXcv6zwwRK2AAosTNXZaJ20XTSxeJGtVxfzGceax7YKZwNoY5pZAEqWtJStj2Ubvg61hiWz550q3+P1GaYY57gA9FtoR+MOEIN9soHbgWn/KvcWyP1xCla4ancijgSytrUmr7pdX5NA2G4179mJwWzmqc/gCrdvbEAubrYJeOY4B9sJ40kMfBOWbf62cJzrroDoivbitPcucEnubwv21Wq9fQfNaT3ohRZ5S78OmQqTzg/gy93qUPLuMUlZ/3ZMqh3MTJ07fcuGTb/z+dzyoD4MGw9byFMe8yhhm4XHXXrUQ1R+6hz1MHTPUWYXH+76bL6s20HvwnuwNmz60pCHfX46F2xhBniH/qX98sIJfR1O7/XNLDOgnM8LaNWgQyXWcPZeALRIUHhEIda+9GUoogpZSETa8z6JtQfhyunT+7YAEfgrFL4pdr/E4hvfFMo/Q2JYcFYPaD+ynwnnETSJguSKf6p8kaspRM2XqQygBJMtlec/H3/5nyQxBWgsFe5/TrywPvv3GAET7O/GGAKD+Mqu1G8YQMEC9Eue5q8BHZAtyoocCqAEZiIAf6Ic4giQXKEQQK6xWIAXJMIAzf8PEObBxaqIAXphIRKBEoSk+/zrnTZv9eDvAWmwBrsBEErAAT5wB6VqBMoh+zJpx1KJEThwC3xwJpCw+6CGBGEpCexLAFyJCuwhmz7tBTEBSGDPBrVwC98gM3asAimwALqiEnqJA/yL9cwBBD+wigQwC0oQI14MFoiMR15wBGJQM7KQC/VwD8tAqUbg/noBBd6Bm7bpCNRpAwnr//yvr+KKCYlsj56QF6iAkh6hChHwATyiR/KQDzlxD1FDES0JC85iEPrpoJYBEQ1t/LrI0piQEoABBetrGLoCKFpwC9avBBaQATtxF3nxNFzvCO4wjTIRozaxF41x/jKPpYIxq7z/4AleqhiPMRoDKxlJahlFjvqwMRu1cRu5sRu98RvBMRzFcRzJsRzN8Rxv6BdxSh2hAwDc8R3hMR7lcR7psR7t8R7xMR/1cR/5sR/98R8BMiAFciDpcQAI8iARMiEVciEJkho9o8CWsDEgsi+uUAYZ8iIxMiM1ciM5siP50SA9MiRFciQbEpSegjkm8hWawhmqKikcIi1Sci8q8iPOov3akSRxMid1cid58iN78ieBkiMTA5pYgBFTIyWJ0iizQK7oihBEEMDwiiKVkAsKohxA4fu6ACSDciu5siu9sh+18ivFcizrcSgx6CIYaBhW0AvITwvscC2H4QL5CI9eQYug/+kiRKqyjBKQvCgpctAYjIkBigAT+VIA0lIqvCASkgIV/kkhosYrlmLkyHIyKbMySTIsLTMzt9IsveABJksI3mkK/+CS6OEDnOCdhsH+BjH71qkd6lK5Gsj9lpK4tkCdnuAcuEkS2oqtwMg2FQg0n3AU8gmMGhMJ3I/9vsELNHM5mbM5/REznTM6Q9IsOWEEwIgXKqEERSH7OCAXdgyBjMIUhMESkHITXEk2gbGyhtG/JOEFsfNHrpA9rUC+pACWegI9UROgJFM6+bM/mRM6/TNAFZI6JWImIgIhIvEPnEARSuAJbawJfHC/zgk31wg2wagoc5EpdWwJmGCdcJMQmP9BlYDhECeBxRQhOH/hvYjzmwqCFh6gQp8BQAV0Rml0J2W0RnH0I00ykeZo0bhi0xTCCPCByKZCEUbRMGUin+xSg4ozPacoKUgzKfrSC/4SCr3iCgvTRxtBviLBCEqwSRkos9BQOYOSAAwAHhXgRnN0TTcTRwdAATiSACJAIeU0Ix0yq4YxVKzx48iUHg2AEgigI80UTdWUTQ2VJ9UUH7wAAQJ1Hg2gUTcTTjcSASQVISnVTvtCJ5zxafa03PrUUec0TTsgTs/0HdP0UFGVKxMVAdyRACoAUuHxUbvyTTdSAVg1IW1VI++0ojpV3D5VHg1gTgGgAgrgUQ0AARoAArz/YE4JAAEqYAAgIAMagBKiNU3TtAAIYFFHNVu9oFTdMU2VFQE6oAAqIAMAgAAg4FwLNVXZ9SBX9R3RFQAigBIIhF5t1QsKgFDDdVTTAQEi4F7TAQCgFV/llV4BwFiRVVkHYE6TlRLgNFsxMgJglSAlVlfVsVeH6lfjMVgBAB8awAAgoAEAAAQYtgI6oFkzIAMY9R2nNQXSNFA7wGQB4ARAoANodVBNdQBGFQRAAAAQIF9/Vl3bdWgx8l2/NSwjIF1ldVjzNQUqgFB3tmcHoGeZFgCcVmAD1VXhMWkPNmRHtmQ7AARK9WbX9R8zYADMFSHPNm2L9mLZ8Sb91GCXFgFM/wFbSzVYO+BP8fVUO9YUfvZWcfZoW5VVzTQFbpVoEZchjfZc09VVF/VgA3VaTUFkBfdcWZVWJZcSphVO07QBHHcAWHVu6zZoBbZSL5IAqBYhUXcjzVKCPC2cZnIxqEIAqCBPWbIVxeIuYjIeHCCb8IKBPAAr99NPhdUdl5Zk4XFQG4BYufZsC4BvY3ZU3dFmd9ZbAYBvIWBOM6ACIKBRITZxwXcgjdZVC6BlZzZ0T8AdiXUesXdOabVq35FWTwBZByAFzhdy3RF535FnAcBmH7Zs/REC7DchBZh1TZINr+gbYrekImISbDcvuUA7t88udnec9IKXdKn8zM0eOfYdl/+2Yb3AcymhZxXgWen2ebWSWxe2YKHVetPUC7x2Zsu1VQE4fG1YHhOVEkhXbxGAVRX1eekWdAkVhkX2fQH2chcVTnk4dBsVhAegATqAbpX1fxkyZhXSig14Cxwhj0Zgj5KArfzvLIzJS4OCMBezFrtgkDyAMHsMQyEYxzSos15yHlwpMTErCxwBKP4vd4ugSAGJMb8Jgw2RBfK4vooi/TQWIAN3I5f2hh35H2tYIPk2H99XLE8gfRPykoXSJMd4lAbCkhpUkIBhjvOhrUpgEOYKskCCF7xTEXJMCm43gpswEcgYFLyqwCrUAgDzD4ogm045EyK0OAW5HXJ5l0Eiku3/cZEzMgXQ9pGdGSw7cpLxsZIZMnNnL4gpwVutWYmwuVtZthsn1h2pEyiW6pM1oSLis5bj0xTgqgs+oBQwyRJKdNwc0QRRgJQnANPcAZeHIpd6+RHWT7hmC4tKgJD72Xdr65kVOkeReaEtkzo1wp1cYftUCZ0HoRBAYUSLCwm6zyuc4Lhc+f9g+Y0H8BEHwZ0wOgtO2bJgcxSE4hd2yxw2WphRoRTy+aDrIpEdeqebs6F5miwJlJkW4QGYQBy64gOoyBMy+gg0EIw+TaCjgB6IohBBDndlLKnzoRJIoNMYCqd/AQVuoqk3aQuAtxyySR+O+afV2jl9eq29clfrB2OB/0qn3bqu39qupROu3Ueuc4qu8fqve7KtATuw3fZtk1OwBzuxFVexNVOvQ4evb8qvGXuyWZeyK9OxPQeynxGxLbuzodmzxxKzpUazWQodTfu0UTu1VXu1Wbu1Xfu1YTu2Zfsc23ShORu0C5JGb/uyJ3O3gdq3ERK4Z1S4cVucdRtVifsik3tWlzsgm5s/n7uzozsnpzsoq7shDVWyR/K6/7O4F5K7RRK8EbW3s1u8p9mhzRuw01sokZu82VS7wxu9vXtAj/tQ1/uz1xS+p1O+5zu46zu73Tu/7zu3bVutlXm7E/LAVVe/BxzBgbq8a7sfrflwc7YfpTmwBbIAghgCTP/3IBV8YxuVmhPcej+8aPXRadN2WqUXXq03Ic+2w+2xweP7wd9bxuPRp6eVctkXmS98vAGSmfNVXsN5IEvcg4ecTkm8xStbH9eXceWxyAPSZn3SvgOcoW0cHnH8iXPWfrM3iCn1TdOBWqVVYUHAy7FcYfN1XgkWdJcVhvMXhtl2yv8RBDCZZRU2fUF2WQEAhEEAhJm1h6HVZpcVYdU8HRQ1zBUAhNO3WaU4zr28A8B1AGRWhbU5m2k1Tc8WzdUVdFf8OffxBEqVURX9XA1gczs2dIP4WCVdZEEAzpMXhqNYzym5vWlcwCOcHyfcaitAbK8XJF8WHluW1ysXy7OWwrn/dgACNQKQdXPR1Vy7F5ID0gCCfH97NmYVwADOtHOF/Wv33GSbtQG2126NN4bdkWuX9k3519q/PdznEQFOwFoPNgL8l9STt1QjYE7vHWvP1WRllmadex9tNgNKOAPSvQIUwExNXcMP9kzxAU4ZtdkB4NmnV2fl1QB6PMZpPbQh3Lr/McfjcV7NlW+hV2/7ddp7nFYV/nMv92HHVgEKfYU9HSD19x13uFgj94lJ12frFmd/FmeXVuXxt3RrnuenPQMK/V9B8t4Vnt5Z/FsrwOMvPcx1+N/3sXvzfehLHeWZuNeNV05NoXiX3lYvviwzXiyvnHXP3rj90ePf0XCxvddD/z7p09V5tx3TbxxONdx857d0mf5NIZ7q/5GZG1Vi0/1NZTXHt33mmb7n0xV/9R59xVkBCv/gQ33a8cHZkb7c5Z3it93Jx51q5VdcZVZ8+bFZDX5kq93vzzRgjxV/+fZR/x4eqXdkLT6S037JNb7Gb30fJ1xUVTYCMiBcRd6E04HPg1+I4xfvQ3dRV77v4bTVCTbmFflZB8DiR/3wn5jPndhzKz9mF3Zpl7hvEX3Uid7OFzXz5RXfYdh6vX9OmVlSdfh/ZR3a9/Fsb5X8z5RbIWDrXx8ICADQoFgAIAGEIqSjGCSj0ih0ar1is9otF1vtgsPcr7hsPluL6LWX7X7Dp//kOL1uVxqSA4V9fv9n+QEOjhG+CRomUiEqyjU+HkJKEjZUpOjx1TFOwm1y/nl+UokqqpGOnqY6qrK2IoW6FsbewZLWzoKZqt7iAvL2AkcGl/0OtwUXG0vppno+ARgItRLkIT3HJf897Q1GK+vdbWfeUV9lf4Mjo58xnzpDedPFn5VHX4vdo6ZCSGfNmxk4YiYfl3JszmXht4UbvQjm1qFBWAoiMYmatDz790ajGIMACHYBCcBinArjsHAME0FgGZFZPEa8Y3LhSTEFHKahaIYkIZ7A2tmS0qDIAAgZMgpZMgCBkz0DCigdkEcBAiMjIRgpQJRlA6wDTuBZ0iBJ1Dz/9qBEqIbgCJGiGQggqGq06tJlbAzQxTugQoOhTI4W3dtBK5IIhosgiLD1I92oWvkUQACNGgKqVqPhRdLBK4golp8+uQQhAl0E1JZoLeKwa5G2A3CyI0sXgtdLpZtirTC4imHFS30/VULUwHC1BZ48KdDW6OkBYze3TqczjE9f03NVd4NoaAqkHXQDOAHiiZAOAy6Vq3AkRYWRSSVrBNH5uwK4J83zqUfgWVokawkYBQA/cDWQgXoiSWRAHo8BYFoS3CEHzUq8OcRQYRAAUEE/3gwFGXwQjKUeAOxBAyJZGE4hIonsgTBVFfZFoVUGLZJVzRpfEDiUEP0lgcAJERow/2FhFZ4UQRMWcsPjWuQpEeCAlZ24ynVdZEfLlGNUeaMUHRBnBFKpIXZNZEhQ4xdRHQIwpkZrIREQTGlKhsdk/BkH3GsGLSlIgkJcEw2XW11jGGEAGDZSfhUgNtRYbQqBppqNElVEA/80QAQEXEXqHKEDZPDRi9UU4JVzbJJpY0ylvpKfARkAF0GgQhJKpBKILjUmJoQaF2ikEcBUaVEsZTlLsHQMywpQosxhJAAZgAYPAd91kMQ15kVLo4i3qglWFPIBgN+b1A5h1n5QwPWRegB2imqDx3Eq5Rne9EmAssyyO+QTfY1mKHfhSaZhEgZoG1xm8VzLqBXlJlHwiAgo6P9pp3iClYJzNJKJopbqckONjAK6SuG9XRG57wlMIYmeZAoc+GKA6kqB8EhXUjlMsbvMLMYcKC/V7GTCqXaPbwwzhpihcKZpFRKsfSWnFL5BIO4zDcglomtQGZcBVnFK9y6fVdiDaFX1xgrNXvly02Vc5hZBQGpQMQGfNJ+5HYVjnpX2RAcZJGb1UgYpVRW+rX332sVKZ2wA0om9KnYFZPNhtmRRdeAb1EWlnMTUMM39Csyy/LR5IDVTZwcIsE0HuuecmP5I6kGpc3oaqy8UR5cmTgm76xO5bjvqMt8uh+7H9H5Q8Kf/PkjxkBwf8/CvJG/X8qc+X/vtzePe+fPHfiL/yAkrR//QG9unC0xAf0B9CVmkx5Z79y+3vjz2uwvFFxKRMVGT+29UsiizWDNkqxTbpC0JWFlUPBQ1BWZFS2IJbA8AKsGedA0lWnIjSmeIA6n62IhNKAsflIQHiJQEwn42gwOYBCcFEHpBhOmznvuol7XCaEtiAuHV+tjHhghoq0kzGRrRpnCvWVljcdIooKamoJAT+Es8ZHLItQA0hXJBjTLO6ZBHSHUpa2BtcHdAoTlUmAsSZnEKXEyDF4nBu+tt4gTBscI13rTCHpkPBDkM4l6OoBepVEV+OXsNExroFbDARS7hK5FqilbIO+pFfn2TIB1FhJkwkgQB5muQvHDS/78wWkNTSiQUCGxFxEVJQYn86IxCGsSHE6ilH7JBwuiCpCAqZlAgm6ShdtiwnAwYAEPsccxTEnMbnknlTNBjg/9KNCINbeWRvyyLMGvZvuG9z0ANY2N2/FDE8UXBXwWoAC4XxA0HDWBHCOjLHrhFHwIZiCXQcBEoZdQwBpkGWuHpTMKEsE1c0k4fN1rUE47CTR4WU1q7yoCBUmCgxknDgFP4joEaOoAEosg8/hwkmSTznQIEiTx7qKJAMLqsdjmTHk4SAgRAMJN4DICePToBfm6lxTWU0CElPekQ89kgliKpjCN8ZvDet00DBtItpSnHZ6DwGTt6BX2aW8aiRhcFhf86B15cE0LhUkUqNxknChxyTqjOJFVGlRBrUJ2UKl/IjkXZ6QgMcaIPNYW3E8R0Z90CaYoIQEq2gqAf/CjUE4nikCANoQgYTJj5PGrXTqzBTqtJmly5wSq/FtNCb4RpGIeirXh447GqiaxOQ8fT3r0PYDtDZ+XkVAGwPENF7WnYD50XBUkiQWLS4JW/CMDNr+6sqoYy50az+i9IQS1iUd0ao+RZ11nhsqxLZQNsC1oxAeXBag6xbfh+iDdqaKufIxsLaeZaE5MKAYlgYVb44DITf63yX4vdg8QgU0RRTtKDIh1kScsWMPd2ajQtfUV8dwJGKdS3cZe1Z7v0WzJsnLH/hVcwU13wBLYyaepemSJrA4uoTxiShVYGUADOHEnc3KoqVUgDpG8Npqi+DddTBosK6TpsR+XaMLFg2eaDHgodqXQqr56JFAjA5R8C4JIJ0XLjEhJ4HiWo9KMW/Wd624QTxZyyCAW71HcQvIapGaAztt3NU7hxuOkSJXKSGiZMd5XlWXEZo43ySmKAKWYLv1RY0cMeWwvq4H6aNilQUNhWQWnW/NXQe2wANBca+gYIdBYJEOhvEk4A44Fw8wRzlK/nXGgISwMPmohwUGHyWrWrlSM1VQlaXfrsrkZzL9BmPQP4VC0U2F5Efd3DtKA1TQ5Mcs7VWqC1rmMn6zkn2NZx/1DKDnfa60Ac+xu8Dun1gt3TKrlReZ8wkJ//wFZpL4yRyf5E+S5MCJjcw3D/MppnDTG5R1/a2biINpWgbapyb+FPqqHoGTy6BnafEN3ugjVdpMKzVAPCjV3dGxYkplQsKLTQdWHeUkS4P3OEyVzhK8YYsQBuKIgHAtsDJgPhPQhUbsElzA4DqQ5mKqtZzb9PjRSu/+cJlCb6ie9O1ULcPVksGIieCrApGrBpiBS0PCfzs1jJwaXxRLyJSUqzgoKYvIWEbwFAOwyObQ8GgWJT4QhVFxCwylDxK1x8fv7muBkToWOMBCsbJZd5FFJwArervMbVvou+CzJzHn4O7HFxy/+gCrVHpikBAYgK0C2bU+1auOxBSSWk4JRUgBt3phKdUmMROmBetyBtNZwhKl0KEOS9IAGB0sZhj5jQALZiTvCYX/wjkQaCzDM+AmaCjVOf/lBSuQbGCnWQc6dgGr4Gxzxz/z1OIBd8Tar0F2BiW1G0DRytD4fUGAfBaFDUJXVi+4mzqc2mrBKY4DhoKGAyk1FcXxrHG77w0YCza8VQ8hHPnsEL93jCQ8OxJ1ytKWEJZla2socRB54gTVAR5MFtAIevuMUyIAJpFUDfVYg4kVN9IABBmQa6CAgBwMipYQGPnIlTVQKXsBP6WUx4BMwkwQUF2tVq6AbFmNZ6mARd+Uf/zH2Bz4VeSfFNFp3gdXmgbuTSWLDgDoKgp5zeuznINrScE5UDgciVUBTRmARUJk3USBxBd7ncRO2XFBJKnNhbjHWBN4ALjyzNkYSYv4Tb3MXdwYyTjuBKFChLOAUeJVUYhdVYCrBgoBgHjFjgk+iU2rGEOZkETOQBwGUfg0kGi7hItYwHuXTQhTSWAvihBBZIwbQUTPjI0ORhWdGZcTigJVZDbzmZYrEb4onVqESKmsWh4/nKFYFH4L3GW1RDkPRbL7EEhEVKA6gRepmStNFgqaCeqRgELJZiPJRcLJriib1b7fWQ79UiX6WEQh3UFU1BWo0EYmhbYZRiZFHj/NgI/8XZU5xQhdzQylrECYSNhciRWct0YojZltBww5iEX4rJmywKVGHcYTWA4t21H8mxxFVRjTVGSsxdGNRtSqe0UWWQSzWsY6lJwx7wo4Mlga1Qg2YJTpLsigKCXa5MEeMQzmBVAlRwTyh2QSWsylxVCun0WbmgzCxK0ggiwbnkQUciY7jUSIZgH0l+VDUCD+l9xKpYzbM8lIDMUTnApElKww8SZRxeW2wxVrlcIZ5Bg6NN4HXJpNydCAPhYu850RpdIVaKoR5g3yZxIReIFriwoMiQTLXkQW1VySYYROGY5dCoCZhR2Lw8RR22C0q6ZMWUFz56WxeUHG/Vh8WkAAEM5v9kQR3QsVYVjMYzCOWRjcxTpgpgOqRm/GSLbAzZoIcgMs9F+ocdjY2stGV9UBArbQVIdkE8RkAGIE2KKcrkXB3z1aU0GMhfREXkicrfpBTnhYlfxVbQSUmoHI1XjKRSpFpt+pFXJRRnrCaFKUrgkM7AOQhMRIBK3RObCQHWMdiquCFDPWTHRdAawQSNHc1DGR/2QWNYbsHaEKe2OU73NY0hYUUfvEQ6ykl7tuPJMEGK4czXuJ7ejFPU9CNpGgG+rRoXxCIAOmd4dABLGSbL2Q3edIzpMeYrIoZkrM3//ZHSrB3TGA6bOYTkTI1FGgsnkBdn1sHXLVeDMJoWEKghIBr/GERDCvBlEE1e3QEYQF7BBhXodSyblXwW2q3D+0zCsrVoGSSlr/UmTs7nN3zd0U1Ct+1o6axPj/ZlFpijsGAalbLOtv2o9Myauk1PlnJprY2pnP1as3Up8YhpmeYjm7aClt5cT4Fp7qypm6aonY7omd5PmlZandopnI4poJYdsPHp5gipJAjqkOJpLCSqx0HTnKpppkjqpFJqpVrqpWJqpmrqpnJqp3rqp4JqqIrqqJJqqZrqqaJqqqrqqrJqq7rqq1Lqmy4qes5q9kzPlEJqn8rqojbqsfVq9j1qocLMoSLPrP6qrh0rkqIpCwnbLhhrreYp8eCqsF4JsarOs0Jr/zPc6pdSa+34qZsmq6qFK7JxK7M+267i6bjWkLqSabCaK2h9K5uya7lW2rS+a5ii659mq7bqqbv2wrzWXL6C6766w7YS6r3SqcDKK8Fuab3SKy4A7K7Fa5lG7J5K68OaqYJFq74yrK32q5x2K49ObKB2rMde7MH+65yRBMiN3MKWrKJ+LGjlqqFaBAEKQ7q+LMye7LKmLBq9QZHm2sDmbLHGrMH2rMayAdAqq9AObSNUbJTuLMSq7M/O6BfxatNea9FqrbP6rBso7a5hK9YmwtPeqb9KbdfeSDOdI8WKbfU4LMqeLdLyK862bbpt7dsebbPOLcfWrfEYrcXm7bluLP/T9i0o/K3ZZqzeFuzVFq513K2hzuywjiyXkq3MPu6wRm61Tu62Ve7hVqu9Bi68KizbNq7hXu7nhmzpbG6yde7pKhvoxq3iNizhli6xeK7lIqyaji7J1q58ui6PZq637i7l9q7vRi3iMurUDq7LFq+VHS/I5q6uLi/pNi9i/a6Upq5OWKvThm31tizqwm3iCi7X0q33fq+Xhm/yohGssm/7uu/7wm/8yu/80m/92u/94m+rDi/nmu/N4i3gxu747i3t9u8ZQi7Gqq/cLm75FnCcoi/PBrDoTi/vNrADAy8Cu0LrLsL+sm4Fr+0DA7D4SjD58q0HG9v/Im8GKy8JE7D/CQct5mIwB0uuDPeaBqMw+EKwCOPrBBOvC5/wAaevCqPtADOvDwMrDodwAssusnSvES8tDAcxDQsvD/OvEx8xCKewFIusFourFV/xBUcxFdMsG9zYwf1wEXtxpgFxDiuxAJtBAYCFj31wD6cxuT4v7obuDruB6MUZ9dZxuyJxFovxDG/EpBkwGv9xmwYy9OZxwrKBdPlvCydy2S4yHkewHp9BSlovA09ylYIxGwuxApeBYlGaJE9y5dqwJw+y5nJxoKUyFN+wJeuwI7MwIncyrX5yEofyEptsCd8yJWMxI18yLROxH/8yLmNvGNcyJi+wL/8yKsPuLOvuKiPrMauy//ZGcxuPcDFTsDVDcwxT8xaHcxdbMzDnsiAvMzE3sykn8jcrMzdPczrTsTffbj2Ps/aurq+WszknMyi3MkVsr9uy8x+7sz/fM0Dncw3vMzJjMzjLs/Q+dAfvc0Hr8j9DRECPbRM/sz3fsUUHaf6CdEiL9EiTdEmb9EmjdEqTqke/cxpTNDrDM0THtESX80sLszTL9DrbcifbtCxrMzPP7k6fMkfHMksrW0JX80QT9RoPczzPtD4r9fU2dPSO8UFnM08vNSw3dU4HtTFvtFQDdPCKc0RDdU1ndSUbtTJgtN1y8ld3NFhnrSgzMeOaNVwHqVirblrDtEufdTDvsht3df83H3NP9zX8yHUvD3QdE7ZdC/Q2D0T0lbJQt3Nh9/NWV7UbOFBke/UtL/ZbkzUrv4HwabZgu3VRM3ZGDzEaVIWNPvFmY/VpqzVe4zMc4E1NnrFrDzVsGwOgvvJaR2Oj4KIFV3Fde7Zpf/YUowH9pNT5zvNgU/ZUN7JT6zRuT7Zuy7bO8rJhOzNnP3dYZy9C6/VNc7d1fzeirvBTK3RUFzdT4/Rlo3dSE7dxy/d0q3NgN3dps7d4/7Vj2/dw0zN5U/V7j7WAk3N857dP7zdQz3Vbj/d6a3V7E/Jxu9oro3Vl73V/uzd933eDz/eD/3R9L/h2v7aDV7iE57VVO7Rid/f/RV/3RSP1hC90Z3d4iD+bStv4jeN4juv4jvN4j8tveCN4bpO4XwP5T7x4gf/3kJ/zh0s3hpd1ks84kaM4Ovi239I1lB/4inNvajt5ehu4hwf5lB91kQN48cp4lou5Wh+5K8e4llN5i380mSu5D585mMs5lt45mhO0m79uecd5ml+4Fdd5iRP4bAO6fgt5lC95goM4Ykv2npe5ZRc6eB96mEP6nEO3pIO2ibO5eiu6hTM5V5sB1FTtC1P3pX96pkP4pqOB3pR6a5M2h+t5qhPtYYfBaIDhHPu3c0f6qnc5cr9LHuS6cNM0ltt5r9sul4eB/L26HYt4os96tP/6gCdW/7M7e2LzNbIzep5nME8M+yGfuoprO7cnu61jN7Z78aBLOadTOrtfNbQfO6bXenaf+6OLu7yzuJ9T+Zqva5uPe6Vbubmb95XzOr7ftb6POcD/e92q+6KTu7Hw+7tXt8G/OcKr+cM7/MTTer4HOKtr+K7jd7xv/JYL/Lyju6DzeWxb/G5HfIpnO8X3eccD+8cXe8GPfMXLPLVPO5LbvLQTOs1H+KRLPKr7/LoL/Uf7eNIr/dIzfdM7/dO/L8aD+ojffMxHt6g7eri/fNWrfM6fuLu7fLqn/G7D+b5LvarLusgXvXYDNo3b+9av/dSfvS20fEuL/cIffVzT+8AzONXHPf/abzvWs/3b3z3Md/3VZ/jOd/qX/7zaK367571BE73jN77bK3jWx7rfU77RA73HP/7Q3zvXk/3Ky0zdS37o/713e72hg73dozzed/7n/3nrnz7cb37G0/7FrwGDsfa1E/7rG/7orz7kjzr76XrNh3zlc77sm/3uj+Zob7jmKz/uR77uu8F39L4a/74TN7zcKzzE+gSKar/WF77olz3J733UxTHWgXvmw/v0e3/uszwbfIYhD+qza3zqczziBz0QAIRDYtF4RCaHA2XT+YRGpU/m1HrFZrXbaJX7BQO8YTJ5XA6f0WvrQM2GvuFztJx+x+eFdn29/y/iA0QSHKwr7EP/NFzcY3R87IIsU5TUoly8rJxy08zUpPP8FF0LHSUqNVVC1VtNDWyddGWEla2lst3E5aIF1c3irOT1jRsu/hIONr5CZmMeBZZ0VjaSnjatnrWWwk7TpuJu824WJ08CHzyPrk13hIZkL4YvB5TPq8dcnye8V9Xv9tfHrxdAavkILhFI6OCWhAtjBXS4xOBCd48auroY8Zi/jPYmHqzYTuOykdY6Pox4sp9DNy1dvoQZU+ZMmjVt3sSZU+dOnj19/gQaVOhQokWNHkWaVOlSpk1ViimZK6qxp2CqwrlakOXTrO+mUuU4suuplFy/Ejvra+wvsR8JhsyWtslauYHCaqQL/3Vrp7or+8rKGw6vW4Bw8f09Eriv4m1tAZfli1ir5Gt3UxLmaJYy2c3PLLPEHFBzZ72kI89jzDA06tGdU6d9fWvw473JTMf+inuuY4yQbZPWHTW4Od6phsdpvfn4bNTFK9dWd9v0p+WTQdOmmJxy9evNmRv3rUUBBMONpU//XY67k7zrzbVqMCCC1enu336muFp9qxMG/gFHLz1y7CMOO5BaMaACNyBoQLXzArQIP5D0G7AVEAgQAoL5LKkPQq8g+u657LYgAIIMAIDgBAcB9FAkEC8z8C1YQHDDgBM5fLBFQwgkUKEYC9NOsh5fVM85z6D7kEUdd5Twvh8zO821Jf8P8w7G3pCMMMcpE2myMArFKQ+dDrekp0szBQQySuXILJPI/J4UTc3t2PyDRyNFGfKUIBHLs0g3J4STNTmFpJPLP528ckQ0CS3Uo0O9DHS/Qfls1NEquwMPSxeVrHQOO0M8UtHoOO10nEfPHPVAp1ZltVVXX4U1VllnpbVWW29datK/+hwQVT8TPVDXxUod6NI3gZVR2Lp4BdPXXiOtUFm5mPXmUyszFTVJKYnFytlmoQVzz1257fZUc1NNdlFKySXF22q/rFbcYdn149xfsQ1W3XHpReneY/FNF905+TXDXW3aC0/bNQn+z19AkU1T33kZ3sjeZyGGUuJlKabP4m//MY5T42k5rtjYhwGOOIsIXNqQLS1JJsnjd8GNF4wMEChgxW1hdtlkRFHOmAsCENhlTJ6xsBZTEfPdooEKUij65aMjkflgeA+mJQL/oiZ1aqp9hhRkQbfoYAAFSt7Za/PANphJTa0wAISOu1abvbanQfhtKtOuWza2q3Y72yzp7rvAvw9XOOXEGS3cb4d/Xjrgxddt3G7A8b7aJHk3rtxyxC8GOmSBGe/c8MfDDn3s0Skv3cfPP05dUpFha92v0+9uU/BN+a6ds9dnFlv21fft3TrQ/41c8cF5L7602y/PnenJiW9eIujBohlraWmv3vfnf99b8uUX7r6R6+PJHG9c/9dnv33334c/fvnnp1+o7c+i1urzh8lb97gI713SkBcq6Y1vYOVz3vFOlrygTW9i5RPgAgkovt2RD4K4w17wojU7/CHQfOAzSfqUEaboWbB7EYTcBJVXwQNecH9qESFVNjcyD6IQdQwUnQM5h0AbYtBQ/gtfC0/oQ/7FMB4z5B4PiQjD7GnufrnxYAJhN0A8JcyApBviC3XRvwJeoQHkGYCNcATA2vVQi3dgFgmfcAIIAMBpOesZ84pnRhCKSW9SKADOMlCBDoxRjgFc4haNyD9YfDECFZCbH01YPTp+T4fh4gIIVAQAA0wSaUZzYR1HOEi1zKiNGUiRIoXIyEDigv+LFLTCF2t0o0tKbY6ltMUpV/i/P5YRlpxkhRVZiEVSnjGWuDQlEjtYw1s2MYgNvCLrsqjJDMZug8N74DIdqcAq3tGOZGxdI6lJHV3ScpHN0+YUVYjMXSqzl8xEnzFHKEwoEtOXwMRDGtk5lfyF8J3qvGYXvTlKcBZTg4+sGQfbqcR7/jOZqgPoMAmKziLi84hPpGcUwwk8Z4arfhfFaEY1ulGOdtSjsYKocCTqz4oeVHgJHWgmpynOagIxcLXMJklxGFIZ0vROryxoScuJUJPuUKXblGm/UHlMc/YzpzMVqPpsCiqjMpSJBtVeUkXqTqcK0qGEXOq1pAnUowp1lkT/pd5WWXrDceawpzRc6EopitRnojSiVFWr/qDqRKmWpJ6Y62pLdUpXaPpUrGuVoF6H+tJv4rSqpoTnOgoJRku2Epulm6hc96rULYBAbg1AANTiWFhA5pWbV+0kFyCQSEmKkpdNjas950pZ8SDADRVorGAe27nIqnay6yRDBTC0WX4aNrV4XS1uwZAgVsZstpWrLXBvW9OmLaiPpi2qb7l62GLpE6zRPOdvNwnaLc5zqmmdrnbr1M3r+jW74UXvTk961iT+dKxBLZg1S9jbzlI3sdUdbD45a0vPZjWX8h2vK+sr3nQGl7l9Rat7AZtCwX6VsPTlr325aynrPvi00n1v/3/Rlt/5XnjA6V3wZ12qXwjHVMMIZm9UUaxQBUuWiiKuMIk9HGECN9TAR/xojnW8Yx732Mc/dpV/X/zhDEvYVCPucHSJHGL4NozDAT5u45K73Rtjta43XbKLAwvjJ/8QppBtspDjSV4LK5nGINZyg8m5zxmb2MjLTTJP1Wte1KLZtmyF5JWZimEmn1hnXf5vlAs35WbiOaArTulf00xWNZt1zglW9J23LGbFUprRfF50mDfsYBmb2c01fiqcrZyF/gyBAAsq7te+TFtNI7q8eUZaGIVQtj6GUrarRm6r3VpmOU+BAFsrkRB+bVxcS1nXKWazo30NbGAT7db7/bSdlf9raBVjYdgACDa2tyYVQfeN0AUWdWi1cG1aoyi2aOl23b5t43B31xItadCpB2AiYkMbzH5G9qsPvWu7jhTfj863cF393RZLmsFc5nScsVvnIoN6zAD2sr1Z/e9kWxoj3u03XKVN5XYH0+IUZ9O6Q01tvvIby2du+MahHGOF0xnTBr/0x6+B8ZNHO+U3r/h6Ac7iSE970noW98AzDl6cZxro7j76kFHe5zfXC8krl3iuQc7rpMeS5nvOMsyPzdvMANnrXwd72MU+9vrJ3OEkE7lVqxx0k2N96UZvulfXrG+en7foWq96pfMe87fjPe7xfXrES3zvvyO80b2me6LtzvT/s+M34VAf/MQLb3ansxzybSZ84+/rKTJ3OqyLh7vmyxX4QBd70FvPudAfunfUh7z1VFf9qNuuVdD7XfRHtrzgMS/523f84aQ3ggF2C3jTe/v1nme9cfjgWjeAIN7+Ef4VFGCHu66t4D4/OOWps/ycNcAACGBl9K0wfdNF3dhTR37s2W4EnA3hacMWfnzOlkc3gnE+BrA/AJjvbLsIuO/Y5zv1QzokaD8hED74IwD5AwD6A4H5cJoOMAD/mL4GID/XKT51O76Wm70BPIICBID3g74ENJsFJBrmc4MCiL74oEDqw6Se4zilE0CPS4L28z6iQUAxyJnvA4AGJIIUHIAV/0w160k3tUk7xJowq1MCEwSBE7lBeYMAolElN/A+DFFBUBoA/vMe8zs99NPAgDuwDYTBzFM5cCM51gLDn7M5xhvD0gM0CtNC4+PCyzM8ZUu8tyI6Nby79IO1M8y+/3tBNORDwLg62mM4PDTEOhS4QMzAJSnCXzpCvYtBQOS9NRy5skI82IO02gPARUS33GPDyJO6yUs+3GvD37tAIuTETzw8nUu9TCzE0KNEUyxFNGpBTfzDPoxESFTEONSRRty80VMVshPGYSTGYjTGY6wJ7TtEOBTFXHS8ucPE9nLBQpPEnSs5L6w5MczDW5zDS9RDabRFasTFXZw5ZYTFUOy9Mv+MxmrDRrdLw3Ncxm9kR2u0w+vjxlT0HE+0hLNxnDfEQF5UxW5kRSOIj5fgxyU4yEBISNvxR1QESDe0xIFEgmujhoVEyE5sSK/xxUd8RjqcSGBzrpWRwv3roxHsR1A8v2Ykx3aBOFPzj3LTGjFYSARQEZPMx4ycmo1cu4D0RiMYNvoDAAUgmhHMAJGUD5nESJTcQpVsR93zyCMYtnIDAf8YAKgpgAE4EQ1BypPcPXSMRSPcSRmEgmtzwj4SyShEgPmwyd3wv3e0va/syJ6Uw897xbfcxrmUSHlUvLrcxIdkS+CTRaVkxnSMSGe8OCwQP+LDyaPRSd+jxZYMvuFzMsH//EempMd1vMYoSMzJ7MqUJMxVNEzlI0AM2aMUUAAFqYAcFMH5s0HmgwAwghp5Q4DnMh7KdEjLbMWm5EAiGBpsIxrdWsAKyID4G0H6G5oGiA8M0ZoO4CMAOIFEqs3OXMrPFMjQLMcj2KPxKAAV3IMpVEDj3JoR/LWrbAkszELb1Eh8DEzQ3MMiiAAEEM4PxBACEM7oG4ActMHwPJtfY07atMDF5JnGVEe9NMMiSE4hOM0BSE1Kms8Fyc892E//kLejTIxa5Mt79EuGfDynpMuX60vcrLcN5cmF81AMBdFnE1GIlM7BhMtfJMUUXU9P08Z4NNGVxJNBVJpwJMNqzM15/+zRvSxRcQxAG90+c7RLz2xRjuQ8yIzRDs26D6XOuQlGZKTSKrXSK8XS+QmALeXSLvXSLwXTMBXTMSXTMjXTM0XTNFXTNWXTNnXTN4XTOJXTOaXTOrXTO8XTPNXTPcVTN+DTPwXUQBXUQSXUQjXUQ0XURFXURUVUP2XUR4XUSJXUSaXUSrXUS8XUPh2ATOXUTvXUTwXVUBXVUX1URyXVU0XVVFXVVWXVVj1UU3XVWJXVWaXVWrVVT4XVW9XVXeXVXvXVXzXTXLXTAxBWYDXWY0XWZFXWNy3WFWiJC9iANR2ABdiAaQ2ABDgAMV2ATS1Ta03Tbd1ScF3WcSXXcjXXQv8VVhUIAQwIABHQAHZlUxHg1jn1VjQV13PF13zV131t03QNgQXo0m3VgAGQABEIAGIlWIM1ATcIgQCYVglwgwvA1oNtCYMN1009AAmAWA3YAHd1AxO4gJbAgAGgAAm4AAnI1pHFAAwY2AEwAYglWHBlWTdYgYPV2AHg2A1IAIYNgG0FWH4F2qAVWlot1gMY2BDI1m1VWBMQgRAw2BUwgYyFV4ddAHHFVnn92YDFWAnAgA0IAQow2i71VpfdUpQNAJU1gQTgUnEFVxMwgXb9V6n1WgrY1mi92Kwd2rzV273F1XkF06ZVAXHNWApwCZO9ALGtWm7F1pIFU3A9ALUNAAn/oAAMWFgNoACq3VJvNVuVldy15VZw7dxrBVvI7VxnRVq+Rd3UVd1JFdYDgFa4Tdwt1YALaFqLtdmpnVarPQCs/VLHJd3L3dKMdVgVyNyfTYDDJVbKhdyeHYBobdu3xdrHLVvgbdcBwACfXd3s1d7t3VNhXYCWHYCkbYl3pdiIvVaezV3FzVaEHQDb9d3pZd/LDVnr9dZtxVnrnVmX3YCBlQCZbdmald7IpdtnZV685d4DRuAEPtNi7V2/VeAHhuAIPlYG9tJ7leALxuAMjlUK1uAO9uAPRlUOBuERJuESZl0HNuEUVuEVNlQRZuEXhuEYdlMXluEatuEbFlsUxuEd/+bhGqbhHgbiIO7gLCXiIjbiI0biooiiJWbiGqq+JobiKBZNKabiKs7JJ7biLNZie8DiLfbiLzaDLgbjMSbjNhDjMkbjNN4HNWbjNoaNM3bjOAZjNZLjOrZj2bvjPNbj9dvjPvbjG/3jQBbkaIDjQTZkKSvkQ1ZkjUzkRXZktGvkR5ZkfqHjSbbkS9YTTNbkTV5jTvZkTq7kTxblPw7lUTblPE7iVFblVWblIj7lV1bkUoblWVZjWablWx5jW8blXdZiXeblX5ZiXwbmYV5iYSbmYz6hSEbmZc5MZnbmJjbmZ5ZmdVPmabbmKb7mbGakatbmbrYIbvbmcEYHcBbncrXmYnNGZ0ZO53WGmWhm53cOEHeG53l2DXKm53veBHvG531mD33m539ODH8G6IHeA4EmaIBu5YRW6IVm6B476Ie+DYOGaHyW54m26H276IymJ4nWaHau6I4GaSQM6ZEGTJI26d086ZRuZpVmaT5u6ZcWaZiW6Zie6Zq+TpvG6SLN6Z0mZJ726Xbg6J8G5o8W6qJGDqNG6ngK6qSmZaJm6qdGCKiW6jRY6qke5YbG6qzW6q2+lSAAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Maintenance concentration and subsequent dilutions reported as volume/volume (v/v) dilutions with maintenance concentration 1:1 v/v.",
"    <div class=\"footnotes\">",
"     AU: allergy unit; BAU: bioequivalent allergy unit; W/V: weight per volume ratio; PNU: protein nitrogen unit; G: 50 percent glycerinated; Aq: aqueous; Ly: lyophilized; AP: alum precipitated; AcP: acetone precipitated.",
"     <br>",
"      * Volume to add = (maintenance concentration/concentration of manufacturer's extract) x total volume.",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       Target maintenance dose volume is 0.5 mL per injection.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Cox L, Nelson H, Lockey R. Allergen immunotherapy: A practice parameter third update. J Allergy Clin Immunol 2011; 127(1 Supp):S1. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_52_18241=[""].join("\n");
var outline_f17_52_18241=null;
var title_f17_52_18242="Follicular thyroid cancer magnification";
var content_f17_52_18242=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F51148&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F51148&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Follicular thyroid cancer: Magnification of surgical specimen",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Magnification of surgical specimen demonstrating capsular invasion of a follicular neoplasm. Diagnosis of FTC is based on the identification of capsular and/or vascular invasion of the tumor, not simply cytologic features.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephanie L. Lee",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_52_18242=[""].join("\n");
var outline_f17_52_18242=null;
var title_f17_52_18243="Construction of a double barrel end colostomy";
var content_f17_52_18243=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F68563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F68563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Construction of a double barrel end colostomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 434px; height: 544px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts the divided proximal and distal limbs exteriorized through the same abdominal wall aperture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_52_18243=[""].join("\n");
var outline_f17_52_18243=null;
var title_f17_52_18244="Trihexyphenidyl: Pediatric drug information";
var content_f17_52_18244=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Trihexyphenidyl: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?6/1/6165?source=see_link\">",
"    see \"Trihexyphenidyl: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?38/30/39396?source=see_link\">",
"    see \"Trihexyphenidyl: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F231189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      PMS-Trihexyphenidyl;",
"     </li>",
"     <li>",
"      Trihexyphen;",
"     </li>",
"     <li>",
"      Trihexyphenidyl",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1062725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-Parkinson's Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticholinergic Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Drug-induced Dystonic Reactions",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1062719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/1/6165?source=see_link\">",
"      see \"Trihexyphenidyl: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 2-17 years: Dystonia in cerebral palsy: Initial: 0.1-0.2 mg/kg/day in three divided doses for 1 week; increase by 0.05-0.3 mg/kg/day in three divided doses for the second week; thereafter, titrate up weekly by 0.05-0.5 mg/kg/day in three divided doses as clinically tolerated; dosage is based on a prospective trial of 23 patients (Sanger, 2007); maximum dose: 0.75 mg/kg/day; however, a double-blind, prospective crossover study of 16 patients evaluating the effects of higher dosage resulted in improved clinical outcomes with doses ranging between 0.05-2.6 mg/kg/day in three divided doses although adverse reactions were common per author report (n=8 doses &ge;2 mg/kg/day; Rice, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Parkinson&rsquo;s disease: Initial: 1 mg/day; increase by 2 mg increments at intervals of 3-5 days; usual dose: 6-10 mg/day in 3-4 divided doses; doses of 12-15 mg/day may be required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Drug-induced extrapyramidal symptoms: Initial: 1 mg/day; increase as necessary to usual range: 5-15 mg/day in 3-4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Use in combination with levodopa: Usual range: 3-6 mg/day in divided doses",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F231170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elixir, oral, as hydrochloride: 2 mg/5 mL (473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 2 mg, 5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F231156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1062729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May be taken before or after meals; tolerated best if given in 3 daily doses and with food. High doses (&gt;10 mg/day) may be divided into 4 doses, at meal times and at bedtime.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10484664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1062728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunctive treatment of Parkinson's disease and treatment of drug-induced extrapyramidal symptoms (EPS) (FDA approved in adults); has also been used for treatment of dystonia in cerebral palsy",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F231237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Trihexyphenidyl may be confused with trifluoperazine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F231235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, confusion, delusions, dizziness, drowsiness, euphoria, hallucinations, headache, nervousness, paranoia, psychiatric disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, dilatation of colon, ileus, nausea, parotitis, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, glaucoma, intraocular pressure increased, mydriasis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1062733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to trihexyphenidyl or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1062718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hyperthyroidism, renal or hepatic dysfunction, cardiovascular disease (including hypertension), glaucoma, prostatic hyperplasia, obstructive disease of the GI tract, and/or urinary stricture or retention. Does not relieve symptoms of tardive dyskinesia; may exacerbate mental symptoms when used to treat extrapyramidal symptoms. May cause anhidrosis and hyperthermia, which may be severe; use with caution in hot weather or during exercise, especially when administered concomitantly with other anticholinergic drugs to chronically-ill patients, alcoholics, patients with CNS disease, or persons doing manual labor in a hot environment. Trihexyphenidyl may impair physical or mental abilities; until effects on an individual patient are known, patients should be warned to use caution when performing tasks which require mental alertness (eg, operating machinery or driving). When given in large doses or to susceptible patients, may cause weakness and inability to move particular muscle groups.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F231165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F13823804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13823805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. One case report did not show evidence of adverse events after trihexyphenidyl administration during pregnancy (Robottom, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1062724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intraocular pressure monitoring and gonioscopic evaluations (baseline and at regular intervals)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1062717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Presumed to act by blocking excess acetylcholine at cerebral synapses inhibiting parasympathetic nervous system; pharmacologic effects are similar to atropine",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1062732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hydroxylation of the alicyclic groups",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:  1.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 33  hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine and bile",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1062723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/30/39396?source=see_link\">",
"      see \"Trihexyphenidyl: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth. Patients may be more vulnerable to overheating and dehydration while taking this medication; maintain adequate hydration unless advised by prescriber to restrict fluids.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Brocks DR, \"Anticholinergic Drugs Used in Parkinson's Disease: An Overlooked Class of Drugs From a Pharmacokinetic Perspective,\"",
"      <i>",
"       J Pharm Pharm Sci",
"      </i>",
"      , 1999, 2(2):39-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/52/18244/abstract-text/10952768/pubmed\" id=\"10952768\" target=\"_blank\">",
"        10952768",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      He H, McKay G, Wirshing B, et al, \"Development and Application of a Specific and Sensitive Radioimmunoassay for Trihexyphenidyl to a Pharmacokinetic Study in Humans,\"",
"      <i>",
"       J Pharm Sci",
"      </i>",
"      , 1995, 84(5):561-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/52/18244/abstract-text/7658345/pubmed\" id=\"7658345\" target=\"_blank\">",
"        7658345",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rice J and Waugh MC, \"Pilot Study on Trihexyphenidyl in the Treatment of Dystonia in Children With Cerebral Palsy,\"",
"      <i>",
"       Child Neurol",
"      </i>",
"      , 2009, 24(2):176-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/52/18244/abstract-text/19182155/pubmed\" id=\"19182155\" target=\"_blank\">",
"        19182155",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sanger TD, Bastian A, Brunstrom J, et al, \"Prospective Open-Label Clinical Trial of Trihexyphenidyl in Children With Secondary Dystonia Due to Cerebral Palsy,\"",
"      <i>",
"       J Child Neurol",
"      </i>",
"      , 2007, 22(5):530-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/52/18244/abstract-text/17690057/pubmed\" id=\"17690057\" target=\"_blank\">",
"        17690057",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12863 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-E0BEA709E4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_52_18244=[""].join("\n");
var outline_f17_52_18244=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231189\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062725\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062719\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231170\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231156\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062729\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10484664\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062728\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231237\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231235\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062733\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062718\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300176\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231165\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13823804\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13823805\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062724\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062717\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062732\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062723\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12863\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12863|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/1/6165?source=related_link\">",
"      Trihexyphenidyl: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/30/39396?source=related_link\">",
"      Trihexyphenidyl: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_52_18245="Levalbuterol: Pediatric drug information";
var content_f17_52_18245=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Levalbuterol: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?42/27/43445?source=see_link\">",
"    see \"Levalbuterol: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?22/7/22645?source=see_link\">",
"    see \"Levalbuterol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F187525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Xopenex HFA&trade;;",
"     </li>",
"     <li>",
"      Xopenex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F187526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Xopenex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1059708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adrenergic Agonist Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiasthmatic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Beta",
"       <sub>",
"        2",
"       </sub>",
"       -Adrenergic Agonist",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Bronchodilator",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Sympathomimetic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11443761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     May consider using half of the albuterol dose; albuterol is a 1:1 racemic mixture and levalbuterol is the active isomer; limited data available; further studies needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebulization",
"     <b>",
"      (dosage expressed in terms of mg levalbuterol)",
"     </b>",
"     : 0.31 mg/dose every 8 hours was administered to 31 VLBW neonates (mean GA: 28.1 weeks; mean birth weight: 1127 g) for &gt;2 weeks; no untoward hemodynamic effects were noted (Mhanna, 2009)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1059701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/27/43445?source=see_link\">",
"      see \"Levalbuterol: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acute asthma exacerbation (NAEPP, 2007)",
"     <b>",
"      (dosage expressed in terms of mg levalbuterol)",
"     </b>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Nebulization:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children: 0.075 mg/kg (minimum dose: 1.25 mg) every 20 minutes for 3 doses then 0.075-0.15 mg/kg (not to exceed 5 mg) every 1-4 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adults: 1.25-2.5 mg every 20 minutes for 3 doses then 1.25-5 mg every 1-4 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Inhalation: MDI: 45 mcg/spray:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children: 4-8 puffs every 20 minutes for 3 doses then every 1-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adults: 4-8 puffs every 20 minutes for up to 4 hours then every 1-4 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maintenance therapy (nonacute) (NAEPP, 2007):  Not recommended for long-term, daily maintenance treatment; regular use exceeding 2 days/week for symptom control indicates the need for additional long-term control therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Nebulization:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 0-4 years:  0.31-1.25 mg every 4-6 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &ge;5 years and Adults: 0.31-0.63 mg every 8 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Inhalation: MDI: 45 mcg/spray:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &lt;5 years: Not FDA approved",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &ge;5 years and Adults: 2 inhalations every 4-6 hours as needed",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F187503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, for oral inhalation, as tartrate [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Xopenex HFA&trade;: 45 mcg/actuation (15 g) [chlorofluorocarbon free; 200 actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, for nebulization, as hydrochloride [strength expressed as base, preservative free]: 0.31 mg/3 mL (24s); 0.63 mg/3 mL (24s); 1.25 mg/3 mL (24s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Xopenex&reg;: 0.31 mg/3 mL (24s); 0.63 mg/3 mL (24s); 1.25 mg/3 mL (24s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, for nebulization, as hydrochloride [strength expressed as base, concentrate, preservative free]: 1.25 mg/0.5 mL (30s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F187488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes aerosol",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1059711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalation: Nebulization: dilution required for concentrated solution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral inhalation: Prime the inhaler (before first use or if it has not been used for more than 2 weeks) by releasing 4 test sprays into the air away from the face; shake well before use; use spacer for children &lt;8 years of age",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F5521766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Solution for nebulization:",
"     <b>",
"      Compatible",
"     </b>",
"     with budesonide suspension",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1059704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store all formulations at room temperature; protect from light; discard nebulized solution if it is not colorless; after the foil covering is opened, use within 2 weeks; if removed from the foil pouch, use within 1 week; vials of concentrated solution should be used immediately after removing from foil pouch; store aerosol with mouthpiece up; discard after 200 actuations",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1059710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment and prevention of bronchospasm in patients with reversible obstructive airway disease",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F187551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Xopenex&reg; may be confused with Xanax&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F187549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, dizziness, headache, migraine, nervousness, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Serum glucose increased, serum potassium decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, dyspepsia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Leg cramps, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthma, cough, nasal edema, pharyngitis, rhinitis, sinusitis, viral infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Accidental injury, flu-like syndrome, viral infection,",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abnormal ECG, acne, anaphylaxis, angina, angioedema, arrhythmia, atrial fibrillation, chest pain, chills, constipation, conjunctivitis, cough, diaphoresis, dysmenorrhea, dyspnea, epistaxis, extrasystole, gastroenteritis, hematuria, hyper-/hypotension, hypoesthesia (hand), hypokalemia, insomnia, itching eyes, lymphadenopathy, metabolic acidosis, myalgia, nausea, oropharyngeal dryness, paresthesia, supraventricular arrhythmia, syncope, vaginal moniliasis, vertigo, vomiting, wheezing, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Immediate hypersensitivity reactions have occurred (including angioedema, oropharyngeal edema, urticaria, and anaphylaxis).",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1059715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to levalbuterol, any component, albuterol, or adrenergic amine",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1059700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hyperthyroidism, hypokalemia, diabetes mellitus, cardiovascular disorders including coronary insufficiency, hypertension, or history of cardiac arrhythmias; excessive or prolonged use can lead to tolerance",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1059699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Paradoxical bronchospasm may occur, especially with the first use. Excessive use of inhaled sympathomimetics has been associated with death possibly due to cardiac arrest. Increasing use (&gt;2 days/week) for symptom relief generally indicates inadequate control of asthma and the need for initiating or intensifying anti-inflammatory treatment.  Regularly scheduled, daily, chronic use of short-acting beta agonists (eg, levalbuterol) is not recommended (NAEPP, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F187497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Blockers: May diminish the therapeutic effect of Beta2-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the tachycardic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atosiban: Beta2-Agonists may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers (Beta1 Selective): May diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers (Nonselective): May diminish the bronchodilatory effect of Beta2-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: May diminish the therapeutic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1059718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Caffeinated beverages may increase side effects of levalbuterol",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F187499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F187512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies; however, racemic albuterol was teratogenic in some species. There are no adequate and well-controlled studies in pregnant women. This drug should be used during pregnancy only if benefit exceeds risk. Use caution if needed for bronchospasm during labor and delivery; has potential to interfere with uterine contractions.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1059707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum potassium, oxygen saturation, heart rate, pulmonary function tests, respiratory rate, use of accessory muscles during respiration, suprasternal retractions; arterial or capillary blood gases (if patient's condition warrants)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1059698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     R-enantiomer of racemic albuterol; relaxes bronchial smooth muscle by action on beta",
"     <sub>",
"      2",
"     </sub>",
"     -receptors with little effect on heart rate",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1059713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Nebulized: 10-17 minutes; aerosol: 5.5-10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: Nebulized: 1.5 hours; aerosol: 77 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Nebulized: 5-6 hours; aerosol: 3-6 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1059714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nebulization:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 1900 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver to an inactive sulfate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 3.3-4.0 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 0.2-1.8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 3% to 6% excreted unchanged in urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1059706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/7/22645?source=see_link\">",
"      see \"Levalbuterol: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not exceed recommended dosage; may cause dry mouth; rinse mouth with water following each inhalation to help with dry throat and mouth; if more than one inhalation is necessary, wait at least 1 full minute between inhalations; notify physician if palpitations, tachycardia, chest pain, muscle tremors, dizziness, or headache occur, or if breathing difficulty persists; limit caffeinated beverages",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1059716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Levalbuterol administered in",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     the mg dose of albuterol (eg, 0.63 mg levalbuterol to 1.25 mg albuterol) provides comparable efficacy and safety. Levalbuterol has not been evaluated by continuous nebulization (NIH Guidelines, 2007).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Gawchik SM, Saccar CL, Noonan M, et al, &ldquo;The Safety and Efficacy of Nebulized Levalbuterol Compared With Racemic Albuterol and Placebo in the Treatment of Asthma in Pediatric Patients,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 1999, 103(4):615-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/52/18245/abstract-text/10200010 /pubmed\" id=\"10200010 \" target=\"_blank\">",
"        10200010",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lotvall J, Palmqvist M, Arvidsson P, et al, &ldquo;The Therapeutic Ratio of R-Albuterol Is Comparable With That of RS-Albuterol in Asthmatic Patients,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 2001, 108(5):726-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/52/18245/abstract-text/11692096/pubmed\" id=\"11692096\" target=\"_blank\">",
"        11692096",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mhanna MJ, Patel JS, Patel S, et al, \"The Effects of Racemic Albuterol Versus Levalbuterol in Very Low Birth Weight Infants,\"",
"      <i>",
"       Pediatr Pulmonol",
"      </i>",
"      , 2009, 44(8):778-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/52/18245/abstract-text/19598281/pubmed\" id=\"19598281\" target=\"_blank\">",
"        19598281",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Milgrom H, Skoner DP, Bensch G, et al, &ldquo;Low-Dose Levalbuterol in Children With Asthma: Safety and Efficacy in Comparison With Placebo and Racemic Albuterol,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 2001, 108(6):938-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/52/18245/abstract-text/11742271/pubmed\" id=\"11742271\" target=\"_blank\">",
"        11742271",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;National Asthma Education and Prevention Program. Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics--2002,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 2002, 110(5 Suppl):S141-219.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/52/18245/abstract-text/12542074/pubmed\" id=\"12542074\" target=\"_blank\">",
"        12542074",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Asthma Education and Prevention Program (NAEPP), &ldquo;Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma,&rdquo;",
"      <i>",
"       Clinical Practice Guidelines",
"      </i>",
"      , National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007; available at file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12546 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-427C511A25-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_52_18245=[""].join("\n");
var outline_f17_52_18245=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187525\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187526\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059708\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11443761\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059701\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187503\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187488\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059711\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5521766\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059704\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059710\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187551\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187549\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059715\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059700\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059699\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299585\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187497\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059718\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187499\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187512\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059707\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059698\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059713\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059714\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059706\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059716\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12546\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12546|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/27/43445?source=related_link\">",
"      Levalbuterol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/7/22645?source=related_link\">",
"      Levalbuterol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_52_18246="Selegiline: Patient drug information";
var content_f17_52_18246=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Selegiline: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25448?source=see_link\">",
"     see \"Selegiline: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F220310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Eldepryl&reg;;",
"     </li>",
"     <li>",
"      Emsam&reg;;",
"     </li>",
"     <li>",
"      Zelapar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F220311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Selegiline&reg;;",
"     </li>",
"     <li>",
"      Gen-Selegiline;",
"     </li>",
"     <li>",
"      Mylan-Selegiline;",
"     </li>",
"     <li>",
"      Novo-Selegiline;",
"     </li>",
"     <li>",
"      Nu-Selegiline",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10017784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700557",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Children and teens who take this drug may be at a greater risk of having thoughts or actions of suicide. Adults may also be at risk. The risk may be greater in people who have had these thoughts or actions in the past. Watch people who take this drug closely. Call the doctor right away if signs like low mood (depression), nervousness, restlessness, grouchiness, panic attacks, or changes in mood or actions are new or worse. Call the doctor right away if any thoughts or actions of suicide occur.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692011",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Parkinson's disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low mood (depression).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702911",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to selegiline or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin patch:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703804",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have pheochromocytoma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701004",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Stop fluoxetine for at least 5 weeks before starting this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697067",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a high dose (more than 10 mg per day of the capsule or tablet, more than 2.5 mg per day of the oral disintegrating tablet, or more than 6 mg per day of the skin patch) of this drug, avoid aged meats and cheeses, soy sauce, some types of beans, sauerkraut, beer, yeast extracts, and others. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have PKU, talk with your doctor. Some products have phenylalanine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take good care of your teeth. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin patch:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696687",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid products that have caffeine, phenylalanine, St John's wort, tryptophan, or tyrosine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696692",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid use of heat sources (such as sunlamps, tanning beds, heating pads, electric blankets, heat lamps, saunas, hot tubs, heated waterbeds). Avoid long, hot baths or sunbathing. Your temperature may rise and cause too much drug to pass into your body.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698706",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are planning to harm yourself or the want to harm yourself gets worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705902",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Strong urges that are hard to control (such as gambling or sex).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699028",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696213",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use this drug early in the day to stop sleep problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694863",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow a diet plan. Some foods and drinks taken with higher doses of this drug may cause very risky effects such as sudden high blood pressure. To avoid these problems, get a list of foods to avoid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698545",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a diary of your signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705565",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablets and capsules:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705488",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral-disintegrating tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695516",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Place on your tongue and let it melt. Water is not needed. Do not swallow it whole. Do not chew, break, or crush it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3452346",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not eat or drink for at least 5 minutes after taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin patch:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694483",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put patch on clean, dry, healthy skin on the chest, back, upper leg, or upper arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695471",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Move the patch site with each patch.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699639",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use oral disintegrating tablets within 3 months of opening pouch.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11043 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-4B2100FB5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_52_18246=[""].join("\n");
var outline_f17_52_18246=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220310\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220311\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017784\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017786\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017785\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017790\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017791\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017793\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017788\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017789\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017794\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017795\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25448?source=related_link\">",
"      Selegiline: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_52_18247="Definition and pathogenesis of left ventricular hypertrophy in hypertension";
var content_f17_52_18247=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Definition and pathogenesis of left ventricular hypertrophy in hypertension",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/52/18247/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/52/18247/contributors\">",
"     Pamela S Douglas, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/52/18247/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/52/18247/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/52/18247/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/52/18247/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/52/18247/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/52/18247/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/52/18247/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left ventricular hypertrophy (LVH) is a common finding in patients with fixed or borderline hypertension and can be diagnosed either by ECG or by echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18247/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Echocardiography is the procedure of choice, since the sensitivity of the different ECG criteria may be as low as 7 to 35 percent with mild LVH and only 10 to 50 percent with moderate to severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18247/abstract/3\">",
"     3",
"    </a>",
"    ]. In a report from the Treatment of Mild Hypertension Study, for example, almost none of 844 patients had ECG criteria for LVH, while echocardiographic LVH (indexed by body surface area, see below) was present in 13 percent of men and 20 percent of women [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18247/abstract/4\">",
"     4",
"    </a>",
"    ]. Nevertheless, if echocardiography is unavailable or too expensive, appropriate ECG criteria can be used to detect increased LV mass [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18247/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3285?source=see_link\">",
"     \"Electrocardiographic diagnosis of left ventricular hypertrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The definition and pathogenesis of LVH in hypertension will be reviewed here. The clinical implications of and effects of therapy on this complication and the indications for echocardiography in hypertensive patients are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17959?source=see_link\">",
"     \"Clinical implications and treatment of left ventricular hypertrophy in hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left ventricular hypertrophy is defined as an increase in the mass of the left ventricle, which can be secondary to an increase in wall thickness, an increase in cavity size, or both. LVH as a consequence of hypertension usually presents with an increase in wall thickness, with or without an increase in cavity size. This increase in mass predominantly results from a chronic increase in afterload of the LV caused by the hypertension, although there is also a genetic component. A significant increase in the number and",
"    <span class=\"nowrap\">",
"     /or",
"    </span>",
"    size of sarcomeres within each myocardial cell is the pathologic mechanism.",
"   </p>",
"   <p>",
"    The estimation of LV mass is commonly derived from LV measurements obtained by 2D echocardiography. The American Society of Echocardiography with the European Association of Echocardiography has issued the following criteria for LVH using modified Simpson's rule [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18247/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Estimated LV mass of 201-227 g (103 -116",
"      <span class=\"nowrap\">",
"       g/m2)",
"      </span>",
"      for men and 151-171 g (89 -100",
"      <span class=\"nowrap\">",
"       g/m2)",
"      </span>",
"      for women is mildly abnormal",
"     </li>",
"     <li>",
"      Estimated LV mass of 228 -254 g (117-130",
"      <span class=\"nowrap\">",
"       g/m2)",
"      </span>",
"      for men and 172 -182 g (101-112",
"      <span class=\"nowrap\">",
"       g/m2)",
"      </span>",
"      for women is moderately abnormal",
"     </li>",
"     <li>",
"      Estimated LV mass &gt; 255 g (&gt;131",
"      <span class=\"nowrap\">",
"       g/m2)",
"      </span>",
"      for men and &gt;193 g (&gt;113",
"      <span class=\"nowrap\">",
"       g/m2)",
"      </span>",
"      for women is severely abnormal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the absolute increase in mass, the geometric pattern of left ventricular hypertrophy also may be important [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18247/abstract/8\">",
"     8",
"    </a>",
"    ]. Patients without an increase in absolute mass, but with an increase in relative wall thickness or in the wall thickness-to-cavity diameter ratio (called concentric remodeling) have the same adverse risk as those with an increase in both mass and relative wall thickness (called concentric hypertrophy). The elevation in risk with either finding is for both cardiovascular disease and death, and is independent of the level of blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18247/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypertension may also result in interstitial fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18247/abstract/10\">",
"     10",
"    </a>",
"    ]. Both factors contribute to an increase in left ventricular stiffness, resulting in diastolic dysfunction and an elevation in left ventricular end diastolic pressure. Glucose intolerance, if present, can contribute to the development of interstitial fibrosis and diastolic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18247/abstract/11\">",
"     11",
"    </a>",
"    ], presumably due to microvascular ischemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43368?source=see_link\">",
"     \"Clinical manifestations and diagnosis of diastolic heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although it is relatively insensitive, the ECG does have prognostic significance [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18247/abstract/12\">",
"     12",
"    </a>",
"    ]. Hypertensive patients with echocardiographically proven LVH who also meet ECG criteria have a greater left ventricular mass than those without the expected ECG changes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18247/abstract/13\">",
"     13",
"    </a>",
"    ]. Left ventricular mass is highest in those with a \"strain\" pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18247/abstract/14\">",
"     14",
"    </a>",
"    ]. Serial monitoring of ECG voltage also may be helpful. In particular, changes in ECG voltage over time may reflect changes in left ventricular mass and correlate with cardiovascular risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3285?source=see_link\">",
"     \"Electrocardiographic diagnosis of left ventricular hypertrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     LVH IN HYPERTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of LVH is a relatively early response to hypertension, demonstrable (by echocardiography) in children and adolescents with borderline elevations in blood pressure (BP) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18247/abstract/15\">",
"     15",
"    </a>",
"    ]. Patients who have exaggerated transient elevations in BP during mental stress (particularly at work) or exercise may be particularly prone to the development of LVH [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18247/abstract/16\">",
"     16",
"    </a>",
"    ]. Ambulatory BP monitoring has suggested that there may be two additional risk factors for LVH:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The daily BP load (the percentage of pressures above",
"      <span class=\"nowrap\">",
"       135/85",
"      </span>",
"      during the day and",
"      <span class=\"nowrap\">",
"       120/80",
"      </span>",
"      mmHg at night)",
"     </li>",
"     <li>",
"      Nocturnal hypertension (in which the expected nighttime reduction in BP is not seen)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other studies have suggested that the maximal daytime blood pressure or peak exercise blood pressure are most predictive of the level of hypertrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18247/abstract/17\">",
"     17",
"    </a>",
"    ]. These factors may explain why the ambulatory blood pressure values may correlate more closely with the development of LVH than the casual BP taken in the physician's office. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7113?source=see_link\">",
"     \"Ambulatory blood pressure monitoring and white coat hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is also evidence that left ventricular mass may be increased",
"    <strong>",
"     prior",
"    </strong>",
"    to the development of overt hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18247/abstract/18\">",
"     18",
"    </a>",
"    ]. Data from the Framingham Heart Study, for example, demonstrated a direct and continuous relationship between left ventricular mass and the subsequent development of hypertension in previously normotensive subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18247/abstract/18\">",
"     18",
"    </a>",
"    ]. These observations can be explained in one of three ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The progressors may have had a higher mean blood pressure to begin with.",
"     </li>",
"     <li>",
"      The same factors, such as angiotensin II, norepinephrine, epinephrine, increased peripheral and cardiac sympathetic drive [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18247/abstract/19,20\">",
"       19,20",
"      </a>",
"      ], and endothelin, promote both hypertension and LVH.",
"     </li>",
"     <li>",
"      The tendency to LVH may be an inherited trait that predisposes to the development of hypertension.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Role of renin-angiotensin system",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been proposed that a",
"    <strong>",
"     cardiac",
"    </strong>",
"    renin-angiotensin system and angiotensin converting enzyme activity may be an important determinant of the hypertrophic response [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18247/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. Compatible with a role for angiotensin II is the observation that myocardial hypertrophy develops independent of hypertension in transgenic mice which overexpress the rat angiotensinogen gene, specifically in the heart [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18247/abstract/24\">",
"     24",
"    </a>",
"    ]. The effect of angiotensin II may be related in part to the promotion of myocardial fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18247/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19865?source=see_link&amp;anchor=H4#H4\">",
"     \"Cardiac remodeling: Basic aspects\", section on 'Cellular and molecular changes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is unclear, however, whether this system is regulated in vivo by in situ renin release or by uptake of circulating renin with subsequent local production of angiotensin II [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18247/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36825?source=see_link\">",
"     \"Actions of angiotensin II on the heart\"",
"    </a>",
"    .) Furthermore, although angiotensin II may promote the development of pressure-overload cardiac hypertrophy, studies in angiotensin II type 1 receptor knockout mice have shown that angiotensin II signaling via this receptor is not essential for this process to occur [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18247/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study in humans which evaluated correlates of left ventricular mass in 84 young healthy subjects aged 16 to 24 provided findings compatible with a direct role for angiotensin II in the development of LVH [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18247/abstract/28\">",
"     28",
"    </a>",
"    ]. Regression analysis showed that plasma angiotensin II, renin, and angiotensin converting enzyme levels correlated significantly with left ventricular mass, with the most important component being angiotensin II levels (p&lt;0.001). This relationship was independent of systolic blood pressure and body size.",
"   </p>",
"   <p>",
"    The importance of angiotensin II in the development of LVH in hypertensive patients is also suggested indirectly by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antihypertensive therapy with an ACE inhibitor or angiotensin II receptor blocker more predictably causes regression of LVH than beta blockers (",
"      <a class=\"graphic graphic_figure graphicRef82558 \" href=\"UTD.htm?42/42/43693\">",
"       figure 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18247/abstract/29\">",
"       29",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17959?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical implications and treatment of left ventricular hypertrophy in hypertension\", section on 'Effect of antihypertensive therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with atherosclerotic renovascular disease (and presumably elevated angiotensin II), have a significantly greater left ventricular mass and a higher prevalence of LVH than control individuals with similar blood pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18247/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Role of endothelin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies in experimental animals suggest that endothelin plays a role in the development of myocardial hypertrophy in response to elevated pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18247/abstract/31\">",
"     31",
"    </a>",
"    ]. As an example, the use of a specific endothelin receptor antagonist prevented the development of hypertrophy without affecting pressure loading conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18247/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Role of heterotrimeric G proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the hormones and neurotransmitters implicated in the initiation and exacerbation of myocardial hypertrophy, including angiotensin II and endothelin, bind to cell membrane receptors which couple to a subset of intracellular heterotrimeric G proteins, the G(q) subclass. Direct evidence for the importance of this subclass is provided by the phenotype of transgenic mice which selectively overexpress the carboxyl-terminal peptide of the alpha subunit G(q) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18247/abstract/33\">",
"     33",
"    </a>",
"    ]. This peptide competes with endogenously expressed G proteins, thereby inhibiting intracellular signaling of coupled cell surface receptors. In response to surgically induced pressure overload, transgenic animals develop significantly less myocardial hypertrophy compared to control mice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Genetic tendency to LVH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The findings that LVH may precede hypertension and that patients with similar degrees of hypertension may have marked differences in left ventricular mass suggest that genetic factors can both promote and retard the development of LVH. The observation that middle-aged men with the DD genotype of the ACE gene, which is associated with higher tissue and plasma levels of ACE, are at increased risk for LVH is compatible with the importance of both genetics and local angiotensin II formation in the pathogenesis of LVH [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18247/abstract/34\">",
"     34",
"    </a>",
"    ]. The increased risk associated with the DD genotype has been extended to patients who have recently undergone renal transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18247/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36825?source=see_link&amp;anchor=H4#H4\">",
"     \"Actions of angiotensin II on the heart\", section on 'ACE gene polymorphism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An additional genetic abnormality associated with the development of LVH is bradykinin 2 receptor gene (B2BKR) polymorphism. Among subjects undergoing physical training, those with a 9 bp deletion of the receptor gene (+9) had lower concentrations of bradykinin and bradykinin receptor and a greater degree of LVH compared to those without this deletion (-9) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18247/abstract/36\">",
"     36",
"    </a>",
"    ]. The degree of LVH was greatest in those with the DD genotype of the ACE gene and the",
"    <span class=\"nowrap\">",
"     +9/+9",
"    </span>",
"    genotype of the B2BKR gene. Since ACE inhibitors cause regression of LVH, the effect may be mediated in part by increased kinin levels (ACE is also a kininase).",
"   </p>",
"   <p>",
"    Overexpression of the gene responsible for protein kinase C has also been implicated in the development of pathologic hypertrophy. Protein kinase C comprises a family of",
"    <span class=\"nowrap\">",
"     serine/threonine",
"    </span>",
"    kinases that influence a variety of cellular functions, including proteins in the sarcolemma and sarcoplasmic reticulum that regulate calcium homeostasis, sarcomeric proteins that influence the calcium sensitivity of the contractile machinery, and modulation of cardiac gene expression and the development of hypertrophy. In one transgenic animal model overexpression of protein kinase C in an adult animal resulted in progressive LVH and impaired diastolic relaxation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18247/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/38/30313?source=see_link\">",
"     \"Cellular mechanisms of diastolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is also evidence from large population based studies of an increased tendency to LVH in blacks, independent of body composition [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18247/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. As an example, in one study of 1335 black and 858 white participants, the prevalence of LVH indexed for fat free mass was 8 and 3 percent among black and white women, respectively, and 8 and 5 percent among black and white men, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18247/abstract/39\">",
"     39",
"    </a>",
"    ]. It is unclear, however, whether this is due to genetic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    environmental factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/58/11174?source=see_link\">",
"     \"Hypertensive complications in blacks\"",
"    </a>",
"    .) Hypertensive women also have a greater prevalence of LVH than men with the same degree of blood pressure elevation. Furthermore, LVH in blacks and women may be associated with a greater increase in the relative risk of death than in white men [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18247/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is also experimental evidence supporting variable susceptibility, possible genetic, to the development of LVH and associated myocardial dysfunction. The results of one report suggested that variations in the set point for regulating myocardial growth may be important [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18247/abstract/42\">",
"     42",
"    </a>",
"    ], while a study in the spontaneously hypertensive rat found a genetic locus on chromosome 2 that affected relative left ventricular mass independent of blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18247/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Impact of coronary artery disease or valvular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among hypertensive patients, the degree of LVH may be increased by concurrent coronary disease or valvular disease. In an echocardiographic study of 963 patients with LVH, those with coronary disease had larger left ventricular internal dimensions, greater left ventricular mass, a lower ejection fraction, and higher end-systolic wall stress compared to those without coronary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18247/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Left ventricular hypertrophy (LVH) is a common finding in patients with fixed or borderline hypertension and can be diagnosed either by ECG or by echocardiography. Echocardiography is more sensitive and is the procedure of choice. If echocardiography is unavailable or too expensive, appropriate ECG criteria can be used to detect increased LV mass. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Left ventricular hypertrophy is defined as an increase in the mass of the left ventricle, which can be secondary to an increase in wall thickness, an increase in cavity size, or both. LVH as a consequence of hypertension usually presents with an increase in wall thickness, with or without an increase in cavity size. The estimation of LV mass is commonly derived from LV measurements obtained by 2D echocardiography. The American Society of Echocardiography with the European Association of Echocardiography has issued criteria for LVH. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The development of LVH as detected by echocardiography is an early response to hypertension. Risk factors for the development of LVH include exaggerated transient elevations in BP during mental stress or exercise; a high percentage of pressures above",
"      <span class=\"nowrap\">",
"       135/85",
"      </span>",
"      during the day and",
"      <span class=\"nowrap\">",
"       120/80",
"      </span>",
"      mmHg at night; and nocturnal hypertension (in which the expected nighttime reduction in BP is not seen). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'LVH in hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Left ventricular mass may be increased",
"      <strong>",
"       prior",
"      </strong>",
"      to the development of overt hypertension. This observation may be explained by the fact that the same factors, such as angiotensin II, norepinephrine, epinephrine, increased peripheral and cardiac sympathetic drive, and endothelin, promote both hypertension and LVH. Alternatively the tendency to LVH may be an inherited trait that predisposes to the development of hypertension. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'LVH in hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genetic factors can both promote and retard the development of LVH. Genes for angiotensin converting enzyme (ACE), the bradykinin 2 receptor (B2BKR), and protein kinase C have been implicated in the development of pathologic hypertrophy. Black individuals have an increased tendency for LVH, although it is unclear whether this is due to genetic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      environmental factors. Hypertensive women have a greater prevalence of LVH than men with the same degree of blood pressure elevation. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Genetic tendency to LVH'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/1\">",
"      Frohlich ED, Apstein C, Chobanian AV, et al. The heart in hypertension. N Engl J Med 1992; 327:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/2\">",
"      Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 2000; 102:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/3\">",
"      Devereux RB. Is the electrocardiogram still useful for detection of left ventricular hypertrophy? Circulation 1990; 81:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/4\">",
"      Liebson PR, Grandits G, Prineas R, et al. Echocardiographic correlates of left ventricular structure among 844 mildly hypertensive men and women in the Treatment of Mild Hypertension Study (TOMHS). Circulation 1993; 87:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/5\">",
"      de Vries SO, Heesen WF, Beltman FW, et al. Prediction of the left ventricular mass from the electrocardiogram in systemic hypertension. Am J Cardiol 1996; 77:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/6\">",
"      Norman JE Jr, Levy D. Improved electrocardiographic detection of echocardiographic left ventricular hypertrophy: results of a correlated data base approach. J Am Coll Cardiol 1995; 26:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/7\">",
"      Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/8\">",
"      Krumholz HM, Larson M, Levy D. Prognosis of left ventricular geometric patterns in the Framingham Heart Study. J Am Coll Cardiol 1995; 25:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/9\">",
"      Verdecchia P, Schillaci G, Borgioni C, et al. Adverse prognostic significance of concentric remodeling of the left ventricle in hypertensive patients with normal left ventricular mass. J Am Coll Cardiol 1995; 25:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/10\">",
"      van Hoeven KH, Factor SM. A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. Circulation 1990; 82:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/11\">",
"      Jain A, Avendano G, Dharamsey S, et al. Left ventricular diastolic function in hypertension and role of plasma glucose and insulin. Comparison with diabetic heart. Circulation 1996; 93:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/12\">",
"      Okin PM, Devereux RB, Nieminen MS, et al. Electrocardiographic strain pattern and prediction of cardiovascular morbidity and mortality in hypertensive patients. Hypertension 2004; 44:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/13\">",
"      Fragola PV, Colivicchi F, Fabrizi E, et al. Assessment of left ventricular hypertrophy in patients with essential hypertension. A rational basis for the electrocardiogram. Am J Hypertens 1993; 6:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/14\">",
"      Okin PM, Devereux RB, Nieminen MS, et al. Relationship of the electrocardiographic strain pattern to left ventricular structure and function in hypertensive patients: the LIFE study. Losartan Intervention For End point. J Am Coll Cardiol 2001; 38:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/15\">",
"      Daniels SD, Meyer RA, Loggie JM. Determinants of cardiac involvement in children and adolescents with essential hypertension. Circulation 1990; 82:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/16\">",
"      Schnall PL, Pieper C, Schwartz JE, et al. The relationship between 'job strain,' workplace diastolic blood pressure, and left ventricular mass index. Results of a case-control study. JAMA 1990; 263:1929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/17\">",
"      Devereux RB, Pickering TG, Harshfield GA, et al. Left ventricular hypertrophy in patients with hypertension: importance of blood pressure response to regularly recurring stress. Circulation 1983; 68:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/18\">",
"      Post WS, Larson MG, Levy D. Impact of left ventricular structure on the incidence of hypertension. The Framingham Heart Study. Circulation 1994; 90:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/19\">",
"      Greenwood JP, Scott EM, Stoker JB, Mary DA. Hypertensive left ventricular hypertrophy: relation to peripheral sympathetic drive. J Am Coll Cardiol 2001; 38:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/20\">",
"      Schlaich MP, Kaye DM, Lambert E, et al. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 2003; 108:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/21\">",
"      Re RN. Intracellular renin and the nature of intracrine enzymes. Hypertension 2003; 42:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/22\">",
"      Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 1993; 153:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/23\">",
"      Sadoshima J, Xu Y, Slayter HS, Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 1993; 75:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/24\">",
"      Mazzolai L, Nussberger J, Aubert JF, et al. Blood pressure-independent cardiac hypertrophy induced by locally activated renin-angiotensin system. Hypertension 1998; 31:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/25\">",
"      Cuspidi C, Ciulla M, Zanchetti A. Hypertensive myocardial fibrosis. Nephrol Dial Transplant 2006; 21:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/26\">",
"      Danser AH, van Kats JP, Admiraal PJ, et al. Cardiac renin and angiotensins. Uptake from plasma versus in situ synthesis. Hypertension 1994; 24:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/27\">",
"      Harada K, Komuro I, Shiojima I, et al. Pressure overload induces cardiac hypertrophy in angiotensin II type 1A receptor knockout mice. Circulation 1998; 97:1952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/28\">",
"      Harrap SB, Dominiczak AF, Fraser R, et al. Plasma angiotensin II, predisposition to hypertension, and left ventricular size in healthy young adults. Circulation 1996; 93:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/29\">",
"      Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/30\">",
"      Wright JR, Shurrab AE, Cooper A, et al. Left ventricular morphology and function in patients with atherosclerotic renovascular disease. J Am Soc Nephrol 2005; 16:2746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/31\">",
"      Masaki T, Kimura S, Yanagisawa M, Goto K. Molecular and cellular mechanism of endothelin regulation. Implications for vascular function. Circulation 1991; 84:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/32\">",
"      Ichikawa KI, Hidai C, Okuda C, et al. Endogenous endothelin-1 mediates cardiac hypertrophy and switching of myosin heavy chain gene expression in rat ventricular myocardium. J Am Coll Cardiol 1996; 27:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/33\">",
"      Akhter SA, Luttrell LM, Rockman HA, et al. Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. Science 1998; 280:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/34\">",
"      Schunkert H, Hense HW, Holmer SR, et al. Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. N Engl J Med 1994; 330:1634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/35\">",
"      Hern&aacute;ndez D, Lacalzada J, Rufino M, et al. Prediction of left ventricular mass changes after renal transplantation by polymorphism of the angiotensin-converting-enzyme gene. Kidney Int 1997; 51:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/36\">",
"      Brull D, Dhamrait S, Myerson S, et al. Bradykinin B2BKR receptor polymorphism and left-ventricular growth response. Lancet 2001; 358:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/37\">",
"      Bowman JC, Steinberg SF, Jiang T, et al. Expression of protein kinase C beta in the heart causes hypertrophy in adult mice and sudden death in neonates. J Clin Invest 1997; 100:2189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/38\">",
"      Kizer JR, Arnett DK, Bella JN, et al. Differences in left ventricular structure between black and white hypertensive adults: the Hypertension Genetic Epidemiology Network study. Hypertension 2004; 43:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/39\">",
"      Drazner MH, Dries DL, Peshock RM, et al. Left ventricular hypertrophy is more prevalent in blacks than whites in the general population: the Dallas Heart Study. Hypertension 2005; 46:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/40\">",
"      Liao Y, Cooper RS, McGee DL, et al. The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. JAMA 1995; 273:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/41\">",
"      Levy D, Garrison RJ, Savage DD, et al. Left ventricular mass and incidence of coronary heart disease in an elderly cohort. The Framingham Heart Study. Ann Intern Med 1989; 110:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/42\">",
"      Koide M, Nagatsu M, Zile MR, et al. Premorbid determinants of left ventricular dysfunction in a novel model of gradually induced pressure overload in the adult canine. Circulation 1997; 95:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/43\">",
"      Innes BA, McLaughlin MG, Kapuscinski MK, et al. Independent genetic susceptibility to cardiac hypertrophy in inherited hypertension. Hypertension 1998; 31:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18247/abstract/44\">",
"      Zabalgoitia M, Berning J, Koren MJ, et al. Impact of coronary artery disease on left ventricular systolic function and geometry in hypertensive patients with left ventricular hypertrophy (the LIFE study). Am J Cardiol 2001; 88:646.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3821 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-82D89F4E57-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_52_18247=[""].join("\n");
var outline_f17_52_18247=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      LVH IN HYPERTENSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Role of renin-angiotensin system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Role of endothelin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Role of heterotrimeric G proteins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Genetic tendency to LVH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Impact of coronary artery disease or valvular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3821\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3821|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/42/43693\" title=\"figure 1\">",
"      Regression of LV hypertrophy with antihypertensive therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36825?source=related_link\">",
"      Actions of angiotensin II on the heart",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7113?source=related_link\">",
"      Ambulatory blood pressure monitoring and white coat hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19865?source=related_link\">",
"      Cardiac remodeling: Basic aspects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/38/30313?source=related_link\">",
"      Cellular mechanisms of diastolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17959?source=related_link\">",
"      Clinical implications and treatment of left ventricular hypertrophy in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43368?source=related_link\">",
"      Clinical manifestations and diagnosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3285?source=related_link\">",
"      Electrocardiographic diagnosis of left ventricular hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/58/11174?source=related_link\">",
"      Hypertensive complications in blacks",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_52_18248="Growth hormone treatment for idiopathic short stature";
var content_f17_52_18248=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Growth hormone treatment for idiopathic short stature",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/52/18248/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/52/18248/contributors\">",
"     Alan D Rogol, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/52/18248/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/52/18248/contributors\">",
"     Mitchell Geffner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/52/18248/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/52/18248/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/52/18248/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of children and adolescents with growth hormone for idiopathic short stature (ISS) is controversial for two reasons. First, the response to growth hormone is highly variable, probably because of the heterogeneous endocrinologic profile in children with ISS, and those children who respond to growth hormone treatment have only modest increases in linear growth. Second, there is little evidence that short stature represents a substantial psychosocial burden to most short children. The possible psychosocial benefit must be weighed against the substantial cost and possible adverse effects of treatment.",
"   </p>",
"   <p>",
"    The efficacy and potential risks of growth hormone and alternative treatments for children with idiopathic short stature are discussed below. The clinical evaluation of children with short stature is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18376?source=see_link\">",
"     \"Diagnostic approach to short stature\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=see_link\">",
"     \"Causes of short stature\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic short stature (ISS) is a clinical description rather than a disease. It is a term used for a heterogeneous group of children whose stature is 2 standard deviations (SD) or more below the mean for age (approximately the 2nd percentile) and for whom no endocrine, metabolic, or other diagnosis can be made [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In defining ISS for the indication of growth hormone treatment, the US Food and Drug Administration (FDA) uses the more stringent criteria of 2.25 SD below the mean (approximately the 1st percentile). The clinical approach to diagnosis of ISS is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18376?source=see_link\">",
"     \"Diagnostic approach to short stature\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with ISS fall into two main groups: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Familial short stature (in which bone age is not delayed and the child is growing within the parental target range)",
"     </li>",
"     <li>",
"      Constitutional delay of growth (in which bone age is delayed)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some children have a combination of these findings. Many healthy children with short stature will have normal variants of growth which fall into one or both of the above categories. The term ISS is generally reserved for children at the more severe end of the spectrum in each category, but the distinction between normal and abnormal growth patterns is not clear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=see_link&amp;anchor=H4#H4\">",
"     \"Causes of short stature\", section on 'Patterns of abnormal growth'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adolescent boys with constitutional delay of growth and puberty, and moderate short stature (taller than -2.5 SD) are more appropriately treated with testosterone replacement rather than growth hormone (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Testosterone'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Endocrine findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with ISS have normal growth velocity (often near or at the lower limit), no biochemical or other evidence for a specific growth-retarding condition, and have normal growth hormone (GH) responses to pharmacologic agents that lead to growth hormone release. Thus, children with ISS do not have growth hormone deficiency according to the classic criteria.",
"   </p>",
"   <p>",
"    Nonetheless, some children with ISS may have reduced activity of the GH-IGF-I axis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/3-5\">",
"     3-5",
"    </a>",
"    ], including low serum concentrations of IGF-I and normal or elevated serum GH, suggesting that they may be relatively insensitive to the effects of GH [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. These children may respond to supraphysiologic levels of growth hormone given as treatment, or to direct stimulation by IGF-I. However, a reduced level of IGF-I, in combination with a normal or minimally elevated GH level, is much more often the result of chronic illness or undernutrition. These causes should be considered when interpreting the endocrine findings of a child with short stature. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Other treatments'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Exclusion of other diagnoses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many systemic diseases and conditions may contribute to short stature, including renal, neoplastic, pulmonary, cardiac, gastrointestinal, immunological, and metabolic disease. In addition, some therapies such as corticosteroid treatment can cause growth failure. Presence of significant disease in these categories precludes the diagnosis of ISS. On the other hand, mutations in the SHOX gene are responsible for up to 4 percent of cases of apparent \"idiopathic\" short stature; growth hormone treatment is effective in these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18376?source=see_link&amp;anchor=H10#H10\">",
"     \"Diagnostic approach to short stature\", section on 'Idiopathic short stature'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=see_link&amp;anchor=H15021208#H15021208\">",
"     \"Causes of short stature\", section on 'Idiopathic short stature'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     GROWTH HORMONE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have demonstrated that growth hormone therapy generally increases height velocity acutely and may increase adult height in children with ISS. Growth hormone therapy for these children was approved by the United States Food and Drug Administration (FDA) in 2003. The indication is for children with current height below -2.25 SD of the mean, in whom the epiphyses are not closed, and whose expected adult height is less than 63 inches (160 cm) for boys and 59 inches (150 cm) for girls [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite FDA approval, the use of growth hormone for ISS remains controversial. &nbsp;The controversy stems from several issues:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A majority of children with short stature will experience some catch-up growth during puberty without GH treatment. In one study of children with ISS, height was approximately 2.7 SD below the mean at the onset of puberty, but increased to approximately 1.5 SD below the mean by adulthood. The adult heights were 5 to 6 cm below target height [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/9\">",
"       9",
"      </a>",
"      ]. Other studies report a spontaneous increase of between 0.5 and 1.9 SD in untreated children [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/10\">",
"       10",
"      </a>",
"      ]. Spontaneous improvement is most likely in children with constitutional delay in growth as compared with the familial short stature pattern of growth, but the distinctions between these groups are not always clear and the degree of spontaneous catch-up growth cannot be accurately predicted. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18376?source=see_link&amp;anchor=H4#H4\">",
"       \"Diagnostic approach to short stature\", section on 'Prediction of height potential'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is little evidence that short stature has a detrimental effect on an individual's psychosocial or physical functioning.",
"     </li>",
"     <li>",
"      It is difficult to predict responsiveness to GH treatment, due to the clinical and molecular heterogeneity of the condition and also the inconsistent criteria for ISS and GH treatment doses used in clinical trials [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/10-14\">",
"       10-14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The available evidence suggests only modest efficacy for GH treatment in children and adolescents with ISS, which must be weighed against the potential adverse financial, psychosocial, and physiological effects of the treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of the published clinical trials of GH treatment in ISS is complicated by the use of variable inclusion criteria and outcomes, small sample sizes, high drop-out rates, and lack of an adequate control group (in most studies). The studies generally support the view that GH treatment results in modest increases in short-term growth rates and in adult height, although treated individuals remain relatively short compared with their peers [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/10-15\">",
"     10-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis that included data from 1985-2000 showed that GH treatment leads to increases in short-term growth velocity and adult height [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/12\">",
"       12",
"      </a>",
"      ]. For the three included studies reporting adult height, there was an average increase of approximately 4 to 6 cm (range, 2.3 to 8.7 cm), or 0.84 SD, with GH therapy. The mean treatment duration in these studies was 5.3 years. Short-term increases in growth velocities were also noted; the one-year growth velocity of the GH treated group was 2.87",
"      <span class=\"nowrap\">",
"       cm/year",
"      </span>",
"      greater than that of controls.",
"     </li>",
"     <li>",
"      A second meta-analysis that included published trials up to 2010 found that GH treatment leads to a mean increase in height of 0.65 SD score [95% CI 0.40 to 0.91 SD] (about 4 cm) as compared to untreated children [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/16\">",
"       16",
"      </a>",
"      ]. &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      In a multicenter postmarketing surveillance study of children with ISS, mean first-year growth velocities increased by 4.6",
"      <span class=\"nowrap\">",
"       cm/year",
"      </span>",
"      over pre-treatment growth velocities for children between age 5 and puberty (n=2520). Children who were under age five at study entry or pubertal had slightly lower increases in growth velocity during the first year of treatment (3.9",
"      <span class=\"nowrap\">",
"       cm/year",
"      </span>",
"      and 4.4",
"      <span class=\"nowrap\">",
"       cm/year,",
"      </span>",
"      respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/14\">",
"       14",
"      </a>",
"      ]. A consensus conference concluded that the optimal age for initiating growth hormone therapy is between age five and early puberty [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Disadvantages",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth hormone treatment at standard doses appears to have minimal physiological adverse effects.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A large multicenter postmarketing surveillance study detected no clear increase in adverse effects over that reported in the general population [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Placebo-controlled trials have generally shown no increase in physiological adverse effects as compared to placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/10,12\">",
"       10,12",
"      </a>",
"      ], but these studies are not adequately powered to detect rare adverse events, have limited length of follow-up, and use a variety of dosing schemes.",
"     </li>",
"     <li>",
"      High-dose GH treatment (71",
"      <span class=\"nowrap\">",
"       mcg/kg/day)",
"      </span>",
"      was reported to accelerate the onset of puberty and epiphyseal closure in children with ISS [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/17\">",
"       17",
"      </a>",
"      ], but lower doses (34 or 53",
"      <span class=\"nowrap\">",
"       mcg/kg/day)",
"      </span>",
"      did not [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients treated with GH for ISS, there are no significant differences in physiological adverse effects as compared to patients treated for GH deficiency or Turner syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, patients with substantial GH excess, such as those with acromegaly, exhibit important adverse effects, and this prompts caution regarding escalating GH doses. Adverse effects of endogenous GH excess include edema, cardiomyopathy, insulin resistance, arthropathy, pseudotumor cerebri, gynecomastia, and pancreatitis. Some but not all studies of adults with acromegaly have suggested an increased incidence of colonic and uterine neoplasia. Some of these effects have been reported in patients with growth hormone deficiency treated with exogenous growth hormone, but these are rare and in many cases not increased as compared to control groups [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/20\">",
"     20",
"    </a>",
"    ]. The risks of giving excessive doses of exogenous GH may theoretically be reduced by using IGF-I targeted dosing strategies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/0/14345?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of growth hormone deficiency in children\", section on 'Dosing and monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Psychosocial considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to treat children and adolescents with ISS using growth hormone requires complex psychosocial considerations [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. GH treatment should be considered only if the short stature represents a disability to the child and is not amenable to counseling and reassurance, and if growth augmentation is likely to provide psychosocial benefit to the child. If GH treatment achieves an increase in height, it might be expected to improve a child's self-image and social efficacy. On the other hand, GH treatment could have adverse psychosocial consequences due to the extreme focus on a child's stature conferred by GH treatment. In addition, a meaningful",
"    <span class=\"nowrap\">",
"     benefit/cost",
"    </span>",
"    assessment must be applied [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients with ISS have normal psychosocial functioning. In a population-based sample, negative stereotypes regarding the social adjustment of individuals were noted (eg, teasing and bullying, less social acceptance, and fewer friends). A few short children had problems with peer relationships, but short stature could not be established as the cause of the disturbance. In most children with extremes of short or tall stature there is minimal impact on peer perceptions of social behavior, friendship, or peer acceptance [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/21,24\">",
"     21,24",
"    </a>",
"    ]. However, the psychosocial effects of severe short stature (height &lt;-2.5 SD) have not been adequately studied [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinic-based populations may display greater psychosocial dysfunction. Children referred for treatment may have significantly more externalizing behavior problems and poorer social skills [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/25\">",
"     25",
"    </a>",
"    ]. However, in this population, most problems were identified by the parents' report, and children tended to score normally on measures of self-esteem and functioning when based on the child's self-report or report of teachers [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/26\">",
"     26",
"    </a>",
"    ]. Children referred for medical treatment for their short stature likely represent a population selected for a higher level of parental concern.",
"   </p>",
"   <p>",
"    Effects of GH treatment on psychosocial functioning were addressed in three small studies with untreated controls [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. None of these studies showed differences between the treatment groups in behavior, self-esteem, or quality of life. These studies were limited by small sample size (about 30 children in each study).",
"   </p>",
"   <p>",
"    Specific effects of GH treatment on child behavior and social functioning were addressed in a placebo-controlled trial of 68 children with ISS [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/30\">",
"     30",
"    </a>",
"    ]. In this study there was a significant decrease in behavioral problems among the group treated with GH when compared to placebo, as measured by parent report, but both groups remained in the normal range for these measures. There was no difference in measures of social competency. The study was limited by small sample size and male predominance. Because it compared GH treatment to placebo, this study did not address the non-specific effects of GH treatment (for example, whether the focus on a child's stature conferred by treatment might have adverse psychosocial consequences).",
"   </p>",
"   <p>",
"    None of the above studies has specifically addressed the problem of unmet expectations. Children presenting for GH therapy often believe that the treatment will make them of average height or taller than average. However, even if the treatment is successful in adding 5 cm (2 inches) to the height of a person who is destined to be 155 cm (61 inches) and now permits an adult height of 160 cm (63 inches), that person, especially if male, will still be a short adult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Costs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment costs of GH therapy are substantial and present an important consideration for allocation of medical resources. Given the current costs of GH treatment in the United States, this corresponds to more than $50,000 per inch (2.54 cm) gained in adult height [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/31\">",
"     31",
"    </a>",
"    ]; this is a significant expense for any health system and potentially diverts a limited pool of resources away from other needs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Today, about 100,000 children worldwide are treated with rhGH, but dosing remains largely arbitrary particularly for indications other than GH deficiency.",
"   </p>",
"   <p>",
"    Children with true GH deficiency may respond to relatively low doses of GH, commonly in the range of 20 to 40",
"    <span class=\"nowrap\">",
"     mcg/kg/day,",
"    </span>",
"    and this dose may be readjusted based on IGF-I levels. The potential benefits and risks of larger doses are unclear. The doses used in the United States are often at the higher end of the range, and doses as high as 100",
"    <span class=\"nowrap\">",
"     mcg/kg/day",
"    </span>",
"    have been approved by the FDA for treatment of adolescents with GH deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/0/14345?source=see_link\">",
"     \"Treatment of growth hormone deficiency in children\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    For children with ISS the optimal dosing range is less established. In prepubertal children with ISS, GH routinely is used in the range of 25 to 50",
"    <span class=\"nowrap\">",
"     mcg/kg/day.",
"    </span>",
"    Higher doses lead to modest increases in short-term growth velocity and adult height [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/15\">",
"     15",
"    </a>",
"    ]. In a multicenter study of children with ISS, GH doses of 0.37",
"    <span class=\"nowrap\">",
"     mg/kg/week",
"    </span>",
"    (53",
"    <span class=\"nowrap\">",
"     mcg/kg/day)",
"    </span>",
"    were significantly more effective than doses of 0.24",
"    <span class=\"nowrap\">",
"     mg/kg/week",
"    </span>",
"    (35",
"    <span class=\"nowrap\">",
"     mcg/kg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/32\">",
"     32",
"    </a>",
"    ]. Adult height was increased by 7.2 and 5.4 cm, respectively in the two treatment groups, and 94 versus 71 percent were within the range of normal adult height (within 2 SD of the mean).",
"   </p>",
"   <p>",
"    When treatment is chosen for children with ISS, we suggest a dosing scheme similar to that used for children with growth hormone deficiency. &nbsp;In our practice, we use a starting dose of approximately 40",
"    <span class=\"nowrap\">",
"     mcg/kg/day,",
"    </span>",
"    and then readjust the dose based on serial measures of IGF-I. (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Dose adjustment for IGF-I levels'",
"    </a>",
"    below). Because the response to treatment is variable, the linear growth rate and treatment plan should be reevaluated periodically.",
"   </p>",
"   <p>",
"    Subsequent treatment decisions are based on the growth response:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We continue treatment only if the height velocity increases by 50 percent or at least 2.5",
"      <span class=\"nowrap\">",
"       cm/year",
"      </span>",
"      above the baseline height velocity. Other criteria for a poor response to GH treatment are a height velocity less than +1 SD, or change in height SD less than 0.3 to 0.5 (depending on the age), after one year of treatment. If a patient has a poor response to GH despite adherence to treatment and appropriate dosing according to IGF-I levels, then GH treatment should be stopped and alternative therapies considered [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Other treatments'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      If the initial growth response is significant (at least 2.5",
"      <span class=\"nowrap\">",
"       cm/year",
"      </span>",
"      above the baseline height velocity), treatment is continued until linear growth decreases to less than 2.0 to 2.5 cm (about 1",
"      <span class=\"nowrap\">",
"       inch)/year.",
"      </span>",
"      This usually occurs in late puberty, equating to a bone age of 15.5 to 16 years in boys and 13 to 13.5 years in girls. &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Dose adjustment for IGF-I levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emerging evidence supports the idea of adjusting GH dose based on IGF-I levels when treating children with ISS. The rationale for this approach is that children with ISS may have a variety of abnormalities in the GH-IGF axis, conferring varied levels of GH resistance. Some studies in children with GH deficiency or ISS suggest GH responsiveness is closely associated with IGF-I levels [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/10,33\">",
"     10,33",
"    </a>",
"    ]. In addition, some side effects of GH, such as arthralgias and edema, are associated with supraphysiologic IGF-I levels in other populations. IGF-I targeted dosing is now commonly used for treating growth hormone deficiency, but its utility in ISS is less well established.",
"   </p>",
"   <p>",
"    One study assessed the safety and effectiveness of targeting GH doses to IGF-I levels in children with ISS [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/34\">",
"     34",
"    </a>",
"    ]. GH dosing was adjusted to produce a low-target IGF-I level (0 &plusmn; 0.5 SD from the mean for age and gender) or a high target IGF-I level (2 &plusmn; 0.5 SD). Those with the higher IGF-I target level grew at a faster rate, although they required more than 2.5 times the amount of GH (median dose of 120",
"    <span class=\"nowrap\">",
"     mcg/kg/day)",
"    </span>",
"    as compared to the low-IGF-I target group. There was a wide range of final doses (up to 250",
"    <span class=\"nowrap\">",
"     mcg/kg/day).",
"    </span>",
"    Adverse event profiles were similar in both groups. Within each treatment group (low and high IGF-I target) the ISS subjects showed significantly less growth than a group of GH deficient subjects, consistent with the hypothesis that some children with ISS have GH resistance. This study is consistent with other observations that baseline IGF-I levels (and the response of IGF-I to GH administration) correlate with GH responsiveness in populations with ISS [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/10,35\">",
"     10,35",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Safety'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p>",
"    Although the evidence is preliminary and inferential, it appears that adjustment of GH dose based on IGF-I levels may increase efficacy and safety of GH treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/2\">",
"     2",
"    </a>",
"    ]. We therefore suggest that GH dosing be adjusted to maintain IGF-I within a normal range. Optimization and cost-effectiveness of this technique require further study. In our practice, we adjust the GH dose to keep the IGF-I level at approximately 1 SD above the mean for age and gender. If IGF-I levels are consistently elevated (&gt;2.5 SD), the GH dose should be reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/2\">",
"     2",
"    </a>",
"    ]. We check IGF-I levels approximately four weeks after beginning therapy or changing the GH dose, and approximately every 6 to 12 months thereafter, similar to the approach we use for patients with GH deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/0/14345?source=see_link&amp;anchor=H562846#H562846\">",
"     \"Treatment of growth hormone deficiency in children\", section on 'Dose adjustment based on IGF-I response'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although patients with significant GH resistance may benefit from IGF-I targeted dosing (which would tend to dictate higher GH doses for these children), this is also the group for which direct replacement of IGF-I may be most effective. Clinical trials will be necessary to determine the roles of GH versus recombinant IGF-I, or GH combined with recombinant IGF-I in subsets of children with ISS. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Recombinant human IGF-I'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     OTHER TREATMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the molecular basis for short stature becomes better characterized, treatments other than or combined with GH may emerge as alternatives or advances over GH therapy for some subgroups. At present, the following treatment alternatives might be helpful for some subgroups of children with ISS, but there is insufficient evidence to determine selection criteria or efficacy in this population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Recombinant human IGF-I",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recombinant IGF-I (rhIGF-I) has been effectively used for treatment of children with \"severe primary IGF-I deficiency\" [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. A preparation of rhIGF-I (Mecasermin, Increlex&trade;) is approved by the FDA for this use. However, it is less clear whether this agent has a role in the treatment of children with ISS, some of whom may have lesser degrees of IGF-I deficiency and growth hormone insensitivity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39270?source=see_link\">",
"     \"Growth hormone insensitivity syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe primary IGF-I deficiency, also known as Laron syndrome, is caused by complete absence or insensitivity of the growth hormone receptor. Thus, by definition, these individuals do not have \"idiopathic\" short stature. Deletions of the IGF-I gene cause a similar phenotype. These disorders are rare and severe; affected individuals have growth rates about half normal, leading to adult stature between 4 and 12 SD below the mean [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with ISS may have lesser degrees of growth hormone insensitivity and a similar endocrine profile, with normal or elevated circulating serum GH levels but low levels of insulin-like growth factor-I (IGF-I) and IGF binding protein 3 (IGFBP-3). For these children, direct replacement of IGF-I may be more effective than GH treatment. This condition has sometimes been termed \"primary IGF-I deficiency\", but it should not be confused with \"severe primary IGF-I deficiency\" or Laron syndrome described above. Caution should be used in extrapolating the results of IGF-I treatment for individuals with complete GH insensitivity, such as those with Laron syndrome, to those with partial GH insensitivity and to the ISS population in general [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/38-40\">",
"       38-40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There has not been enough experience in the treatment of severe (and less severe) primary IGF-I deficiency to permit one to determine the role of recombinant IGF-I in the therapeutic armamentarium. However, because these agents can bypass molecular defects that cause GH insensitivity, they hold promise for patients with diminished responses to GH, including some patients with ISS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     GnRH analogs",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative approach to attempt to increase adult height in those very short children with ISS is to delay pubertal development and epiphyseal fusion with gonadotropin releasing hormone analogues (GnRHa). The range of the effect is limited to approximately 0 to 4 cm when the change in predicted adult height is compared to measured adult height [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Testosterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Boys with mild to moderate short stature (height taller than -2.5 SD) whose puberty and bone age are delayed (ie, have constitutional delay of growth) will often have a predicted adult height in the normal range. In this case, treatment with testosterone during adolescence may be helpful to promote puberty and accelerate linear growth; if given in modest doses the treatment will not significantly affect adult height (either positively or negatively) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Aromatase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aromatase inhibitors (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/26/36261?source=see_link\">",
"     letrozole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/49/22294?source=see_link\">",
"     anastrozole",
"    </a>",
"    ) facilitate growth in adolescent males by delaying epiphyseal closure. In girls, aromatase inhibitors would be expected to slow growth because they inhibit estrogen production. Preliminary studies suggest that treatment of adolescent boys with aromatase inhibitors, with [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/42\">",
"     42",
"    </a>",
"    ] or without [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/43\">",
"     43",
"    </a>",
"    ] concomitant growth hormone, increases predicted adult height. However, long-term safety and efficacy results are not available [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18248/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/12/3266?source=see_link\">",
"       \"Patient information: My child is short (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of children with idiopathic short stature (ISS) with growth hormone is controversial because of variable efficacy and high costs.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many children with ISS will experience some catch-up growth without growth hormone therapy. Spontaneous height increases between 0.5 and 1.9 SD are reported in studies of untreated children with ISS. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Growth hormone therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of children with ISS do not have impaired self-esteem or psychosocial functioning. Among children referred for treatment, parents often report psychosocial concerns, but studies based on child self-report, or reports from peers or teachers generally show normal psychosocial function among children with ISS. Furthermore, limited data do not suggest an improvement in quality of life with growth hormone treatment. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Psychosocial considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Costs of treatment with growth hormone are high, corresponding to more than $50,000 per inch gained in adult height. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Costs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      GH is approved by the US FDA for children with current height below -2.25 SD of the mean, in whom the predicted adult height is unlikely to fall within the normal range and the epiphyses are not closed. Nevertheless, the decision to treat children with ISS using growth hormone depends on individual considerations. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Growth hormone therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Growth hormone treatment is likely to yield only modest gains in height compared with no treatment (an increase in adult height of approximately 4 to 6 cm). Adult height will usually be below average despite therapy. When treatment is contemplated, it is critical for the provider to discuss realistic expectations with the patient and family. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest NOT treating children with ISS with growth hormone unless there is objective evidence supporting concerns of current or future adverse psychosocial consequences related to short stature (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This suggestion assumes that the possible psychosocial benefits associated with a modest increment in growth do not outweigh the cost and burden to the child of long-term therapy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Efficacy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Psychosocial considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When treatment is chosen for children with ISS, we suggest a dosing scheme that adjusts doses based on IGF-I levels, similar to that used for children with growth hormone deficiency (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In our practice, we use a starting dose is approximately 40",
"      <span class=\"nowrap\">",
"       mcg/kg/day.",
"      </span>",
"      The target level of IGF-I is 1 SD above the mean for age and gender (upper limit 2 SD above the mean). We continue treatment only if the height velocity increases by at least 2.5",
"      <span class=\"nowrap\">",
"       cm/year",
"      </span>",
"      above the baseline height velocity. Treatment is continued until the time the height velocity slows to less than 2.0 to 2.5",
"      <span class=\"nowrap\">",
"       cm/year",
"      </span>",
"      in late puberty. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Dosing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Dose adjustment for IGF-I levels'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with ISS and low baseline IGF-I levels may have partial growth hormone insensitivity. In such children, we offer a six-month trial of growth hormone treatment to determine GH responsiveness. If growth does not accelerate significantly during the treatment trial, then we do not continue treatment. In this case alternative treatments might be considered. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Other treatments'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/1\">",
"      Ranke MB. Towards a consensus on the definition of idiopathic short stature. Horm Res 1996; 45 Suppl 2:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/2\">",
"      Cohen P, Rogol AD, Deal CL, et al. Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab 2008; 93:4210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/3\">",
"      Gubitosi-Klug RA, Cuttler L. Idiopathic short stature. Endocrinol Metab Clin North Am 2005; 34:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/4\">",
"      Rosenfeld RG, Albertsson-Wikland K, Cassorla F, et al. Diagnostic controversy: the diagnosis of childhood growth hormone deficiency revisited. J Clin Endocrinol Metab 1995; 80:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/5\">",
"      Rogol AD, Blethen SL, Sy JP, Veldhuis JD. Do growth hormone (GH) serial sampling, insulin-like growth factor-I (IGF-I) or auxological measurements have an advantage over GH stimulation testing in predicting the linear growth response to GH therapy? Clin Endocrinol (Oxf) 2003; 58:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/6\">",
"      Attie KM, Carlsson LM, Rundle AC, Sherman BM. Evidence for partial growth hormone insensitivity among patients with idiopathic short stature. The National Cooperative Growth Study. J Pediatr 1995; 127:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/7\">",
"      Buckway CK, Guevara-Aguirre J, Pratt KL, et al. The IGF-I generation test revisited: a marker of GH sensitivity. J Clin Endocrinol Metab 2001; 86:5176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/8\">",
"      Food and drug administration. FDA approves humatrope for short stature. Fed Regist 2003; 68:24003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/9\">",
"      Rekers-Mombarg LT, Wit JM, Massa GG, et al. Spontaneous growth in idiopathic short stature. European Study Group. Arch Dis Child 1996; 75:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/10\">",
"      Leschek EW, Rose SR, Yanovski JA, et al. Effect of growth hormone treatment on adult height in peripubertal children with idiopathic short stature: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2004; 89:3140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/11\">",
"      Hintz RL, Attie KM, Baptista J, Roche A. Effect of growth hormone treatment on adult height of children with idiopathic short stature. Genentech Collaborative Group. N Engl J Med 1999; 340:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/12\">",
"      Finkelstein BS, Imperiale TF, Speroff T, et al. Effect of growth hormone therapy on height in children with idiopathic short stature: a meta-analysis. Arch Pediatr Adolesc Med 2002; 156:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/13\">",
"      Bryant J, Baxter L, Cave CB, Milne R. Recombinant growth hormone for idiopathic short stature in children and adolescents. Cochrane Database Syst Rev 2007; :CD004440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/14\">",
"      Kemp SF, Kuntze J, Attie KM, et al. Efficacy and safety results of long-term growth hormone treatment of idiopathic short stature. J Clin Endocrinol Metab 2005; 90:5247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/15\">",
"      Albertsson-Wikland K, Aronson AS, Gustafsson J, et al. Dose-dependent effect of growth hormone on final height in children with short stature without growth hormone deficiency. J Clin Endocrinol Metab 2008; 93:4342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/16\">",
"      Deodati A, Cianfarani S. Impact of growth hormone therapy on adult height of children with idiopathic short stature: systematic review. BMJ 2011; 342:c7157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/17\">",
"      Kamp GA, Waelkens JJ, de Muinck Keizer-Schrama SM, et al. High dose growth hormone treatment induces acceleration of skeletal maturation and an earlier onset of puberty in children with idiopathic short stature. Arch Dis Child 2002; 87:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/18\">",
"      Crowe BJ, Rekers-Mombarg LT, Robling K, et al. Effect of growth hormone dose on bone maturation and puberty in children with idiopathic short stature. J Clin Endocrinol Metab 2006; 91:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/19\">",
"      Quigley CA, Gill AM, Crowe BJ, et al. Safety of growth hormone treatment in pediatric patients with idiopathic short stature. J Clin Endocrinol Metab 2005; 90:5188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/20\">",
"      Critical evaluation of the safety of recombinant human growth hormone administration: statement from the Growth Hormone Research Society. J Clin Endocrinol Metab 2001; 86:1868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/21\">",
"      Sandberg DE, Bukowski WM, Fung CM, Noll RB. Height and social adjustment: are extremes a cause for concern and action? Pediatrics 2004; 114:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/22\">",
"      Allen DB, Fost N. hGH for short stature: ethical issues raised by expanded access. J Pediatr 2004; 144:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/23\">",
"      Rosenfeld RG. A tale of two centimeters. J Pediatr 2005; 146:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/24\">",
"      Lee JM, Appugliese D, Coleman SM, et al. Short stature in a population-based cohort: social, emotional, and behavioral functioning. Pediatrics 2009; 124:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/25\">",
"      Kranzler JH, Rosenbloom AL, Proctor B, et al. Is short stature a handicap? A comparison of the psychosocial functioning of referred and nonreferred children with normal short stature and children with normal stature. J Pediatr 2000; 136:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/26\">",
"      Visser-van Balen H, Sinnema G, Geenen R. Growing up with idiopathic short stature: psychosocial development and hormone treatment; a critical review. Arch Dis Child 2006; 91:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/27\">",
"      Downie AB, Mulligan J, McCaughey ES, et al. Psychological response to growth hormone treatment in short normal children. Arch Dis Child 1996; 75:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/28\">",
"      Theunissen NC, Kamp GA, Koopman HM, et al. Quality of life and self-esteem in children treated for idiopathic short stature. J Pediatr 2002; 140:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/29\">",
"      Visser-van Balen H, Geenen R, Kamp GA, et al. Long-term psychosocial consequences of hormone treatment for short stature. Acta Paediatr 2007; 96:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/30\">",
"      Ross JL, Sandberg DE, Rose SR, et al. Psychological adaptation in children with idiopathic short stature treated with growth hormone or placebo. J Clin Endocrinol Metab 2004; 89:4873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/31\">",
"      Lee JM, Davis MM, Clark SJ, et al. Estimated cost-effectiveness of growth hormone therapy for idiopathic short stature. Arch Pediatr Adolesc Med 2006; 160:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/32\">",
"      Wit JM, Rekers-Mombarg LT, Cutler GB, et al. Growth hormone (GH) treatment to final height in children with idiopathic short stature: evidence for a dose effect. J Pediatr 2005; 146:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/33\">",
"      Park P, Cohen P. Insulin-like growth factor I (IGF-I) measurements in growth hormone (GH) therapy of idiopathic short stature (ISS). Growth Horm IGF Res 2005; 15 Suppl A:S13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/34\">",
"      Cohen P, Germak J, Rogol AD, et al. Variable degree of growth hormone (GH) and insulin-like growth factor (IGF) sensitivity in children with idiopathic short stature compared with GH-deficient patients: evidence from an IGF-based dosing study of short children. J Clin Endocrinol Metab 2010; 95:2089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/35\">",
"      Kamp GA, Zwinderman AH, Van Doorn J, et al. Biochemical markers of growth hormone (GH) sensitivity in children with idiopathic short stature: individual capacity of IGF-I generation after high-dose GH treatment determines the growth response to GH. Clin Endocrinol (Oxf) 2002; 57:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/36\">",
"      Guevara-Aguirre J, Rosenbloom AL, Vasconez O, et al. Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency. J Clin Endocrinol Metab 1997; 82:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/37\">",
"      Underwood LE, Backeljauw P, Duncan V. Effects of insulin-like growth factor I treatment on statural growth, body composition and phenotype of children with growth hormone insensitivity syndrome. GHIS Collaborative Group. Acta Paediatr Suppl 1999; 88:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/38\">",
"      Rosenbloom AL. The role of recombinant insulin-like growth factor I in the treatment of the short child. Curr Opin Pediatr 2007; 19:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/39\">",
"      Rosenbloom AL. Recombinant human insulin-like growth factor I (rhIGF-I) and rhIGF-I/rhIGF-binding-protein-3: new growth treatment options? J Pediatr 2007; 150:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/40\">",
"      Collett-Solberg PF, Misra M, Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. The role of recombinant human insulin-like growth factor-I in treating children with short stature. J Clin Endocrinol Metab 2008; 93:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/41\">",
"      Yanovski JA, Rose SR, Municchi G, et al. Treatment with a luteinizing hormone-releasing hormone agonist in adolescents with short stature. N Engl J Med 2003; 348:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/42\">",
"      Mauras N, Gonzalez de Pijem L, Hsiang HY, et al. Anastrozole increases predicted adult height of short adolescent males treated with growth hormone: a randomized, placebo-controlled, multicenter trial for one to three years. J Clin Endocrinol Metab 2008; 93:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18248/abstract/43\">",
"      Hero M, Wickman S, Dunkel L. Treatment with the aromatase inhibitor letrozole during adolescence increases near-final height in boys with constitutional delay of puberty. Clin Endocrinol (Oxf) 2006; 64:510.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5824 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-201.211.0.116-FF9DEC9E2E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_52_18248=[""].join("\n");
var outline_f17_52_18248=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Endocrine findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Exclusion of other diagnoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      GROWTH HORMONE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Disadvantages",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Safety",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Psychosocial considerations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Costs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Dose adjustment for IGF-I levels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      OTHER TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Recombinant human IGF-I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      GnRH analogs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Testosterone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Aromatase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=related_link\">",
"      Causes of short stature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18376?source=related_link\">",
"      Diagnostic approach to short stature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39270?source=related_link\">",
"      Growth hormone insensitivity syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/12/3266?source=related_link\">",
"      Patient information: My child is short (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/0/14345?source=related_link\">",
"      Treatment of growth hormone deficiency in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_52_18249="Complications and outcome of infective endocarditis";
var content_f17_52_18249=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Complications and outcome of infective endocarditis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/52/18249/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/52/18249/contributors\">",
"     Denis Spelman, MBBS, FRACP, FRCPA, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/52/18249/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/52/18249/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/52/18249/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/52/18249/contributors\">",
"     Gabriel S Aldea, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/52/18249/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/52/18249/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/52/18249/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/52/18249/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/52/18249/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infective endocarditis (IE) is associated with a myriad of complications, one or more of which occur in the majority of patients. This was illustrated in a review of 223 episodes of IE in which 57 percent of patients had one complication, 26 percent had two, 8 percent had three or more, and 6 percent had six or more complications [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/1\">",
"     1",
"    </a>",
"    ]. Complications, such as heart failure and stroke, are relatively common and feared outcomes of IE; other complications, such as blindness and septic arthritis, are, fortunately, rare in modern practice.",
"   </p>",
"   <p>",
"    The frequency and type of complications due to IE have changed with advances in diagnosis and therapy. Renal failure and uncontrolled intracardiac or metastatic infection, for example, which were previously common complications of IE, are infrequent in the antibiotic era. The frequency of specific complications depends upon variables, such as the infecting pathogen, duration of illness prior to therapy, and the type of treatment facility (eg, referral versus community hospital). It is often difficult to assess the true incidence of complications despite extensive literature on the subject because different reviews and case series are generally based upon retrospective chart reviews and use different diagnostic criteria to define cases of IE. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31094?source=see_link\">",
"     \"Infective endocarditis: Historical and Duke criteria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Complications and outcomes are related in part to underlying comorbidities. For example, patients with IE involving congenital bicuspid aortic valves appear to be more prone to perivalvular complications than those with IE involving tricuspid aortic valves [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, complications and severe outcomes tend to occur with greater frequency among the elderly and patients with renal failure than otherwise healthy individuals with drug abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40215?source=see_link\">",
"     \"Infective endocarditis in injection drug users\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major complications of IE will be reviewed here. Frequency of these complications will only be described as relatively common, rare, or very rare because accurate numbers are not available. Complications can occur before, during and, rarely, even after the end of therapy (eg, ruptured mycotic aneurysm).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of infective endocarditis (IE) can be broadly categorized as:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cardiac",
"     </li>",
"     <li>",
"      Septic",
"     </li>",
"     <li>",
"      Embolic",
"     </li>",
"     <li>",
"      Neurologic",
"     </li>",
"     <li>",
"      Musculoskeletal",
"     </li>",
"     <li>",
"      Renal",
"     </li>",
"     <li>",
"      Associated with medical treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although these categories are broad and organize the complications in an understandable fashion, they do not take into account significant overlapping features. As an example, patients with neurologic involvement can simultaneously have embolic and septic processes.",
"   </p>",
"   <p>",
"    One can also consider complications in terms of their pathogenesis, which leads to different groupings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Embolic (eg, cerebral infarct)",
"     </li>",
"     <li>",
"      Local spread of infection (eg, heart valve destruction)",
"     </li>",
"     <li>",
"      Metastatic infection (eg, vertebral osteomyelitis)",
"     </li>",
"     <li>",
"      Immune-mediated damage (eg, glomerulonephritis)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CARDIAC COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac complications are the most common complications seen in infective endocarditis (IE), occurring in one-third to one-half of patients in most recent case series [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Indications for surgery in patients with cardiac complications are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22297?source=see_link\">",
"     \"Surgery for native valve endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart failure (HF) remains the most common cause of death due to IE in the modern era and is the most frequent reason for cardiac surgery in patients with IE. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22297?source=see_link\">",
"     \"Surgery for native valve endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The usual cause of HF in patients with IE is valvular insufficiency resulting from infection-induced valvular damage. Rarely, embolism of fragments of valvular vegetations or vegetation-induced stenosis of the coronary ostia can cause acute myocardial infarction and subsequent HF [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Perivalvular abscesses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with IE, the reported incidence of perivalvular abscess at surgery or autopsy has ranged from about 30 to 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. The aortic valve and its adjacent annulus are more susceptible to abscess formation and the complications of perivalvular extension of infection than are the mitral valve and ring [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. This was illustrated in an autopsy study of patients with native valve endocarditis: annular extension of infection was far more common in patients with aortic valve compared with mitral valve endocarditis (41 versus 6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Injection drug use may be another risk factor for perivalvular abscess [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/7\">",
"     7",
"    </a>",
"    ]. In contrast, although large vegetation size had been implicated as a risk factor in some series, subsequent studies have shown no correlation between the presence or size of the vegetation and the development of periannular extension [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/7,9\">",
"     7,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Perivalvular abscesses can extend into adjacent cardiac conduction tissues, possibly leading to various forms of heart block. Involvement of the conducting system is most common with infection of the aortic valve, especially when there is involvement of the valve ring between the right and non-coronary cusp (this anatomic site overlies the intraventricular septum that contains the proximal ventricular conduction system). Rarely perivalvular infection can result in extrinsic coronary compression and can cause acute coronary syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Perivalvular abscess should be suspected when fever persists despite appropriate antimicrobial therapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    when conduction abnormalities appear on the ECG [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/11\">",
"     11",
"    </a>",
"    ]. Transesophageal echocardiography (TEE) has a much greater likelihood of detecting a myocardial abscess than transthoracic echocardiography (TTE). One study, for example, evaluated 118 patients with IE, 37 percent of whom had an abscess documented at surgery or autopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/8\">",
"     8",
"    </a>",
"    ]. The sensitivity, specificity, and positive and negative predictive values of TEE imaging were 87, 95, 91, and 92 percent, respectively. The sensitivity of TTE was much lower (28 versus 87 percent), although the specificity was 99 percent. However, some perivalvular abscesses may be missed by TEE. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20617?source=see_link&amp;anchor=H23#H23\">",
"     \"Role of echocardiography in infective endocarditis\", section on 'Perivalvular abscess or fistula'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with perivalvular abscesses appear to have higher rates of systemic embolization and fatal outcomes. In one study comparing outcomes of patients with and without perivalvular abscesses, the rate of embolization was approximately twice as high (64 versus 30 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/7\">",
"     7",
"    </a>",
"    ]. These patients also have a higher mortality rate (23 versus 14 percent in those without abscesses in a report of 118 patients, 44 of whom had a perivalvular abscess) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/8\">",
"     8",
"    </a>",
"    ]. Mortality may be particularly high in patients with at least moderate valvular regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other extravalvular complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other rare extravalvular cardiac complications of IE include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pericarditis, which may be suppurative or nonsuppurative, can rarely cause pain or even cardiac tamponade [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35303?source=see_link\">",
"       \"Purulent pericarditis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37625?source=see_link\">",
"       \"Clinical presentation and diagnostic evaluation of acute pericarditis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fistulous intracardiac connections (eg, aorta-atrial or aorta-ventricular) due to extension of infection from the valve to adjacent myocardium may rarely result in large aneurysms, a pseudoaneurysm if the aortic wall is involved [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/15\">",
"       15",
"      </a>",
"      ], or even myocardial perforation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The incidence of fistulous intracardiac complications was 1.6 percent in a retrospective, multicenter study of 4681 episodes of IE [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/16\">",
"     16",
"    </a>",
"    ]. Surgery was performed in 66 of the 76 patients, with a mortality of 41 percent. Multivariate analysis identified heart failure (odds ratio [OR] 4.3), prosthetic IE (OR 4.6), and urgent or emergent surgical treatment (OR 4.3) as being significantly associated with an increased risk of death.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aortic valve dissection [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Descending thoracic aorta intraluminal infectious masses [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EMBOLIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Embolization remains a distressingly common complication of infective endocarditis (IE) and can occur even after appropriate therapy is well underway. This section will provide a general discussion of embolization in patients with IE. Issues related to embolization in patients with IE who undergo surgery are discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22297?source=see_link&amp;anchor=H7#H7\">",
"     \"Surgery for native valve endocarditis\", section on 'Embolization'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/32/3591?source=see_link&amp;anchor=H7#H7\">",
"     \"Surgery for prosthetic valve endocarditis\", section on 'Embolization'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Systemic emboli most commonly complicate left-sided IE but rarely can occur in tricuspid valve endocarditis via a patent foramen ovale [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/19\">",
"     19",
"    </a>",
"    ]. However, emboli to the lung with subsequent abscess formation occur frequently in patients with tricuspid endocarditis. Small, clinically inapparent embolization probably occurs in most, if not all, patients with IE, but clinically recognized embolism has been reported in 13 to 44 percent of patients in published reports [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Emboli consisting of vegetation fragments can occlude or damage virtually any blood vessel, large or small, in the systemic or pulmonary arterial circulation. As a result, emboli can produce:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stroke",
"     </li>",
"     <li>",
"      Blindness",
"     </li>",
"     <li>",
"      Painful ischemic or frankly gangrenous extremities",
"     </li>",
"     <li>",
"      Unusual pain syndromes (eg, due to splenic or renal infarction)",
"     </li>",
"     <li>",
"      Hypoxia (due to pulmonary emboli in right-sided endocarditis)",
"     </li>",
"     <li>",
"      Paralysis (due to embolic infarction of either the brain or spinal cord)",
"     </li>",
"     <li>",
"      Acute myocardial infarction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The incidence of cerebral emboli detected in patients with IE undergoing magnetic resonance imaging (MRI) is markedly higher than the incidence of emboli detected on the basis of clinical signs and symptoms. In one study, clinical findings consistent with embolism were present in 13 of 65 patients with IE [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/22\">",
"     22",
"    </a>",
"    ]. However, MRI detected emboli in 24 of the remaining 52 patients. In another study, 18 of 60 patients (35 percent) with IE had clinical symptoms and signs of cerebral embolism. Clinically inapparent cerebral emboli were detected in an additional 11 patients (30 percent) using MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/23\">",
"     23",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Emboli can occasionally cause symptoms or signs that mimic other common conditions, such as kidney stones, Bell's palsy, dizziness, or pleurisy.",
"   </p>",
"   <p>",
"    Endocarditis should be considered as a possible etiology in virtually all patients who present with signs or symptoms of systemic arterial embolization. In one study, cerebral infarction was the presenting sign of IE in 4 to 14 percent of all cases of IE [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/19\">",
"     19",
"    </a>",
"    ]. The vast majority of patients with an acute stroke do not have endocarditis, although the occurrence of a stroke in a younger patient or evidence of simultaneous or sequential cerebral and systemic arterial embolization increases the probability of IE. As an example, in one report of 60 patients with IE and cerebral complications, 28 (47 percent) also had clinically identifiable systemic emboli [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/24\">",
"     24",
"    </a>",
"    ], compared with only 2 percent of all stroke patients in a different large series [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptomatic embolization appears to be more common with IE due to fungal pathogens. Whenever emboli to large systemic arterial vessels occur in a patient with IE, the possibility of a fungal etiology should be entertained. In a literature review of 270 patients with fungal endocarditis, peripheral arterial embolization occurred in 45 percent. The most common sites were the cerebral circulation (17 percent) and femoral artery (16 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Histopathologic or microbiologic examination of occluding embolic material in such large vessels may lead to a diagnosis of an underlying fungal IE. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40566?source=see_link\">",
"     \"Candida endocarditis\"",
"    </a>",
"    .) Haemophilus species and other slow growing fastidious gram-negative organisms also seem to predispose to embolization with some frequency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Effect of antibiotic therapy on embolic risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of embolization tends to decline after the institution of effective antimicrobial therapy, and serious embolic events rarely occur several weeks after such therapy is instituted [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/20,27,28\">",
"     20,27,28",
"    </a>",
"    ]. The relationship between the initiation of antibiotic therapy and the risk of embolism is illustrated by a cohort study of 1437 patients diagnosed with left-sided endocarditis at 61 medical centers [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/28\">",
"     28",
"    </a>",
"    ]. In patients receiving appropriate antibiotic therapy, the incidence of stroke was",
"    <span class=\"nowrap\">",
"     4.8/1000",
"    </span>",
"    patient days in the first week of therapy, fell to",
"    <span class=\"nowrap\">",
"     1.7/1000",
"    </span>",
"    patient days in the second week, and continued to fall with continued therapy.",
"   </p>",
"   <p>",
"    These findings suggest that surgery may not be necessary for prevention of embolic stroke in the early weeks following initiation of appropriate antibiotic therapy if there are no other indications for surgery (such as a large mobile vegetation or congestive heart failure due to valvular regurgitation).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Predictors of embolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The size of a vegetation as determined by echocardiography has been assessed as a risk factor for clinical findings of embolization in patients with IE. Although some data are conflicting, vegetation size is generally a risk factor for embolization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20617?source=see_link&amp;anchor=H17#H17\">",
"     \"Role of echocardiography in infective endocarditis\", section on 'Echocardiographic estimation of outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the presence or absence of vegetations, the location of the vegetations, the characteristics of vegetations by TEE, the specific etiologic microorganism, or antiphospholipid antibodies may also have predictive value [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/29-35\">",
"     29-35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A multicenter prospective European study of 384 patients with definite IE by Duke criteria found that emboli were more frequently observed in cases due to Streptococcus bovis and S. aureus infection by multivariate analysis [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/35\">",
"       35",
"      </a>",
"      ]. Multivariate analysis identified vegetation size &gt;10 mm and severe vegetation mobility as additional risk factors for embolic events that occurred in 28 patients after the initiation of antibiotic therapy.",
"     </li>",
"     <li>",
"      Clinical findings of embolization occur more frequently in patients with left-sided than right-sided vegetations [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/30\">",
"       30",
"      </a>",
"      ]. In a review of 281 patients with clinically suspected IE, the incidence of embolic events was greater with mitral than aortic valve vegetations (25 versus 10 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/31\">",
"       31",
"      </a>",
"      ]. The risk was highest with vegetations on the anterior mitral leaflet (37 percent), suggesting that the mechanical effects of broad and abrupt leaflet excursion may contribute to the risk of embolization [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective study of patients with IE due to S. aureus suggested that the risk of embolization was significantly greater in patients who had visible vegetations by both TTE and TEE compared with patients who had vegetations visualized only by TEE [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The absence of valvular abnormalities on TTE may be associated with a decreased incidence of complications [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The presence of antiphospholipid antibodies was correlated with an increased risk of embolization (62 versus 23 percent) in a series of 91 patients with IE, perhaps due to increased endothelial cell activation, generation of thrombin, and defective fibrinolysis [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Effect of prior antiplatelet therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possible protective effect of prior antiplatelet therapy (one or more of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    ) on embolism in IE was evaluated in a retrospective cohort of 600 patients with IE, 147 of whom (25 percent) had a symptomatic embolic event [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/36\">",
"     36",
"    </a>",
"    ]. The patients who had received continuous daily antiplatelet therapy for at least six months prior to hospitalization for IE had a significantly lower rate of a symptomatic embolic event (12 versus 28 percent without such therapy, adjusted odds ratio 0.36, 95% CI 0.19-0.68). The presumed mechanism is that platelet aggregation plays a role in vegetation formation.",
"   </p>",
"   <p>",
"    In contrast to prior therapy, the initiation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    after the diagnosis of IE is of no benefit and may be harmful. This was illustrated in a randomized trial in which 115 patients with IE were assigned to aspirin (325",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo for four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/37\">",
"     37",
"    </a>",
"    ]. Aspirin did not reduce the incidence of embolic events, was associated with a trend toward an increased incidence of bleeding (odds ratio 1.92, 95% CI 0.76-4.86), and had no effect on vegetation resolution or valve function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     NEUROLOGIC COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic cerebrovascular complications occur in about 35 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/19,23,38-42\">",
"     19,23,38-42",
"    </a>",
"    ]. Silent cerebrovascular complications (including ischemia and microhemorrhage) may occur in up to 80 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/23,43-45\">",
"     23,43-45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a prospective study of 60 patients with left-sided endocarditis who underwent neurologic examination and magnetic resonance imaging (MRI) of the brain (regardless of neurological symptoms), most patients with neurologic symptoms presented prior to antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/23\">",
"     23",
"    </a>",
"    ]. Initial neurologic symptoms were observed after initiation of antibiotic therapy in 5 percent of cases, and no new symptomatic cerebrovascular complications were detected after 10 days of antibiotic therapy.",
"   </p>",
"   <p>",
"    In another study of 130 patients with infective endocarditis (IE) (including 16 with neurologic symptoms and 114 without), MRI was notable for brain lesions in 82 and 79 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26649?source=see_link\">",
"     \"Complications of Staphylococcus aureus bacteremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism for and types of neurologic complications are diverse and include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Embolic stroke",
"     </li>",
"     <li>",
"      Acute encephalopathy",
"     </li>",
"     <li>",
"      Meningoencephalitis",
"     </li>",
"     <li>",
"      Purulent or aseptic meningitis",
"     </li>",
"     <li>",
"      Cerebral hemorrhage (due to stroke or a ruptured mycotic aneurysm)",
"     </li>",
"     <li>",
"      Brain abscess or cerebritis",
"     </li>",
"     <li>",
"      Seizures (secondary to abscess or embolic infarction)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Neurologic complications may be the presenting symptom in patients with IE. In a series of 68 patients with stroke and endocarditis, for example, two-thirds presented to the hospital with stroke before the diagnosis of endocarditis was made [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/46\">",
"     46",
"    </a>",
"    ]. Thus, the possibility of IE should be considered in all patients who present with strokes, meningitis, or a brain abscess. Unexplained fever accompanying a stroke in a patient with valvular disease is an important clue in some patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=see_link\">",
"     \"Diagnostic approach to infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reported patient outcomes after a neurologic complication are variable. The following findings have been noted in different series:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among survivors of cardiac surgery for IE, 70 percent of patients with a preoperative stroke experienced a full neurologic recovery [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/42\">",
"       42",
"      </a>",
"      ]. Outcomes were worse in patients with stroke complicated by meningitis, abscess, or intracerebral hemorrhage.",
"     </li>",
"     <li>",
"      Patient mortality in more contemporary series has varied from approximately 20 to 50 percent at one year [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/42,46\">",
"       42,46",
"      </a>",
"      ] to as high as 74 percent (time of follow-up not given) in patients with Staphylococcus aureus endocarditis [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One of the dilemmas that often arises is whether neurologic complications of IE are a contraindication to valve replacement. This important issue is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22297?source=see_link&amp;anchor=H7#H7\">",
"     \"Surgery for native valve endocarditis\", section on 'Embolization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MYCOTIC ANEURYSMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mycotic aneurysms can occur in the cerebral or systemic circulation of patients with infective endocarditis (IE), usually at points of vessel bifurcation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/17/35098?source=see_link\">",
"     \"Overview of infected (mycotic) arterial aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     RENAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal infarction (due to emboli), drug-induced acute interstitial nephritis, glomerulonephritis (due to deposition of immunoglobulins and complement in the glomerular membrane) and, rarely, renal abscess can occur in patients with infective endocarditis (IE). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/27/5556?source=see_link\">",
"     \"Renal disease in the setting of infective endocarditis or an infected ventriculoatrial shunt\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute renal failure, defined as a serum creatinine of 2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (177",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    or greater, has been reported in up to one-third of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/47\">",
"     47",
"    </a>",
"    ]. By contrast, chronic renal failure due to immune-complex mediated glomerulonephritis, which was a common contributing cause of death in patients who presented with classic IE in the preantibiotic era, is now rare. Immune complex-mediated renal disease is also uncommon in the antibiotic era, especially in patients whose infection is detected and treated early.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     METASTATIC ABSCESSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, metastatic abscesses develop in the kidneys, spleen, brain, or soft tissues (eg, the psoas muscle) in the setting of infective endocarditis (IE). There is a strong association between IE and splenic abscess, even though otherwise splenic abscesses are less frequently observed than other types of intraabdominal abscesses.",
"   </p>",
"   <p>",
"    Patients with splenic abscesses usually do not have marked abdominal pain or splenomegaly; persistent fever during or after treatment for IE and occasionally recurrent bacteremia after cure of the valvular infection may be the only clues to the presence of this complication [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/48\">",
"     48",
"    </a>",
"    ]. Splenic abscesses are often diagnosed only at autopsy and generally require splenectomy for cure. In one study of 27 patients with splenic abscesses, mortality was 100 percent in the patients who did not have a splenectomy compared with 18 percent in the patients who had the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Discrete microabscesses or larger solitary brain abscesses can rarely occur in patients with IE. Abscess formation occurs as a sequela of septic embolization. Some patients with IE and brain abscesses also have purulent meningitis. In fact, the presence of meningitis due to S. aureus should suggest the possibility of concomitant S. aureus endocarditis. In one case series of 33 patients with S. aureus meningitis, seven (21 percent) also had endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Appropriate treatment, including drainage of abscesses, is needed not only to control the local infection but also to prevent ongoing bacteremia, which is of particular concern among patients who may require surgical treatment of endocarditis with implantation of a prosthetic valve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MUSCULOSKELETAL COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vertebral osteomyelitis is a well known but relatively rare complication of infective endocarditis (IE). Although the majority of patients with IE and back pain do not have vertebral osteomyelitis, protracted, severe back pain in any patient with IE should alert the clinician to this possibility. Plain films are insensitive for diagnosing vertebral osteomyelitis, especially if taken early in the course of illness [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22985?source=see_link\">",
"     \"Vertebral osteomyelitis and discitis\"",
"    </a>",
"    .) Osteomyelitis more frequently complicates S. aureus endocarditis than IE due to other microorganisms [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute septic arthritis, involving one or more joints, may be the first clue to the presence of IE in a small percentage of patients. IE should be strongly considered in selected cases of septic arthritis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When infections spontaneously arise in joints of the axial skeleton (eg, sacroiliac, pubic, or manubriosternal joints).",
"     </li>",
"     <li>",
"      When organisms with a known propensity to cause IE (eg, S. aureus, viridans streptococci or non-group A beta-hemolytic streptococci) grow from a joint aspirate, particularly in patients without a history of recent surgery, joint infection, or trauma.",
"     </li>",
"     <li>",
"      When multiple joints are infected.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     COMPLICATIONS OF MEDICAL OR SURGICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with infective endocarditis (IE) can develop a number of the complications associated with prolonged parenteral antimicrobial therapy or surgery:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aminoglycoside-induced ototoxicity or nephrotoxicity. (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18072?source=see_link\">",
"       \"Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Secondary bacteremia due to central vascular lines. (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37464?source=see_link\">",
"       \"Epidemiology, pathogenesis, and microbiology of intravascular catheter infections\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Mediastinitis or early postoperative prosthetic valve endocarditis. (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/48/1800?source=see_link\">",
"       \"Postoperative mediastinitis after cardiac surgery\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Intravenous catheter-associated phlebitis.",
"     </li>",
"     <li>",
"      Drug fever. (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/25/2456?source=see_link\">",
"       \"Drug fever\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Allergic or idiosyncratic reactions to various antimicrobial agents.",
"     </li>",
"     <li>",
"      Bleeding due to disturbances in coagulation caused by anticoagulants (in prosthetic valve endocarditis).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies have evaluated death rates in patients with both native and prosthetic valve endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/52-56\">",
"     52-56",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The in-hospital mortality rate is between 18 and 23 percent",
"     </li>",
"     <li>",
"      The six month mortality rate is between 22 and 27 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The outcomes in patients with neurologic complications are described above. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Outcomes'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Predictors of death",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have attempted to identify predictors of death in patients with infective endocarditis (IE). Each patient may have one or more of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infection with S. aureus [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/53,55,57\">",
"       53,55,57",
"      </a>",
"      ]; mortality is lower with streptococcal infection (8 versus 33 percent with S. aureus in one series) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/55\">",
"       55",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Heart failure [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/54,56\">",
"       54,56",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Diabetes mellitus [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/53\">",
"       53",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Embolic events [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/53,57\">",
"       53,57",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Perivalvular abscess [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/8,12,56\">",
"       8,12,56",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Larger vegetation size [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/35,57\">",
"       35,57",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Female gender [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/35\">",
"       35",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Contraindication to surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/55\">",
"       55",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Low serum albumin [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/52\">",
"       52",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Persistent bacteremia [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/56\">",
"       56",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Abnormal mental status [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/55\">",
"       55",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Poor surgical candidacy [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/55\">",
"       55",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All but two of the preceding studies [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/53,55\">",
"     53,55",
"    </a>",
"    ] were retrospective. Because the clinical and echocardiographic features of patients with endocarditis change during the course of illness, some of the above findings should be interpreted with caution. In one of the reports using a prospective study design, neither heart failure as defined by the Framingham criteria nor cardiac surgery was independently associated with in-hospital mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/53\">",
"     53",
"    </a>",
"    ]. However, among patients with moderate to severe heart failure, cardiac surgery in other studies has been associated with a lower rate of long-term mortality compared to medical therapy alone. The data supporting this conclusion are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22297?source=see_link&amp;anchor=H2#H2\">",
"     \"Surgery for native valve endocarditis\", section on 'Efficacy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Investigators have attempted to derive models utilizing certain risk factors to estimate the risk of specific adverse outcome in patients with left-sided IE. In one study, the presence of three risk factors (heart failure, periannular complications, or S. aureus infection) in patients during the first 72 hours of hospitalization were predictive of two complications (in hospital mortality or need for urgent surgery) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18249/abstract/58\">",
"     58",
"    </a>",
"    ]. This model was derived in a cohort of 263 patients with left-sided IE and then validated prospectively in a second cohort of 264 patients. Approximately 60 percent of patients with one risk factor had an adverse outcome, whereas nearly 100 percent of patients with three risk factors had an adverse outcome.",
"   </p>",
"   <p>",
"    In view of the wide disparity in the methods used in the preceding studies, one should be cautious about making prognostic predictions in individual patients with IE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/48/26370?source=see_link\">",
"       \"Patient information: Endocarditis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H781106308\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infective endocarditis (IE) is associated with a myriad of complications, one or more of which occur in the majority of patients. Complications, such as heart failure and stroke, are relatively common and feared outcomes of IE. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications and outcomes are related in part to underlying comorbidities. For example, patients with IE involving congenital bicuspid aortic valves appear to be more prone to perivalvular complications than those with IE involving tricuspid aortic valves. In addition, complications and severe outcomes tend to occur with greater frequency among the elderly and patients with renal failure than otherwise healthy individuals with drug abuse. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cardiac complications are the most common complications seen in IE, occurring in one-third to one-half of patients. Heart failure remains the most common cause of death due to IE and is the most frequent reason for cardiac surgery in patients with IE. Other cardiac complications include perivalvular abscesses, and, more rarely, pericarditis, fistulous intracardiac connections, aortic valve dissection, and intraluminal infectious masses of the descending thoracic aorta. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Cardiac complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Embolization remains a distressingly common complication of IE. Systemic emboli most commonly complicate left-sided IE but occur rarely in tricuspid valve endocarditis via a patent foramen ovale. However, emboli to the lung with subsequent abscess formation occur frequently in patients with tricuspid endocarditis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Embolization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Emboli consisting of vegetation fragments can occlude or damage virtually any blood vessel, large or small, in the systemic or pulmonary arterial circulation. As a result, emboli can produce stroke, blindness, painful ischemic or frankly gangrenous extremities, unusual pain syndromes (eg, due to splenic or renal infarction), hypoxia (due to pulmonary emboli in right-sided endocarditis), paralysis (due to embolic infarction of either the brain or spinal cord), or acute myocardial infarction. Many patients with IE have clinically inapparent cerebral embolization that can be detected by magnetic resonance imaging (MRI).",
"      <a class=\"local\" href=\"#H7\">",
"       'Embolization'",
"      </a>",
"      above",
"     </li>",
"     <li>",
"      The risk of embolization tends to decline after the institution of effective antimicrobial therapy, and serious embolic events rarely occur several weeks after such therapy is instituted. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Effect of antibiotic therapy on embolic risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The size of a vegetation as determined by echocardiography has been assessed as a risk factor for embolization in IE. Although some data are conflicting, vegetation size is generally a risk factor for embolization. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Predictors of embolization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptomatic cerebrovascular complications occur in about 35 percent of patients. The mechanisms for and types of neurologic complications are diverse and include embolic stroke, acute encephalopathy, meningoencephalitis, purulent or aseptic meningitis, cerebral hemorrhage (due to stroke or a ruptured mycotic aneurysm), brain abscess or cerebritis, and seizures (secondary to abscess or embolic infarction). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Neurologic complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Less common complications of IE include mycotic aneurysms, renal complications, metastatic abscesses, and musculoskeletal complications. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Mycotic aneurysms'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Renal disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Metastatic abscesses'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Musculoskeletal complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multiple studies have evaluated death rates in patients with both native and prosthetic valve endocarditis:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The in-hospital mortality rate is between 18 and 23 percent",
"     </li>",
"     <li>",
"      The six-month mortality rate is between 22 and 27 percent (see",
"      <a class=\"local\" href=\"#H19\">",
"       'Mortality'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/1\">",
"      Mansur AJ, Grinberg M, da Luz PL, Bellotti G. The complications of infective endocarditis. A reappraisal in the 1980s. Arch Intern Med 1992; 152:2428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/2\">",
"      Kahveci G, Bayrak F, Pala S, Mutlu B. Impact of bicuspid aortic valve on complications and death in infective endocarditis of native aortic valves. Tex Heart Inst J 2009; 36:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/3\">",
"      Rekik S, Trabelsi I, Hentati M, et al. Infective endocarditis in hemodialysis patients: clinical features, echocardiographic data and outcome: a 10-year descriptive analysis. Clin Exp Nephrol 2009; 13:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/4\">",
"      Huang TY, Tseng HK, Liu CP, Lee CM. Comparison of the clinical manifestations of infective endocarditis between elderly and young patients - a 3-year study. J Microbiol Immunol Infect 2009; 42:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/5\">",
"      Millaire A, Van Belle E, de Groote P, et al. Obstruction of the left main coronary ostium due to an aortic vegetation: survival after early surgery. Clin Infect Dis 1996; 22:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/6\">",
"      Arnett EN, Roberts WC. Valve ring abscess in active infective endocarditis. Frequency, location, and clues to clinical diagnosis from the study of 95 necropsy patients. Circulation 1976; 54:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/7\">",
"      Omari B, Shapiro S, Ginzton L, et al. Predictive risk factors for periannular extension of native valve endocarditis. Clinical and echocardiographic analyses. Chest 1989; 96:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/8\">",
"      Daniel WG, M&uuml;gge A, Martin RP, et al. Improvement in the diagnosis of abscesses associated with endocarditis by transesophageal echocardiography. N Engl J Med 1991; 324:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/9\">",
"      Bayer AS. Infective endocarditis. Clin Infect Dis 1993; 17:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/10\">",
"      Attias D, Messika-Zeitoun D, Wolf M, et al. Acute coronary syndrome in aortic infective endocarditis. Eur J Echocardiogr 2008; 9:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/11\">",
"      Molavi A. Endocarditis: recognition, management, and prophylaxis. Cardiovasc Clin 1993; 23:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/12\">",
"      Cosmi JE, Tunick PA, Kronzon I. Mortality in patients with paravalvular abscess diagnosed by transesophageal echocardiography. J Am Soc Echocardiogr 2004; 17:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/13\">",
"      Rose RL Jr, Higgins LS, Helgason AH. Bacterial endocarditis, pericarditis and cardiac tamponade. Am J Cardiol 1967; 19:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/14\">",
"      Ali&oacute;-Bosch J, Tornos-Mas MP, Soler-Soler J. Cardiac tamponade as an initial clinical presentation of infective endocarditis. Int J Cardiol 1987; 14:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/15\">",
"      Parashara DK, Jacobs LE, Kotler MN, et al. Angina caused by systolic compression of the left coronary artery as a result of pseudoaneurysm of the mitral-aortic intervalvular fibrosa. Am Heart J 1995; 129:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/16\">",
"      Anguera I, Miro JM, Vilacosta I, et al. Aorto-cavitary fistulous tract formation in infective endocarditis: clinical and echocardiographic features of 76 cases and risk factors for mortality. Eur Heart J 2005; 26:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/17\">",
"      Abad C. Acute infectious mitroaortic endocarditis in association with acute aortic dissection. Surgical management of an unusual combination of diseases. Cardiovasc Surg 1995; 3:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/18\">",
"      Adam O, Kramm T, Klein HH, Sch&auml;fers HJ. Intraaortic vegetations as a manifestation of infective endocarditis. N Engl J Med 2007; 356:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/19\">",
"      Jones HR Jr, Siekert RG. Neurological manifestations of infective endocarditis. Review of clinical and therapeutic challenges. Brain 1989; 112 ( Pt 5):1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/20\">",
"      Steckelberg JM, Murphy JG, Ballard D, et al. Emboli in infective endocarditis: the prognostic value of echocardiography. Ann Intern Med 1991; 114:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/21\">",
"      De Castro S, Magni G, Beni S, et al. Role of transthoracic and transesophageal echocardiography in predicting embolic events in patients with active infective endocarditis involving native cardiac valves. Am J Cardiol 1997; 80:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/22\">",
"      Grabowski M, Hryniewiecki T, Janas J, St��pi��ska J. Clinically overt and silent cerebral embolism in the course of infective endocarditis. J Neurol 2011; 258:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/23\">",
"      Snygg-Martin U, Gustafsson L, Rosengren L, et al. Cerebrovascular complications in patients with left-sided infective endocarditis are common: a prospective study using magnetic resonance imaging and neurochemical brain damage markers. Clin Infect Dis 2008; 47:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/24\">",
"      Pruitt AA, Rubin RH, Karchmer AW, Duncan GW. Neurologic complications of bacterial endocarditis. Medicine (Baltimore) 1978; 57:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/25\">",
"      Mohr JP, Caplan LR, Melski JW, et al. The Harvard Cooperative Stroke Registry: a prospective registry. Neurology 1978; 28:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/26\">",
"      Ellis ME, Al-Abdely H, Sandridge A, et al. Fungal endocarditis: evidence in the world literature, 1965-1995. Clin Infect Dis 2001; 32:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/27\">",
"      Fabri J Jr, Issa VS, Pomerantzeff PM, et al. Time-related distribution, risk factors and prognostic influence of embolism in patients with left-sided infective endocarditis. Int J Cardiol 2006; 110:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/28\">",
"      Dickerman SA, Abrutyn E, Barsic B, et al. The relationship between the initiation of antimicrobial therapy and the incidence of stroke in infective endocarditis: an analysis from the ICE Prospective Cohort Study (ICE-PCS). Am Heart J 2007; 154:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/29\">",
"      Di Salvo G, Habib G, Pergola V, et al. Echocardiography predicts embolic events in infective endocarditis. J Am Coll Cardiol 2001; 37:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/30\">",
"      Bayer AS, Bolger AF, Taubert KA, et al. Diagnosis and management of infective endocarditis and its complications. Circulation 1998; 98:2936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/31\">",
"      Rohmann S, Erbel R, G&ouml;rge G, et al. Clinical relevance of vegetation localization by transoesophageal echocardiography in infective endocarditis. Eur Heart J 1992; 13:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/32\">",
"      Fowler VG Jr, Sanders LL, Kong LK, et al. Infective endocarditis due to Staphylococcus aureus: 59 prospectively identified cases with follow-up. Clin Infect Dis 1999; 28:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/33\">",
"      Sanfilippo AJ, Picard MH, Newell JB, et al. Echocardiographic assessment of patients with infectious endocarditis: prediction of risk for complications. J Am Coll Cardiol 1991; 18:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/34\">",
"      Kupferwasser LI, Hafner G, Mohr-Kahaly S, et al. The presence of infection-related antiphospholipid antibodies in infective endocarditis determines a major risk factor for embolic events. J Am Coll Cardiol 1999; 33:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/35\">",
"      Thuny F, Di Salvo G, Disalvo G, et al. Risk of embolism and death in infective endocarditis: prognostic value of echocardiography: a prospective multicenter study. Circulation 2005; 112:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/36\">",
"      Anavekar NS, Tleyjeh IM, Anavekar NS, et al. Impact of prior antiplatelet therapy on risk of embolism in infective endocarditis. Clin Infect Dis 2007; 44:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/37\">",
"      Chan KL, Dumesnil JG, Cujec B, et al. A randomized trial of aspirin on the risk of embolic events in patients with infective endocarditis. J Am Coll Cardiol 2003; 42:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/38\">",
"      Garvey GJ, Neu HC. Infective endocarditis--an evolving disease. A review of endocarditis at the Columbia-Presbyterian Medical Center, 1968-1973. Medicine (Baltimore) 1978; 57:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/39\">",
"      Harrison MJ, Hampton JR. Neurological presentation of bacterial endocarditis. Br Med J 1967; 2:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/40\">",
"      R&oslash;der BL, Wandall DA, Espersen F, et al. Neurologic manifestations in Staphylococcus aureus endocarditis: a review of 260 bacteremic cases in nondrug addicts. Am J Med 1997; 102:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/41\">",
"      Parrino PE, Kron IL, Ross SD, et al. Does a focal neurologic deficit contraindicate operation in a patient with endocarditis? Ann Thorac Surg 1999; 67:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/42\">",
"      Ruttmann E, Willeit J, Ulmer H, et al. Neurological outcome of septic cardioembolic stroke after infective endocarditis. Stroke 2006; 37:2094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/43\">",
"      Cooper HA, Thompson EC, Laureno R, et al. Subclinical brain embolization in left-sided infective endocarditis: results from the evaluation by MRI of the brains of patients with left-sided intracardiac solid masses (EMBOLISM) pilot study. Circulation 2009; 120:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/44\">",
"      Klein I, Iung B, Labreuche J, et al. Cerebral microbleeds are frequent in infective endocarditis: a case-control study. Stroke 2009; 40:3461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/45\">",
"      Duval X, Iung B, Klein I, et al. Effect of early cerebral magnetic resonance imaging on clinical decisions in infective endocarditis: a prospective study. Ann Intern Med 2010; 152:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/46\">",
"      Anderson DJ, Goldstein LB, Wilkinson WE, et al. Stroke location, characterization, severity, and outcome in mitral vs aortic valve endocarditis. Neurology 2003; 61:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/47\">",
"      Conlon PJ, Jefferies F, Krigman HR, et al. Predictors of prognosis and risk of acute renal failure in bacterial endocarditis. Clin Nephrol 1998; 49:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/48\">",
"      Weinstein L. Life-threatening complications of infective endocarditis and their management. Arch Intern Med 1986; 146:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/49\">",
"      Robinson SL, Saxe JM, Lucas CE, et al. Splenic abscess associated with endocarditis. Surgery 1992; 112:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/50\">",
"      Schlesinger LS, Ross SC, Schaberg DR. Staphylococcus aureus meningitis: a broad-based epidemiologic study. Medicine (Baltimore) 1987; 66:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/51\">",
"      Speechly-Dick ME, Swanton RH. Osteomyelitis and infective endocarditis. Postgrad Med J 1994; 70:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/52\">",
"      Wallace SM, Walton BI, Kharbanda RK, et al. Mortality from infective endocarditis: clinical predictors of outcome. Heart 2002; 88:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/53\">",
"      Chu VH, Cabell CH, Benjamin DK Jr, et al. Early predictors of in-hospital death in infective endocarditis. Circulation 2004; 109:1745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/54\">",
"      Hasbun R, Vikram HR, Barakat LA, et al. Complicated left-sided native valve endocarditis in adults: risk classification for mortality. JAMA 2003; 289:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/55\">",
"      Hill EE, Herijgers P, Claus P, et al. Infective endocarditis: changing epidemiology and predictors of 6-month mortality: a prospective cohort study. Eur Heart J 2007; 28:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/56\">",
"      Wang A, Athan E, Pappas PA, et al. Contemporary clinical profile and outcome of prosthetic valve endocarditis. JAMA 2007; 297:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/57\">",
"      Cabell CH, Pond KK, Peterson GE, et al. The risk of stroke and death in patients with aortic and mitral valve endocarditis. Am Heart J 2001; 142:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18249/abstract/58\">",
"      L&oacute;pez J, Fern&aacute;ndez-Hidalgo N, Revilla A, et al. Internal and external validation of a model to predict adverse outcomes in patients with left-sided infective endocarditis. Heart 2011; 97:1138.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2142 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-201.211.0.116-717FAB84F9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_52_18249=[""].join("\n");
var outline_f17_52_18249=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H781106308\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CARDIAC COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Perivalvular abscesses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other extravalvular complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EMBOLIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Effect of antibiotic therapy on embolic risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Predictors of embolization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Effect of prior antiplatelet therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      NEUROLOGIC COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MYCOTIC ANEURYSMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      RENAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      METASTATIC ABSCESSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MUSCULOSKELETAL COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      COMPLICATIONS OF MEDICAL OR SURGICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Predictors of death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H781106308\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40566?source=related_link\">",
"      Candida endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37625?source=related_link\">",
"      Clinical presentation and diagnostic evaluation of acute pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26649?source=related_link\">",
"      Complications of Staphylococcus aureus bacteremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=related_link\">",
"      Diagnostic approach to infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/25/2456?source=related_link\">",
"      Drug fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37464?source=related_link\">",
"      Epidemiology, pathogenesis, and microbiology of intravascular catheter infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40215?source=related_link\">",
"      Infective endocarditis in injection drug users",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31094?source=related_link\">",
"      Infective endocarditis: Historical and Duke criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/17/35098?source=related_link\">",
"      Overview of infected (mycotic) arterial aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18072?source=related_link\">",
"      Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/48/26370?source=related_link\">",
"      Patient information: Endocarditis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/48/1800?source=related_link\">",
"      Postoperative mediastinitis after cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35303?source=related_link\">",
"      Purulent pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/27/5556?source=related_link\">",
"      Renal disease in the setting of infective endocarditis or an infected ventriculoatrial shunt",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20617?source=related_link\">",
"      Role of echocardiography in infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22297?source=related_link\">",
"      Surgery for native valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/32/3591?source=related_link\">",
"      Surgery for prosthetic valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22985?source=related_link\">",
"      Vertebral osteomyelitis and discitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_52_18250="Epidemiology, pathology, and pathogenesis of renal cell carcinoma";
var content_f17_52_18250=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, pathology, and pathogenesis of renal cell carcinoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/52/18250/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/52/18250/contributors\">",
"     Michael B Atkins, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/52/18250/contributors\">",
"     Toni K Choueiri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/52/18250/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/52/18250/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/52/18250/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/52/18250/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/52/18250/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal cell carcinomas (RCCs), which originate within the renal cortex, are responsible for 80 to 85 percent of all primary renal neoplasms. Transitional cell carcinomas of the renal pelvis are the next most common (approximately 8 percent). Other parenchymal epithelial tumors, such as oncocytomas, collecting duct tumors, and renal sarcomas, occur infrequently. Nephroblastoma or Wilms' tumor is common in children (5 to 6 percent of all primary renal tumors), while renal medullary carcinoma is a rare form of RCC, seen in sickle cell disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/3/6202?source=see_link\">",
"     \"Renal manifestations of sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The epidemiology, pathology, and pathogenesis of RCC will be reviewed here. The clinical and radiographic presentation, staging methods, prognosis, and management of these tumors are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35336?source=see_link\">",
"     \"Clinical manifestations, evaluation, and staging of renal cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21192?source=see_link\">",
"     \"Prognostic factors in patients with renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175757290\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H640028829\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Globally, the incidence of RCC varies widely from region to region with the highest rates observed in the Czech Republic and North America [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/1\">",
"     1",
"    </a>",
"    ]. In the United States, there are approximately 65,000 new cases and almost 14,000 deaths from RCC each year [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Gender and age",
"    </span>",
"    &nbsp;&mdash;&nbsp;RCC is approximately 50 percent more common in men compared with women [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/3\">",
"     3",
"    </a>",
"    ]. RCC occurs predominantly in the sixth to eighth decade of life with median age at diagnosis around 64 years of age, according to 2003 to 2007 NCI&rsquo;s Surveillance, Epidemiology and End Results (SEER) Cancer Statistics Review; it is unusual in patients under 40 years of age and rare in children [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H640028914\">",
"    <span class=\"h2\">",
"     Race",
"    </span>",
"    &nbsp;&mdash;&nbsp;Within the United States, Asian Americans or Pacific Islanders have the lowest incidence of renal cancers compared to American",
"    <span class=\"nowrap\">",
"     Indians/Alaska",
"    </span>",
"    natives,",
"    <span class=\"nowrap\">",
"     Hispanic/Latinos,",
"    </span>",
"    Whites, or African Americans [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1046154222\">",
"    <span class=\"h2\">",
"     Extent of disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from the SEER registry covering 2002 through 2008 show the extent of disease at presentation of patients with renal cell carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Localized disease (ie, confined to the kidney) &mdash; 62 percent",
"     </li>",
"     <li>",
"      Regional disease (ie, spread to regional lymph nodes) &mdash; 17 percent",
"     </li>",
"     <li>",
"      Metastatic disease &mdash; 17 percent",
"     </li>",
"     <li>",
"      A rise in the incidence of localized disease (from 51 to 77 percent) and a reduction in the incidence of regional (21 to 14 percent) and metastatic disease (28 to 16 percent) were seen in this time period.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In an analysis of over 29,000 cases from the SEER registry, there has been a steady decrease in the size of tumors at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/9\">",
"     9",
"    </a>",
"    ]. This is likely due to the greater number of incidental tumors detected on abdominal imaging. For example, data from the National Cancer Database showed that the size of stage I tumors decreased from a mean of 4.1 cm in 1993 to 3.6 cm in 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/9\">",
"     9",
"    </a>",
"    ]. Whether all of the asymptomatic RCCs diagnosed through improved imaging are clinically relevant is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1046154382\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The five-year survival rate of patients with kidney cancer has doubled over the last 50 years, from 34 percent in 1954 to 62 percent in 1996, and to 71 percent from 2002 to 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/8,11\">",
"     8,11",
"    </a>",
"    ]. The incidence of RCC has risen threefold higher than the mortality rate (",
"    <a class=\"graphic graphic_figure graphicRef50815 \" href=\"UTD.htm?17/14/17646\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/12\">",
"     12",
"    </a>",
"    ]. This improved survival and case-fatality rate is mostly due to earlier detection of these tumors at smaller sizes (ie, &lt;4 cm) and curative surgical treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ESTABLISHED RISK FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cigarette smoking is associated with an increased risk of developing RCC that is proportional to the extent of exposure, thereby possibly contributing to its development in nearly one-third of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/13\">",
"     13",
"    </a>",
"    ]. Furthermore, increasing use of cigarettes appears to be associated with more advanced disease (pathologic T3, lymph node involvement, or metastatic disease) at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175757375\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension predisposes to RCC development, which seems to be independent of anti-hypertensive medications or obesity. The independent contribution of both has been difficult to sort out due to their close correlation with hypertension itself [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/15\">",
"     15",
"    </a>",
"    ]. The underlying biological explanations linking hypertension to RCC remain largely unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/16-20\">",
"     16-20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H640028216\">",
"    <span class=\"h2\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excessive body weight is a risk factor for RCC in both men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. This was shown in a prospective analysis of over 300,000 participants in the National Institutes of Health and American Association for Retired Persons (NIH-AARP) Diet and Health Study [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/22\">",
"     22",
"    </a>",
"    ]. The relative risk (RR) of RCC increased progressively with baseline body mass index (BMI).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H640028327\">",
"    <span class=\"h2\">",
"     Acquired cystic disease of the kidney",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of developing RCC has been estimated to be 30 times greater in dialysis patients with acquired polycystic disease of the kidney than in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/23\">",
"     23",
"    </a>",
"    ]. Acquired cystic disease develops in approximately 35 to 50 percent of chronic dialysis patients, approximately 6 percent who eventually develop RCC [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23638?source=see_link\">",
"     \"Acquired cystic disease of the kidney in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Occupational exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occupational exposure to toxic compounds, such as cadmium, asbestos, and petroleum by-products, has been associated with an increased risk of RCC [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. In one international multicenter study of over 1700 patients with RCCs and 2300 controls, an increased risk of cancer was observed in those exposed to asbestos (RR 1.4, 95% CI 1.1-1.8), cadmium (RR 2.0, 95% CI 1.0-3.9), and gasoline (RR 1.6, 95% CI 1.2-2.0) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/25\">",
"     25",
"    </a>",
"    ]. Cadmium workers who smoke may have a particularly high incidence of RCC [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/28\">",
"     28",
"    </a>",
"    ]. Studies of occupational exposures are often limited by the lack of specific exposure details. Increased exposure to such carcinogens may be associated with mutations in genes associated with the pathogenesis of RCC, such as the von Hippel-Lindau tumor suppressor gene. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/21/14678?source=see_link\">",
"     \"Molecular biology and pathogenesis of von Hippel-Lindau disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relationship between mutations in this gene and exposure to trichloroethylene, a petroleum by-product used as a metal degreaser, was evaluated in 44 patients with RCC and known exposure to the toxin, 107 with RCC but no known exposure, and 97 healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/29\">",
"     29",
"    </a>",
"    ]. A specific mutational hot spot in this gene was found in 39 percent of those with toxin exposure, but in none of those without exposure or in any of the healthy individuals. Although this data is intriguing and suggests a link among carcinogen exposure, genetic damage in a specific site, and renal cancer, it does not prove causation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Analgesics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prolonged ingestion of analgesic combinations, particularly compounds containing phenacetin (of which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    is a major metabolite) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , can lead to chronic renal failure. Such patients are at increased risk for renal pelvic and urothelial tumors. Epidemiologic studies have demonstrated an increased risk for RCC with heavy use of aspirin, non-steroidal anti-inflammatory drugs (NSAIDS), and acetaminophen [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. In one of the largest prospective studies that included data from 77,525 women followed over 16 years and 49,043 men followed over 20 years, the risk of developing RCC appeared to vary by agent and the regular use of aspirin or acetaminophen was not associated with the development of RCC [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/31\">",
"     31",
"    </a>",
"    ]. In contrast, the routine use of nonaspirin NSAIDs was associated with a greater risk of RCC (hazard ratio [HR] 1.51; 95% CI 1.12-2.04), which increased with more frequent use and longer period of use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1012?source=see_link\">",
"     \"Urinary tract malignancy and atherosclerotic disease in patients with chronic analgesic abuse\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/45/1754?source=see_link\">",
"     \"Malignancies of the renal pelvis and ureter\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of a second, metachronous RCC is increased in patients who have been treated for one renal cancer. This increased risk is most pronounced with younger age at the first RCC, suggesting that early onset renal cancer has a genetic component [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although most RCCs are sporadic, several syndromes associated with RCC have been described. Factors that favor a hereditary contribution in patients without a clear genetic disease include first degree relatives with a tumor, onset before the age of 40, and bilateral or multifocal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/33\">",
"     33",
"    </a>",
"    ]. Other individuals with a clear genetic contribution have abnormalities on chromosome 3 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/34-38\">",
"     34-38",
"    </a>",
"    ], and additional genetic abnormalities have been identified in other families [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/39-41\">",
"     39-41",
"    </a>",
"    ], suggesting that these tumors represent distinct disease entities.",
"   </p>",
"   <p>",
"    Specific inherited syndromes associated with renal cell carcinoma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35910?source=see_link\">",
"     \"Hereditary kidney cancer syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cytotoxic chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of cytotoxic chemotherapy in childhood for malignancies, autoimmune disorders, or bone marrow transplant conditioning has been associated with the subsequent development of translocation RCC [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Translocation carcinomas'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100878941\">",
"    <span class=\"h2\">",
"     Chronic hepatitis C infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;An epidemiologic study of over 67,000 patients found that chronic infection with hepatitis C virus was associated with a significantly increased risk of RCC, , after correcting for age, ethnicity, gender, and the presence of chronic kidney disease (HR 1.77, 95% CI 2.05-2.98) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37353?source=see_link\">",
"     \"Renal disease associated with hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1046155450\">",
"    <span class=\"h2\">",
"     Sickle cell disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with sickle cell trait and (to a lesser extent) sickle cell disease are at risk for renal medullary carcinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/3/6202?source=see_link&amp;anchor=H14#H14\">",
"     \"Renal manifestations of sickle cell disease\", section on 'Renal medullary carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H640028514\">",
"    <span class=\"h1\">",
"     OTHER FACTORS THAT MODIFY RISK",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H640028522\">",
"    <span class=\"h2\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history of diabetes mellitus has been associated with a modest increase in the risk of RCC in some studies but not in others [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/44-47\">",
"     44-47",
"    </a>",
"    ]. This may be mediated through an increase in the incidence of hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H640028661\">",
"    <span class=\"h2\">",
"     Polycystic kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;When RCC occurs in the context of polycystic kidney disease, it has a number of different clinical characteristics even though it does not appear to occur with increased frequency compared to the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. The tumors are more often bilateral at presentation (12 versus 1 to 4 percent in sporadic RCC in the general population), multicentric (28 versus 6 percent), and sarcomatoid in type (33 versus 1 to 5 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30903?source=see_link\">",
"     \"Renal manifestations of autosomal dominant polycystic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1046155726\">",
"    <span class=\"h2\">",
"     Alcohol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol intake is associated with a protective effect on the risk of RCC in both men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. However, this should not be viewed as a reason to begin drinking alcohol. A topic on the risks and benefits of alcohol consumption is covered separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38874?source=see_link\">",
"     \"Overview of the risks and benefits of alcohol consumption\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The protective effect of alcohol on the risk of RCC was shown in a 2012 meta-analysis of 20 studies [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/52\">",
"     52",
"    </a>",
"    ]. Alcohol consumption was associated with a lower risk of developing RCC compared to no alcohol consumption (RR 0.85, 95% CI 0.80-0.92) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/52\">",
"     52",
"    </a>",
"    ]. The reduction in risk was seen with light (0.01 to 12.49",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    and moderate (12.5 to 49.9",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    alcohol consumption, and were not altered after adjustment for smoking, body mass index, or a history of hypertension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H640028732\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional clinical factors that may increase the risk of developing RCC include dietary factors such as the intake of nitrite from processed meat sources [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/53\">",
"     53",
"    </a>",
"    ], reproductive factors (eg, increasing number of pregnancies) and prior radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. For women, the use of oral contraceptives may reduce risk [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/54,55\">",
"     54,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although lesions smaller than 3 cm were previously thought to represent benign adenomas, it is now clear that even small tumors frequently represent carcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. As a result, the distinction between a malignant and a benign growth based upon size alone is no longer made. Instead, basic histologic criteria are used to discriminate between a malignant or benign growth. Thus,",
"    <strong>",
"     all",
"    </strong>",
"    solid renal masses require resection or biopsy for accurate diagnosis unless the presence of a metastatic lesion can be established by biopsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2200?source=see_link\">",
"     \"Diagnostic approach, differential diagnosis, and treatment of a small renal mass\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Previously, RCCs were classified by cell type and growth pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/59\">",
"     59",
"    </a>",
"    ]. This classification has recently changed to more accurately reflect the morphology, growth pattern, cell of origin, histochemical, and molecular basis of the different types of adenocarcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/60-63\">",
"     60-63",
"    </a>",
"    ]. Several distinct subtypes of RCC have been identified, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Clear cell (75 to 85 percent of tumors)",
"     </li>",
"     <li>",
"      Papillary (chromophilic) (10 to 15 percent)",
"     </li>",
"     <li>",
"      Chromophobe (5 to 10 percent)",
"     </li>",
"     <li>",
"      Oncocytic (3 to 7 percent)",
"     </li>",
"     <li>",
"      Collecting duct (Bellini's duct) (very rare)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Less than five percent of RCCs are considered unclassified. In two reports, these tumors had a worse prognosis compared with clear cell cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/64,65\">",
"     64,65",
"    </a>",
"    ], although another report found that the outcome was not different after adjusting for adverse clinicopathologic features such as stage and grade [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The impact of pathology on prognosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21192?source=see_link&amp;anchor=H4#H4\">",
"     \"Prognostic factors in patients with renal cell carcinoma\", section on 'Histopathology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Clear cell carcinomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clear cell carcinomas, which typically have a deletion of chromosome 3p, arise from the proximal tubule [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/67\">",
"     67",
"    </a>",
"    ]. Macroscopically, they may be solid or less commonly, cystic. In addition to occurring in sporadic disease, clear cell carcinomas are specifically associated with von Hippel-Lindau disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=see_link\">",
"     \"Clinical features, diagnosis, and management of von Hippel-Lindau disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A poor prognosis is associated with higher nuclear grade or the presence of a sarcomatoid pattern (particularly with early stage disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. In one study of 42 patients with sarcomatoid RCC, for example, the presence of more components suggestive of a sarcomatoid pattern was associated with a less favorable prognosis for patients with stage I and II disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, a more favorable prognosis has been associated with the rare multilocular variant of cystic clear cell renal cell carcinoma compared to other clear cell carcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/71-74\">",
"     71-74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H403324821\">",
"    <span class=\"h3\">",
"     Genetic alterations in clear cell carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because clear cell carcinoma is the most common subtype of RCC, much work has been done to classify these cancers based on genetic alterations. In one study, genome-wide analysis (for copy number changes) and gene expression profiles were performed on 90 RCC tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/75\">",
"     75",
"    </a>",
"    ]. Common abnormalities between sporadic and von-Hippel Lindau (VHL)-associated RCC including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Loss of 3p (94 percent), which contains several genes associated with RCC, included the VHL and protein polybromo-1 (PBRM1) gene among others (See",
"      <a class=\"local\" href=\"#H403325303\">",
"       'Von Hippel Lindau gene'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H403325040\">",
"       'PBRM1 gene'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Gain of 5q (69 percent)",
"     </li>",
"     <li>",
"      Monosomy or partial loss of 14q (42 percent)",
"     </li>",
"     <li>",
"      7q gain (20 percent)",
"     </li>",
"     <li>",
"      8p deletion (32 percent)",
"     </li>",
"     <li>",
"      9p loss (29 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several specific gene and pathway alterations described in RCC are discussed below:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H403325303\">",
"    <span class=\"h4\">",
"     Von Hippel Lindau gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;The VHL gene is found on chromosome 3 (3p25 to 26) and plays a pivotal role in the development of clear cell RCC in patients with VHL disease. In addition, VHL gene alterations appear to be important in the pathogenesis of sporadic RCC [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/76-78\">",
"     76-78",
"    </a>",
"    ]. In one report of 187 patients with sporadic RCC, somatic mutations or promoter hypermethylation in the VHL gene were observed in 58 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/76\">",
"     76",
"    </a>",
"    ]. Other reports using high throughput methodologies have demonstrated improved identification of VHL alterations; up to 91 percent of patients with clear cell RCC patients harbor a VHL gene alteration through genetic or epigenetic mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/78\">",
"     78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/21/14678?source=see_link\">",
"     \"Molecular biology and pathogenesis of von Hippel-Lindau disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical features, diagnosis, and management of von Hippel-Lindau disease\", section on 'VHL mutations in sporadic tumors'",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H403325040\">",
"    <span class=\"h4\">",
"     PBRM1 gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recently, the",
"    <span class=\"nowrap\">",
"     Switch/Sucrose",
"    </span>",
"    NonFermentable",
"    <span class=\"nowrap\">",
"     (SWI/SNF)",
"    </span>",
"    chromatin remodeling complex gene PBRM1 was found to be a second major clear cell RCC gene, with truncating mutations in 92 of 227 (41 percent) of cases. Interestingly, PBRM1 maps to chromosome 3p21 and is likely a tumor-suppressor gene [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1035988535\">",
"    <span class=\"h4\">",
"     BAP1 gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;The BRCA1 associated protein-1 (BAP1), located at 3p, is mutated in 15 percent of clear-cell RCC and encodes a nuclear deubiquitinase [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/80\">",
"     80",
"    </a>",
"    ]. It is part of the large ubiquitin-mediated proteolysis pathway (UMPP). BAP1-mutant tumors are more likely to be aggressive and display adverse pathologic features, leading to worse survival [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/81\">",
"     81",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H403325062\">",
"     'Ubiquitin-mediated proteolysis pathway (UMPP)'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H403325055\">",
"    <span class=\"h4\">",
"     Inactivation of histone-modifying genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A recent report identified inactivating mutations in two genes encoding enzymes involved in histone modification, including the SET domain containing protein 2 (SETD2) and the Jumonji AT-rich interactive domain 1C (JARID1C), highlighting the important role of components of the chromatin modification machinery in RCC [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H403325062\">",
"    <span class=\"h4\">",
"     Ubiquitin-mediated proteolysis pathway (UMPP)",
"    </span>",
"    &nbsp;&mdash;&nbsp;UMPP is an important pathway for protein degradation through the proteasome. Alterations in UMPP result in similar functional consequences (ie, hypoxia) as VHL inactivation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/83\">",
"     83",
"    </a>",
"    ]. In one study, UMPP was the most frequently altered pathway in clear cell RCC [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/83\">",
"     83",
"    </a>",
"    ]. Of note, the VHL and BAP1 genes are members of this pathway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H342358282\">",
"    <span class=\"h4\">",
"     Abnormalities in cellular division",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of RCCs may also involve abnormalities in genes that control cell division. These include the ras family genes and the p53 tumor suppressor gene. Although mutations in the p53 gene are identified infrequently in RCCs [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/84\">",
"     84",
"    </a>",
"    ], overexpression of p53 protein is detected in approximately one-half of tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/84\">",
"     84",
"    </a>",
"    ]. Overexpression of p53 may be associated with more aggressive behavior and a worse prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. This was illustrated by a series of 175 patients, in which the ten-year disease-specific survival was lower for patients whose tumors stained for p53 (48 versus 78 percent, compared to those not overexpressing p53) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Normal expression of the p53 protein may suppress expression of interleukin-6 (IL-6) and mutations in p53 may result in IL-6 overexpression [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/86\">",
"     86",
"    </a>",
"    ]. IL-6 overexpression has also been associated with decreased responsiveness to immunotherapy and a poorer prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/87,88\">",
"     87,88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Papillary carcinomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Papillary renal cell carcinomas can be multifocal and bilateral, and commonly present as small, early stage tumors. This was illustrated in a series of 1057 patients undergoing resection for RCCs: 75 percent of the 157 patients with papillary tumors had T1 lesions at presentation, and 85 percent had stage I or II disease (",
"    <a class=\"graphic graphic_table graphicRef54563 \" href=\"UTD.htm?14/54/15213\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/89\">",
"     89",
"    </a>",
"    ]. The early stage at diagnosis correlated with a relatively favorable prognosis; the actuarial disease-free survival rate was 82 percent at five years and 68 percent at ten years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with clear cell cancers, papillary RCCs originate from the proximal tubule, but they are morphologically and genetically distinct malignancies. While inherited papillary RCCs have been associated with mutations in the c-met oncogene (",
"    <a class=\"graphic graphic_table graphicRef76473 \" href=\"UTD.htm?16/18/16683\">",
"     table 2",
"    </a>",
"    ), such mutations have been detected in 5 to 13 percent sporadic cases [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/63,90\">",
"     63,90",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Established risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A significant number of sporadic papillary RCCs have duplication of chromosome 7, where",
"    <em>",
"     MET",
"    </em>",
"    is located, which might represent an alternative basis for enhanced MET signaling [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/91\">",
"     91",
"    </a>",
"    ]. Papillary carcinomas have been subdivided into two subtypes, based upon histologic criteria and distinctive gene expression profiles [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/92\">",
"     92",
"    </a>",
"    ]. Type 1 tumors tend to be low-grade and have a better prognosis, while type 2 lesions generally are high-grade and have a poorer prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/93-96\">",
"     93-96",
"    </a>",
"    ]. An analysis of 130 cases of papillary carcinomas found that, at a median follow-up of 48 months, patients with type 1 tumors had significantly better overall and disease-free survivals compared with patients with type 2 tumors (89 and 92 percent versus 55 percent, and 44 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A refinement of this classification system has been proposed based upon pathologic and molecular characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/93\">",
"     93",
"    </a>",
"    ]. In this system, class 1 papillary carcinomas may have G1-S checkpoint gene dysregulation and c-met overexpression. Patients with class 1 papillary RCC have an excellent survival in contrast to patients with papillary type 2 RCC, which are high grade tumors with dysregulation of the G2-M checkpoint gene.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Chromophobe carcinomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologically, chromophobe carcinomas are composed of sheets of cells that are darker than clear cell carcinoma. They lack the abundant lipid and glycogen that is characteristic of most RCCs, and originate from the intercalated cells of the collecting system [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/97-99\">",
"     97-99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chromophobe carcinomas have a hypodiploid number of chromosomes, but have not deleted the 3p chromosomal genetic locus [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/100,101\">",
"     100,101",
"    </a>",
"    ]. One study using comparative genomic hybridization found that 17 of 19 tumors exhibited a wide variety of abnormalities, including various combinations of the loss of chromosomes 1, 2, 6, 10, 13, 17, or 21 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/101\">",
"     101",
"    </a>",
"    ]. In a study of gene expression profiling in RCC, the KIT oncogene was found to be upregulated specifically on the cell membranes of chromophobe RCC [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chromophobe carcinomas may have a lower risk of disease progression and death compared to clear cell carcinomas, although this is likely due to the fact that patients present at a lower stage [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/103-105\">",
"     103-105",
"    </a>",
"    ]. This is illustrated in the following series:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series of 124 patients seen at two institutions, the five-year disease-specific survival was better than with clear cell carcinoma (78 versus 60 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/103\">",
"       103",
"      </a>",
"      ]. However, when corrected for stage, this survival difference disappeared.",
"     </li>",
"     <li>",
"      In the largest series of 392 patients, at a median follow-up of 44 months, the recurrence rate was 9 percent and cancer-related mortality rate was 6 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/105\">",
"       105",
"      </a>",
"      ]. Significant prognostic factors for cancer-specific survival were gender, disease stage, and the presence of sarcomatoid differentiation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Oncocytomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal oncocytomas are uncommon and consist of a pure population of oncocytes, which are large well-differentiated neoplastic cells with intensely eosinophilic granular cytoplasm that is due to a large number of mitochondria [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/106-108\">",
"     106-108",
"    </a>",
"    ]. They account for approximately three to seven percent of all renal tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/109\">",
"     109",
"    </a>",
"    ]. Like chromophobe carcinomas, oncocytomas appear to originate from the intercalated cells of the collecting ducts [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/109\">",
"     109",
"    </a>",
"    ]. While sporadic oncocytomas are usually unilateral and single, multiple and bilateral oncocytomas have been described in patients with tuberous sclerosis complex (TSC) and Birt-Hogg-Dube syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/110,111\">",
"     110,111",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/18/43303?source=see_link\">",
"     \"Renal manifestations of tuberous sclerosis and renal angiomyolipoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35910?source=see_link&amp;anchor=H4#H4\">",
"     \"Hereditary kidney cancer syndromes\", section on 'Birt-Hogg-Dube syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Distinguishing an oncocytoma from an RCC histologically can occasionally be difficult. In one study, approximately 5 percent of solid tumors previously thought to be RCCs may have been oncocytomas [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/106\">",
"     106",
"    </a>",
"    ]. Early reports of \"metastatic oncocytomas\" probably represented chromophobe RCCs [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/112\">",
"     112",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Chromophobe carcinomas'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The heterogeneity of renal oncocytomas has been seen in chromosomal analyses of renal oncocytomas, including combined loss of chromosomes Y and 1, rearrangements involving the cyclin D1 (CCND1) locus located at chromosome 11q13, and involvement of 12q12-13, loss of 14q [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/109\">",
"     109",
"    </a>",
"    ]. This information has been proposed as a means of distinguishing oncocytoma from chromophobe RCC [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/113,114\">",
"     113,114",
"    </a>",
"    ]. In one study, none of 36 chromophobe RCC expressed cyclin D1 (measured by immunohistochemistry) or had a CCND1 rearrangement; however, 21 of 63 (33 percent) oncocytomas showed cyclin D1 overexpression and 12 of these (57 percent) were positive for a CCND1 rearrangement [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Renal oncocytomas almost invariably behave in a benign fashion, despite the recognition that the growth rate could be similar to RCC [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/115\">",
"     115",
"    </a>",
"    ]. Even when very large, they are generally well encapsulated and are rarely invasive or associated with metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/116\">",
"     116",
"    </a>",
"    ]. This benign natural history has important therapeutic implications, and an oncocytoma should be considered in the differential diagnosis of patients with incidentally discovered small renal masses or with tumors found within a solitary kidney. &nbsp;",
"   </p>",
"   <p>",
"    A coexisting RCC can be identified in 10 to 32 percent of patients with oncocytoma, especially in those patients presenting with diffuse oncocytic nodules involving the renal parenchyma (also known as renal oncocytosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/112,117,118\">",
"     112,117,118",
"    </a>",
"    ]. Thus, patients with oncocytomas should be closely monitored and treated if there is evidence of rapid growth of the renal tumor. &nbsp;",
"   </p>",
"   <p>",
"    Despite the high frequency of coexisting RCCs, the risk of metachronous renal tumors after resection of an oncocytoma is low. In a retrospective single institution series of 424 patients who were followed for a median of seven years after radical or partial nephrectomy, 17 subsequent tumors (4 percent) were identified at a median of three years after the original diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/119\">",
"     119",
"    </a>",
"    ]. Of these, eight were oncocytomas, four were RCCs, and no pathology was available on the other five.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Collecting duct tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although collecting duct (Bellini's duct) tumors are rare, they tend to occur in younger patients and are frequently aggressive [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/120,121\">",
"     120,121",
"    </a>",
"    ]. They commonly present with gross hematuria. Sarcomatoid variants have been noted.",
"   </p>",
"   <p>",
"    The largest reported series comes from the Surveillance, Epidemiology and End Results (SEER) database, which identified 160 cases that were compared with 33,000 cases of clear cell carcinoma identified during the same period [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/120\">",
"     120",
"    </a>",
"    ]. Collecting duct carcinomas occurred at a younger age, were more frequent in black patients, and more commonly presented with advanced",
"    <span class=\"nowrap\">",
"     (T3/T4)",
"    </span>",
"    or metastatic disease. On multivariate analysis, there was a significant increase in risk of death after correcting for stage and grade compared to clear cell carcinoma (HR 2.4).",
"   </p>",
"   <p>",
"    Medullary carcinoma, which is a highly aggressive variant of collecting duct carcinomas, is associated with the sickle cell trait and develops in young patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/3/6202?source=see_link&amp;anchor=H14#H14\">",
"     \"Renal manifestations of sickle cell disease\", section on 'Renal medullary carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Collecting duct tumors have not been associated with a consistent pattern of genetic abnormalities. However, immunohistochemical and molecular studies suggest that these tumors more closely resemble transitional cell than RCCs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Translocation carcinomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;A distinct variant of RCC, referred to as translocation carcinoma, is associated with fusion of the TFE3 gene to a number of other genes including ASPL and PRCC on chromosome Xp11.2 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/122-124\">",
"     122-124",
"    </a>",
"    ]. Translocation carcinoma tends to occur at a younger age compared with other RCCs [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/124\">",
"     124",
"    </a>",
"    ]. In one series of 54 patients, the median age was 24 years, and the disease was more common in women than men (57 versus 43 percent). Translocation carcinoma has also been reported in children who have received antecedent chemotherapy for malignancies, autoimmune disorders, or bone marrow transplant conditioning [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective analysis of 53 patients less than 45 years old with translocation carcinomas included 23 patients with metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/125\">",
"     125",
"    </a>",
"    ]. Seven of the 21 patients who received targeted therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"     temsirolimus",
"    </a>",
"    ) had an objective response. Another series with 15 metastatic adult cases showed that this is an aggressive disease that affects a younger population of patients with a female predominance [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/126\">",
"     126",
"    </a>",
"    ]. Although no prospective trials have been conducted in this setting, VEGF-targeted agents appeared to demonstrate some activity in both series [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/125,126\">",
"     125,126",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28170?source=see_link\">",
"     \"Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Other tumor types",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other rare primary malignancies that have been reported to arise in the kidney include lymphomas [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/127\">",
"     127",
"    </a>",
"    ], soft tissue sarcomas (eg, leiomyosarcoma, liposarcoma) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/128\">",
"     128",
"    </a>",
"    ], and carcinoids [",
"    <a class=\"abstract\" href=\"UTD.htm?17/52/18250/abstract/129\">",
"     129",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/37/16978?source=see_link\">",
"       \"Patient information: Cadmium toxicity (Cadmium poisoning) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/53/30546?source=see_link\">",
"       \"Patient information: Renal cell carcinoma (kidney cancer) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Renal cell carcinomas (RCCs) are the most common primary tumor arising in the kidney, accounting for approximately 80 to 85 percent of such tumors. Transitional cell carcinomas arising in the renal pelvis account for about 8 percent, while other rare tumors comprise the rest. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/45/1754?source=see_link\">",
"       \"Malignancies of the renal pelvis and ureter\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The most common histologic pattern of RCC is clear cell (75 to 85 percent). Papillary and chromophobe tumors constitute 10 to 15 and 5 to 10 percent, respectively. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incidence of RCC has been steadily increasing in the United States, while the size of primary RCCs has been gradually decreasing. These trends have been attributed, in part, to the diagnosis of asymptomatic tumors using noninvasive abdominal imaging modalities. (See",
"      <a class=\"local\" href=\"#H175757290\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors associated with a significantly increased incidence of RCC include smoking, obesity, hypertension, and others. RCC has also been associated with a variety of inherited syndromes. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Established risk factors'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35910?source=see_link\">",
"       \"Hereditary kidney cancer syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The pathogenesis of RCC is incompletely understood. Abnormalities of the von Hippel-Lindau tumor suppressor have been implicated in the majority of sporadic cases of RCC. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/21/14678?source=see_link\">",
"       \"Molecular biology and pathogenesis of von Hippel-Lindau disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=see_link&amp;anchor=H18#H18\">",
"       \"Clinical features, diagnosis, and management of von Hippel-Lindau disease\", section on 'VHL mutations in sporadic tumors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/1\">",
"      Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol 2010; 7:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/2\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/3\">",
"      Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/4\">",
"      Siemer S, Hack M, Lehmann J, et al. Outcome of renal tumors in young adults. J Urol 2006; 175:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/5\">",
"      Thompson RH, Ordonez MA, Iasonos A, et al. Renal cell carcinoma in young and old patients--is there a difference? J Urol 2008; 180:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/6\">",
"      Cook A, Lorenzo AJ, Salle JL, et al. Pediatric renal cell carcinoma: single institution 25-year case series and initial experience with partial nephrectomy. J Urol 2006; 175:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/7\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10.",
"     </a>",
"    </li>",
"    <li>",
"     SEER Stat Fact Sheets: Kidney and Renal Pelvis file://seer.cancer.gov/statfacts/html/kidrp.html.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/9\">",
"      Kane CJ, Mallin K, Ritchey J, et al. Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer 2008; 113:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/10\">",
"      Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst 2006; 98:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/11\">",
"      Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol 2001; 166:1611.",
"     </a>",
"    </li>",
"    <li>",
"     Ries LA, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1973-1997, National Cancer Institute, Bethesda 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/13\">",
"      Hunt JD, van der Hel OL, McMillan GP, et al. Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. Int J Cancer 2005; 114:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/14\">",
"      Tsivian M, Moreira DM, Caso JR, et al. Cigarette smoking is associated with advanced renal cell carcinoma. J Clin Oncol 2011; 29:2027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/15\">",
"      Ljungberg B, Campbell SC, Choi HY, et al. The epidemiology of renal cell carcinoma. Eur Urol 2011; 60:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/16\">",
"      Chow WH, Gridley G, Fraumeni JF Jr, J&auml;rvholm B. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med 2000; 343:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/17\">",
"      Choi MY, Jee SH, Sull JW, Nam CM. The effect of hypertension on the risk for kidney cancer in Korean men. Kidney Int 2005; 67:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/18\">",
"      Weikert S, Boeing H, Pischon T, et al. Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition. Am J Epidemiol 2008; 167:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/19\">",
"      Vatten LJ, Trichopoulos D, Holmen J, Nilsen TI. Blood pressure and renal cancer risk: the HUNT Study in Norway. Br J Cancer 2007; 97:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/20\">",
"      Flaherty KT, Fuchs CS, Colditz GA, et al. A prospective study of body mass index, hypertension, and smoking and the risk of renal cell carcinoma (United States). Cancer Causes Control 2005; 16:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/21\">",
"      Pischon T, Lahmann PH, Boeing H, et al. Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 2006; 118:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/22\">",
"      Adams KF, Leitzmann MF, Albanes D, et al. Body size and renal cell cancer incidence in a large US cohort study. Am J Epidemiol 2008; 168:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/23\">",
"      Brennan JF, Stilmant MM, Babayan RK, Siroky MB. Acquired renal cystic disease: implications for the urologist. Br J Urol 1991; 67:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/24\">",
"      Truong LD, Krishnan B, Cao JT, et al. Renal neoplasm in acquired cystic kidney disease. Am J Kidney Dis 1995; 26:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/25\">",
"      Mandel JS, McLaughlin JK, Schlehofer B, et al. International renal-cell cancer study. IV. Occupation. Int J Cancer 1995; 61:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/26\">",
"      Maclure M. Asbestos and renal adenocarcinoma: a case-control study. Environ Res 1987; 42:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/27\">",
"      McLaughlin JK, Blot WJ, Mehl ES, et al. Petroleum-related employment and renal cell cancer. J Occup Med 1985; 27:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/28\">",
"      Kolonel LN. Association of cadmium with renal cancer. Cancer 1976; 37:1782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/29\">",
"      Brauch H, Weirich G, Hornauer MA, et al. Trichloroethylene exposure and specific somatic mutations in patients with renal cell carcinoma. J Natl Cancer Inst 1999; 91:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/30\">",
"      S&oslash;rensen HT, N&oslash;rg&aring;rd B, Friis S, et al. [Non-steroidal anti-inflammatory agents and prevention of colorectal cancer and other types of cancer]. Ugeskr Laeger 2003; 165:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/31\">",
"      Cho E, Curhan G, Hankinson SE, et al. Prospective evaluation of analgesic use and risk of renal cell cancer. Arch Intern Med 2011; 171:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/32\">",
"      Wiklund F, Tretli S, Choueiri TK, et al. Risk of bilateral renal cell cancer. J Clin Oncol 2009; 27:3737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/33\">",
"      Gnarra JR, Glenn GM, Latif F, et al. Molecular genetic studies of sporadic and familial renal cell carcinoma. Urol Clin North Am 1993; 20:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/34\">",
"      Cohen AJ, Li FP, Berg S, et al. Hereditary renal-cell carcinoma associated with a chromosomal translocation. N Engl J Med 1979; 301:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/35\">",
"      Pathak S, Strong LC, Ferrell RE, Trindade A. Familial renal cell carcinoma with a 3;11 chromosome translocation limited to tumor cells. Science 1982; 217:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/36\">",
"      Carroll PR, Murty VV, Reuter V, et al. Abnormalities at chromosome region 3p12-14 characterize clear cell renal carcinoma. Cancer Genet Cytogenet 1987; 26:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/37\">",
"      Zbar B, Brauch H, Talmadge C, Linehan M. Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature 1987; 327:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/38\">",
"      van Kessel AG, Wijnhoven H, Bodmer D, et al. Renal cell cancer: chromosome 3 translocations as risk factors. J Natl Cancer Inst 1999; 91:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/39\">",
"      Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002; 30:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/40\">",
"      Zbar B, Tory K, Merino M, et al. Hereditary papillary renal cell carcinoma. J Urol 1994; 151:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/41\">",
"      Ricketts CJ, Shuch B, Vocke CD, et al. Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. J Urol 2012; 188:2063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/42\">",
"      Argani P, La&eacute; M, Ballard ET, et al. Translocation carcinomas of the kidney after chemotherapy in childhood. J Clin Oncol 2006; 24:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/43\">",
"      Gordon SC, Moonka D, Brown KA, et al. Risk for renal cell carcinoma in chronic hepatitis C infection. Cancer Epidemiol Biomarkers Prev 2010; 19:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/44\">",
"      Lindblad P, Chow WH, Chan J, et al. The role of diabetes mellitus in the aetiology of renal cell cancer. Diabetologia 1999; 42:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/45\">",
"      Setiawan VW, Stram DO, Nomura AM, et al. Risk factors for renal cell cancer: the multiethnic cohort. Am J Epidemiol 2007; 166:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/46\">",
"      Wideroff L, Gridley G, Mellemkjaer L, et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997; 89:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/47\">",
"      Zucchetto A, Dal Maso L, Tavani A, et al. History of treated hypertension and diabetes mellitus and risk of renal cell cancer. Ann Oncol 2007; 18:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/48\">",
"      Keith DS, Torres VE, King BF, et al. Renal cell carcinoma in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1994; 4:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/49\">",
"      Vogelzang NJ, Stadler WM. Kidney cancer. Lancet 1998; 352:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/50\">",
"      Lee JE, Hunter DJ, Spiegelman D, et al. Alcohol intake and renal cell cancer in a pooled analysis of 12 prospective studies. J Natl Cancer Inst 2007; 99:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/51\">",
"      Lew JQ, Chow WH, Hollenbeck AR, et al. Alcohol consumption and risk of renal cell cancer: the NIH-AARP diet and health study. Br J Cancer 2011; 104:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/52\">",
"      Bellocco R, Pasquali E, Rota M, et al. Alcohol drinking and risk of renal cell carcinoma: results of a meta-analysis. Ann Oncol 2012; 23:2235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/53\">",
"      Dellavalle CT, Daniel CR, Aschebrook-Kilfoy B, et al. Dietary intake of nitrate and nitrite and risk of renal cell carcinoma in the NIH-AARP Diet and Health Study. Br J Cancer 2013; 108:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/54\">",
"      Lindblad P, Mellemgaard A, Schlehofer B, et al. International renal-cell cancer study. V. Reproductive factors, gynecologic operations and exogenous hormones. Int J Cancer 1995; 61:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/55\">",
"      Kabat GC, Silvera SA, Miller AB, Rohan TE. A cohort study of reproductive and hormonal factors and renal cell cancer risk in women. Br J Cancer 2007; 96:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/56\">",
"      Vogelzang NJ, Yang X, Goldman S, et al. Radiation induced renal cell cancer: a report of 4 cases and review of the literature. J Urol 1998; 160:1987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/57\">",
"      Bosniak MA, Birnbaum BA, Krinsky GA, Waisman J. Small renal parenchymal neoplasms: further observations on growth. Radiology 1995; 197:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/58\">",
"      Schlomer B, Figenshau RS, Yan Y, et al. Pathological features of renal neoplasms classified by size and symptomatology. J Urol 2006; 176:1317.",
"     </a>",
"    </li>",
"    <li>",
"     Richie JP, Skinner DG. Renal neoplasia. In: The Kidney, 2nd, Brenner BM, Rector F (Eds), WB Saunders, Philadelphia 1981. p.2109.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/60\">",
"      Tannenbaum M. Ultrastructural pathology of human renal cell tumors. Pathol Annu 1971; 6:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/61\">",
"      Thoenes W, St&ouml;rkel S, Rumpelt HJ. Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics. Pathol Res Pract 1986; 181:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/62\">",
"      St&ouml;rkel S, van den Berg E. Morphological classification of renal cancer. World J Urol 1995; 13:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/63\">",
"      Patard JJ, Leray E, Rioux-Leclercq N, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 2005; 23:2763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/64\">",
"      Zisman A, Chao DH, Pantuck AJ, et al. Unclassified renal cell carcinoma: clinical features and prognostic impact of a new histological subtype. J Urol 2002; 168:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/65\">",
"      Karakiewicz PI, Hutterer GC, Trinh QD, et al. Unclassified renal cell carcinoma: an analysis of 85 cases. BJU Int 2007; 100:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/66\">",
"      Crispen PL, Tabidian MR, Allmer C, et al. Unclassified renal cell carcinoma: impact on survival following nephrectomy. Urology 2010; 76:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/67\">",
"      Presti JC Jr, Rao PH, Chen Q, et al. Histopathological, cytogenetic, and molecular characterization of renal cortical tumors. Cancer Res 1991; 51:1544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/68\">",
"      Weiss LM, Gelb AB, Medeiros LJ. Adult renal epithelial neoplasms. Am J Clin Pathol 1995; 103:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/69\">",
"      Sella A, Logothetis CJ, Ro JY, et al. Sarcomatoid renal cell carcinoma. A treatable entity. Cancer 1987; 60:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/70\">",
"      Oda H, Machinami R. Sarcomatoid renal cell carcinoma. A study of its proliferative activity. Cancer 1993; 71:2292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/71\">",
"      Aubert S, Zini L, Delomez J, et al. Cystic renal cell carcinomas in adults. Is preoperative recognition of multilocular cystic renal cell carcinoma possible? J Urol 2005; 174:2115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/72\">",
"      Webster WS, Thompson RH, Cheville JC, et al. Surgical resection provides excellent outcomes for patients with cystic clear cell renal cell carcinoma. Urology 2007; 70:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/73\">",
"      Bielsa O, Lloreta J, Gelabert-Mas A. Cystic renal cell carcinoma: pathological features, survival and implications for treatment. Br J Urol 1998; 82:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/74\">",
"      Suzigan S, L&oacute;pez-Beltr&aacute;n A, Montironi R, et al. Multilocular cystic renal cell carcinoma : a report of 45 cases of a kidney tumor of low malignant potential. Am J Clin Pathol 2006; 125:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/75\">",
"      Beroukhim R, Brunet JP, Di Napoli A, et al. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res 2009; 69:4674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/76\">",
"      Yao M, Yoshida M, Kishida T, et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 2002; 94:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/77\">",
"      Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994; 7:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/78\">",
"      Nickerson ML, Jaeger E, Shi Y, et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 2008; 14:4726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/79\">",
"      Varela I, Tarpey P, Raine K, et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011; 469:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/80\">",
"      Pe&ntilde;a-Llopis S, Vega-Rub&iacute;n-de-Celis S, Liao A, et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet 2012; 44:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/81\">",
"      Kapur P, Pe&ntilde;a-Llopis S, Christie A, et al. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol 2013; 14:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/82\">",
"      Dalgliesh GL, Furge K, Greenman C, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010; 463:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/83\">",
"      Guo G, Gui Y, Gao S, et al. Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat Genet 2012; 44:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/84\">",
"      Uhlman DL, Nguyen PL, Manivel JC, et al. Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma. J Natl Cancer Inst 1994; 86:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/85\">",
"      Oda H, Nakatsuru Y, Ishikawa T. Mutations of the p53 gene and p53 protein overexpression are associated with sarcomatoid transformation in renal cell carcinomas. Cancer Res 1995; 55:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/86\">",
"      Santhanam U, Ray A, Sehgal PB. Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc Natl Acad Sci U S A 1991; 88:7605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/87\">",
"      Blay JY, Rossi JF, Wijdenes J, et al. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer 1997; 72:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/88\">",
"      Blay JY, Negrier S, Combaret V, et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 1992; 52:3317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/89\">",
"      Beck SD, Patel MI, Snyder ME, et al. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol 2004; 11:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/90\">",
"      Schmidt L, Junker K, Nakaigawa N, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 1999; 18:2343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/91\">",
"      Lager DJ, Huston BJ, Timmerman TG, Bonsib SM. Papillary renal tumors. Morphologic, cytochemical, and genotypic features. Cancer 1995; 76:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/92\">",
"      Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol 1997; 10:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/93\">",
"      Yang XJ, Tan MH, Kim HL, et al. A molecular classification of papillary renal cell carcinoma. Cancer Res 2005; 65:5628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/94\">",
"      Pignot G, Elie C, Conquy S, et al. Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification. Urology 2007; 69:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/95\">",
"      Waldert M, Haitel A, Marberger M, et al. Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC. BJU Int 2008; 102:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/96\">",
"      Klatte T, Pantuck AJ, Said JW, et al. Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. Clin Cancer Res 2009; 15:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/97\">",
"      Thoenes W, St&ouml;rkel S, Rumpelt HJ, et al. Chromophobe cell renal carcinoma and its variants--a report on 32 cases. J Pathol 1988; 155:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/98\">",
"      St&ouml;rkel S, Steart PV, Drenckhahn D, Thoenes W. The human chromophobe cell renal carcinoma: its probable relation to intercalated cells of the collecting duct. Virchows Arch B Cell Pathol Incl Mol Pathol 1989; 56:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/99\">",
"      Ortmann M, Vierbuchen M, Fischer R. Sialylated glycoconjugates in chromophobe cell renal carcinoma compared with other renal cell tumors. Indication of its development from the collecting duct epithelium. Virchows Arch B Cell Pathol Incl Mol Pathol 1991; 61:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/100\">",
"      Akhtar M, Kardar H, Linjawi T, et al. Chromophobe cell carcinoma of the kidney. A clinicopathologic study of 21 cases. Am J Surg Pathol 1995; 19:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/101\">",
"      Speicher MR, Schoell B, du Manoir S, et al. Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization. Am J Pathol 1994; 145:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/102\">",
"      Yamazaki K, Sakamoto M, Ohta T, et al. Overexpression of KIT in chromophobe renal cell carcinoma. Oncogene 2003; 22:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/103\">",
"      Klatte T, Han KR, Said JW, et al. Pathobiology and prognosis of chromophobe renal cell carcinoma. Urol Oncol 2008; 26:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/104\">",
"      Motzer RJ, Bacik J, Mariani T, et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002; 20:2376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/105\">",
"      Volpe A, Novara G, Antonelli A, et al. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series. BJU Int 2012; 110:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/106\">",
"      Lieber MM. Renal oncocytoma: prognosis and treatment. Eur Urol 1990; 18 Suppl 2:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/107\">",
"      Zerban H, Nogueira E, Riedasch G, Bannasch P. Renal oncocytoma: origin from the collecting duct. Virchows Arch B Cell Pathol Incl Mol Pathol 1987; 52:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/108\">",
"      Morra MN, Das S. Renal oncocytoma: a review of histogenesis, histopathology, diagnosis and treatment. J Urol 1993; 150:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/109\">",
"      Kuroda N, Toi M, Hiroi M, et al. Review of renal oncocytoma with focus on clinical and pathobiological aspects. Histol Histopathol 2003; 18:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/110\">",
"      Al-Saleem T, Cairns P, Dulaimi EA, et al. The genetics of renal oncocytosis: a possible model for neoplastic progression. Cancer Genet Cytogenet 2004; 152:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/111\">",
"      Henske EP. Tuberous sclerosis and the kidney: from mesenchyme to epithelium, and beyond. Pediatr Nephrol 2005; 20:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/112\">",
"      Chao DH, Zisman A, Pantuck AJ, et al. Changing concepts in the management of renal oncocytoma. Urology 2002; 59:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/113\">",
"      Rohan S, Tu JJ, Kao J, et al. Gene expression profiling separates chromophobe renal cell carcinoma from oncocytoma and identifies vesicular transport and cell junction proteins as differentially expressed genes. Clin Cancer Res 2006; 12:6937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/114\">",
"      Sukov WR, Ketterling RP, Lager DJ, et al. CCND1 rearrangements and cyclin D1 overexpression in renal oncocytomas: frequency, clinicopathologic features, and utility in differentiation from chromophobe renal cell carcinoma. Hum Pathol 2009; 40:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/115\">",
"      Kurup AN, Thompson RH, Leibovich BC, et al. Renal oncocytoma growth rates before intervention. BJU Int 2012; 110:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/116\">",
"      Dechet CB, Bostwick DG, Blute ML, et al. Renal oncocytoma: multifocality, bilateralism, metachronous tumor development and coexistent renal cell carcinoma. J Urol 1999; 162:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/117\">",
"      Tickoo SK, Reuter VE, Amin MB, et al. Renal oncocytosis: a morphologic study of fourteen cases. Am J Surg Pathol 1999; 23:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/118\">",
"      Adamy A, Lowrance WT, Yee DS, et al. Renal oncocytosis: management and clinical outcomes. J Urol 2011; 185:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/119\">",
"      Childs MA, Breau RH, Umbreit EC, et al. Metachronous renal tumours after surgical management of oncocytoma. BJU Int 2011; 108:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/120\">",
"      Wright JL, Risk MC, Hotaling J, Lin DW. Effect of collecting duct histology on renal cell cancer outcome. J Urol 2009; 182:2595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/121\">",
"      Tokuda N, Naito S, Matsuzaki O, et al. Collecting duct (Bellini duct) renal cell carcinoma: a nationwide survey in Japan. J Urol 2006; 176:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/122\">",
"      Argani P, Antonescu CR, Illei PB, et al. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am J Pathol 2001; 159:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/123\">",
"      Argani P, Antonescu CR, Couturier J, et al. PRCC-TFE3 renal carcinomas: morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t(X;1)(p11.2;q21). Am J Surg Pathol 2002; 26:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/124\">",
"      Malouf GG, Camparo P, Molini&eacute; V, et al. Transcription factor E3 and transcription factor EB renal cell carcinomas: clinical features, biological behavior and prognostic factors. J Urol 2011; 185:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/125\">",
"      Malouf GG, Camparo P, Oudard S, et al. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. Ann Oncol 2010; 21:1834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/126\">",
"      Choueiri TK, Lim ZD, Hirsch MS, et al. Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer 2010; 116:5219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/127\">",
"      Zomas A, Leivada A, Gortzolidis G, et al. Primary renal lymphoma presenting with chronic low-grade fever. Int J Hematol 2004; 79:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/128\">",
"      Dotan ZA, Tal R, Golijanin D, et al. Adult genitourinary sarcoma: the 25-year Memorial Sloan-Kettering experience. J Urol 2006; 176:2033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/52/18250/abstract/129\">",
"      Romero FR, Rais-Bahrami S, Permpongkosol S, et al. Primary carcinoid tumors of the kidney. J Urol 2006; 176:2359.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2982 Version 24.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.131.41.98-0FBBA5EC0B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_52_18250=[""].join("\n");
var outline_f17_52_18250=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H175757290\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H640028829\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Gender and age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H640028914\">",
"      Race",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1046154222\">",
"      Extent of disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1046154382\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ESTABLISHED RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Smoking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H175757375\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H640028216\">",
"      Obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H640028327\">",
"      Acquired cystic disease of the kidney",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Occupational exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Analgesics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cytotoxic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H100878941\">",
"      Chronic hepatitis C infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1046155450\">",
"      Sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H640028514\">",
"      OTHER FACTORS THAT MODIFY RISK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H640028522\">",
"      Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H640028661\">",
"      Polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1046155726\">",
"      Alcohol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H640028732\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Clear cell carcinomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H403324821\">",
"      - Genetic alterations in clear cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H403325303\">",
"      Von Hippel Lindau gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H403325040\">",
"      PBRM1 gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1035988535\">",
"      BAP1 gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H403325055\">",
"      Inactivation of histone-modifying genes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H403325062\">",
"      Ubiquitin-mediated proteolysis pathway (UMPP)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H342358282\">",
"      Abnormalities in cellular division",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Papillary carcinomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Chromophobe carcinomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Oncocytomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Collecting duct tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Translocation carcinomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Other tumor types",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2982\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2982|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/14/17646\" title=\"figure 1\">",
"      RCC incidence mortality trends",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2982|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/54/15213\" title=\"table 1\">",
"      TNM staging RCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/18/16683\" title=\"table 2\">",
"      Autosomal dom forms kidn CA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23638?source=related_link\">",
"      Acquired cystic disease of the kidney in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28170?source=related_link\">",
"      Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=related_link\">",
"      Clinical features, diagnosis, and management of von Hippel-Lindau disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35336?source=related_link\">",
"      Clinical manifestations, evaluation, and staging of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2200?source=related_link\">",
"      Diagnostic approach, differential diagnosis, and treatment of a small renal mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35910?source=related_link\">",
"      Hereditary kidney cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/45/1754?source=related_link\">",
"      Malignancies of the renal pelvis and ureter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/21/14678?source=related_link\">",
"      Molecular biology and pathogenesis of von Hippel-Lindau disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38874?source=related_link\">",
"      Overview of the risks and benefits of alcohol consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/37/16978?source=related_link\">",
"      Patient information: Cadmium toxicity (Cadmium poisoning) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/53/30546?source=related_link\">",
"      Patient information: Renal cell carcinoma (kidney cancer) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21192?source=related_link\">",
"      Prognostic factors in patients with renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37353?source=related_link\">",
"      Renal disease associated with hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30903?source=related_link\">",
"      Renal manifestations of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/3/6202?source=related_link\">",
"      Renal manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/18/43303?source=related_link\">",
"      Renal manifestations of tuberous sclerosis and renal angiomyolipoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1012?source=related_link\">",
"      Urinary tract malignancy and atherosclerotic disease in patients with chronic analgesic abuse",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_52_18251="Bedside tests of attention";
var content_f17_52_18251=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F59119&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F59119&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Bedside tests of attention",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Directions",
"       </td>",
"       <td class=\"subtitle1\">",
"        Scoring",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Digit span",
"       </td>",
"       <td>",
"        Ask the subject to listen carefully and repeat a series of",
"random numbers. Begin with a string of 2 digits, then increase. Read",
"each number in a normal tone of voice at a rate of one digit per",
"second, taking care not to group digits in pairs or sequences that",
"could aid repetition; eg, 3 - 52 - 8 - 18 - 4 - 9 - 36 - 3 - 8 - 5 - 15",
"- 7 - 2 - 9 - 4 - 68 - 1 - 9 - 2 - 7 - 5 - 6",
"       </td>",
"       <td>",
"        Inability to repeat a string of at least five digits indicates probable impairment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vigilance \"A\" test",
"       </td>",
"       <td>",
"        Read a list of 60 letters, among which the letter \"A\" appears",
"with greater than random frequency. The subject is required to indicate",
"(eg, by tapping on the desk) whenever the target letter is spoken by",
"the examiner. The letter list is read in a normal tone at a rate of one letter per second; eg, L T P E A O A I C T D A L A A N I A B F S A M R A E O Z",
"D P A K A L U C J T A E O",
"       </td>",
"       <td>",
"        Count errors of omission and commission. More than two errors is considered abnormal.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_52_18251=[""].join("\n");
var outline_f17_52_18251=null;
var title_f17_52_18252="Grading staging NAFLD AGA";
var content_f17_52_18252=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F58613&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F58613&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Grading and staging of NAFLD",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Grading NAFLD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        1. Macrovesicular steatosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\">",
"        Grade 0: none",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\">",
"        Grade 1: up to 33 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\">",
"        Grade 2: 33 percent-66 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\">",
"        Grade 3: &gt;66 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        2. Necroinflammatory activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Grade 1 (mild)",
"       </td>",
"       <td class=\"sublist_other\">",
"        Steatosis up to 66 percent, occasional ballooned hepatocyte (mainly zone 3), scattered intra-acinar neutrophils (PMN) &plusmn; lymphocytes, no or mild portal inflammation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Grade 2 (moderate)",
"       </td>",
"       <td class=\"sublist_other\">",
"        Steatosis of any degree, obvious zone III ballooning degeneration, intra-acinar PMNs, zone III perisinusoidal fibrosis may be present, mild to moderate, portal and intra-acinar inflammation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Grade 3 (severe)",
"       </td>",
"       <td class=\"sublist_other\">",
"        Panacinar steatosis, widespread ballooning, intra-acinar inflammation, PMNs associated with ballooned hepatocytes, mild to moderate portal inflammation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Staging NAFLD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Stage 1",
"       </td>",
"       <td>",
"        Zone III perisinusoidal/pericellular fibrosis; focally or extensively present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Stage 2",
"       </td>",
"       <td>",
"        Zone III perisinusoidal/pericellular fibrosis with focal or extensive periportal fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Stage 3",
"       </td>",
"       <td>",
"        Zone III perisinusoidal/pericellular fibrosis and portal fibrosis with focal or extensive bridging fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Stage 4",
"       </td>",
"       <td>",
"        Cirrhosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Brunt, EM, et al. Am J Gastroenterol 1999; 94:2467.",
"     <br>",
"      Reproduced with permission from: the American Gastroenterological Association. Sanyal, AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123:1705.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_52_18252=[""].join("\n");
var outline_f17_52_18252=null;
var title_f17_52_18253="Tolerable upper intake levels for vitamins";
var content_f17_52_18253=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F86660&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F86660&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Tolerable upper intake levels for vitamins: Dietary reference intakes (DRIs)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"8\" width=\"12%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Life stage group",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vitamin A",
"        <br/>",
"        (mcg/day)*",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vitamin C",
"        <br/>",
"        (mg/day)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vitamin D",
"        <br/>",
"        (mcg/day)",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vitamin E",
"        <br/>",
"        (mg/day)",
"        <sup>",
"         &bull;&Delta;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Niacin",
"        <br/>",
"        (mg/day)",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vitamin B",
"        <sub>",
"         6",
"        </sub>",
"        <br/>",
"        (mg/day)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Folate",
"        <br/>",
"        (mcg/day)",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"8\">",
"        Males",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        19 to 30 years",
"       </td>",
"       <td>",
"        3000",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        1000",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        1000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        31 to 50 years",
"       </td>",
"       <td>",
"        3000",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        1000",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        1000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        51 to 70 years",
"       </td>",
"       <td>",
"        3000",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        1000",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        1000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;70 years",
"       </td>",
"       <td>",
"        3000",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        1000",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        1000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"8\">",
"        Females",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        19 to 30 years",
"       </td>",
"       <td>",
"        3000",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        1000",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        1000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        31 to 50 years",
"       </td>",
"       <td>",
"        3000",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        1000",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        1000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        51 to 70 years",
"       </td>",
"       <td>",
"        3000",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        1000",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        1000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;70 years",
"       </td>",
"       <td>",
"        3000",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        1000",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        1000",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    A tolerable upper intake level (UL) is the highest level of daily nutrient intake that is likely to pose no risk of adverse health effects to almost all individuals in the general population. Unless otherwise specified, the UL represents total intake from food, water, and supplements.",
"    <div class=\"footnotes\">",
"     * As preformed vitamin A only.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull; As alpha-tocopherol; applies to any form of supplemental alpha-tocopherol.",
"       <br>",
"        &Delta; The tolerable upper intake levels for vitamin E, niacin, and folate apply to synthetic forms obtained from supplements, fortified foods, or a combination of the two.",
"        <br>",
"         &loz;&nbsp;1 mcg retinol = 3.33 IU retinol",
"         <br>",
"          &sect;&nbsp;1 mcg = 40 IU",
"         </br>",
"        </br>",
"       </br>",
"      </font>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Otten JJ, Hellwig JP, Meyers LD (Eds). Dietary Reference Intakes: The Essential Guide to Nutrient Requirements. The National Academies Press, Washington, 2006.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_52_18253=[""].join("\n");
var outline_f17_52_18253=null;
var title_f17_52_18254="Findings in children for evaluation of cancer";
var content_f17_52_18254=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54641&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=13\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54641&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=13\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Symptoms and signs in children suggestive of cancer that require immediate evaluation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Symptoms/signs",
"      </td>",
"      <td class=\"subtitle1\">",
"       Laboratory, imaging studies, and consultations",
"      </td>",
"      <td class=\"subtitle1\">",
"       Major associated tumors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hypertension",
"      </td>",
"      <td>",
"       Labs-CXR, abdominal sonogram",
"      </td>",
"      <td>",
"       Renal or adrenal tumor, neuroblastoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Weight loss, sudden onset",
"      </td>",
"      <td>",
"       Labs-abdominal sonogram",
"      </td>",
"      <td>",
"       Any malignancy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Petechiae",
"      </td>",
"      <td>",
"       CBC, plt, diff",
"      </td>",
"      <td>",
"       Leukemia, neuroblastoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Adenopathy unresponsive to antibiotics",
"      </td>",
"      <td>",
"       Surgical consultation, CXR, CBC, diff",
"      </td>",
"      <td>",
"       Leukemia, lymphoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Endocrine abnormalities",
"      </td>",
"      <td class=\"sublist_other_start\">",
"       &nbsp;",
"      </td>",
"      <td class=\"sublist_other_start\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Growth failure",
"      </td>",
"      <td class=\"sublist_other\">",
"       Hormonal assays",
"      </td>",
"      <td class=\"sublist_other\">",
"       Pituitary tumors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Electrolyte disturbance",
"      </td>",
"      <td class=\"sublist_other\">",
"       CT hypothalamic area",
"      </td>",
"      <td class=\"sublist_other\">",
"       Hypothalamic tumors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Sexual abnormalities",
"      </td>",
"      <td class=\"sublist_other\">",
"       Abdominal CT",
"      </td>",
"      <td class=\"sublist_other\">",
"       Gonadal tumors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Cushing's syndrome",
"      </td>",
"      <td class=\"sublist_other\">",
"       Endocrine consultation",
"      </td>",
"      <td class=\"sublist_other\">",
"       Adrenal tumors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Brain",
"      </td>",
"      <td class=\"sublist_other_start\">",
"       Neurology or neurosurgery consultation followed by imaging studies",
"      </td>",
"      <td class=\"sublist_other_start\">",
"       Brain tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Headache, vomiting early am",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Cranial nerve palsy, ataxia",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Dilated pupil, papilledema",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Afebrile seizures",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Hallucinations, aphasia",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Unilateral weakness, paralysis",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Eyes",
"      </td>",
"      <td class=\"sublist_other_start\">",
"       Ophthalmologist consultation",
"      </td>",
"      <td class=\"sublist_other_start\">",
"       Retinoblastoma, metastatic rhabdomyosarcoma, neuroblastoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       White spot, proptosis, blindness",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Wandering eye",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Intraorbital hemorrhage",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Ears",
"      </td>",
"      <td class=\"sublist_other_start\">",
"       CBC, diff, and imaging studies",
"      </td>",
"      <td class=\"sublist_other_start\">",
"       LCH, rhabdomyosarcoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Bulging mass external canal",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Mastoid tenderness, swelling",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Puffy face and neck",
"      </td>",
"      <td class=\"sublist_other\">",
"       CBC, diff, and imaging studies",
"      </td>",
"      <td class=\"sublist_other\">",
"       Mediastinal tumors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Pharyngeal mass",
"      </td>",
"      <td class=\"sublist_other\">",
"       CBC, diff, and imaging studies",
"      </td>",
"      <td class=\"sublist_other\">",
"       Rhabdomyosarcoma, lymphoma, nasopharyngeal carcinoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Periodontal mass, loose teeth",
"      </td>",
"      <td class=\"sublist_other\">",
"       Dental consultation, imaging studies",
"      </td>",
"      <td class=\"sublist_other\">",
"       LCH, Burkitt's lymphoma, neuroblastoma, osteosarcoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Thorax",
"      </td>",
"      <td class=\"sublist_other_start\">",
"       CBC, diff, imaging studies",
"      </td>",
"      <td class=\"sublist_other_start\">",
"       Soft tissue sarcomas, mediastinal tumors, metastatic tumors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Mass",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Intrathoracic: coughing, SOB without fever or no history of asthma, allergies",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Abdomen/pelvis",
"      </td>",
"      <td class=\"sublist_other_start\">",
"       CBC, diff",
"      </td>",
"      <td class=\"sublist_other_start\">",
"       Wilms' tumor, soft tissue sarcoma, neuroblastoma, hepatoblastoma, hepatocarcinoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Intraabdominal mass",
"      </td>",
"      <td class=\"sublist_other\">",
"       Labs, imaging studies",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Genitourinary",
"      </td>",
"      <td class=\"sublist_other_start\">",
"       UA, CBC, diff, sonogram of pelvis/abdomen",
"      </td>",
"      <td class=\"sublist_other_start\">",
"       Germ cell tumor, rhabdomyosarcoma, adrenal tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Testicular or vaginal mass",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Masculinization/feminization",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Musculoskeletal",
"      </td>",
"      <td class=\"sublist_other_start\">",
"       CBC, diff, imaging studies",
"      </td>",
"      <td class=\"sublist_other_start\">",
"       Osteosarcoma, Ewing's sarcoma, leukemia, neuroblastoma, soft tissue sarcoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       <p>",
"        Soft tissue mass",
"       </p>",
"       <p>",
"        Musculoskeletal pain",
"       </p>",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     Signs and symptoms in children that require immediate evaluation that may include laboratory testing, imaging and/or consultation with pediatric subspecialists.",
"    </p>",
"    <div class=\"footnotes\">",
"     CBC: complete blood cell count; CT: computerized tomography; CXR: chest x-ray; diff: differential; labs: laboratory studies, usually hepatic and renal function and electrolytes; LCH: Langerhans' cell histiocytosis; plt: platelet count; SOB: shortness of breath; UA: urinalysis.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Malogolowkin MH, Quinn JL, Steuber CP, Siegel SE. Clinical Assessment and Differential Diagnosis of the Child with Suspected Cancer. In: Principles and Practice of Pediatric Oncology, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2005. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_52_18254=[""].join("\n");
var outline_f17_52_18254=null;
var title_f17_52_18255="Cubitus varus";
var content_f17_52_18255=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F63539&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F63539&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cubitus varus deformity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 379px; height: 499px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Varus deformity of the elbow, also called cubitus varus, results in prominence of the elbow and decreased carrying angle (the forearm pointing towards the body when the arm is anatomic position). This abnormality is a complication of supracondylar fractures and lateral condyle elbow fractures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_52_18255=[""].join("\n");
var outline_f17_52_18255=null;
